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The chemisome is the chemical components of the exposome, defined as the totality of all 
exposures and their impact on health. Most current approaches, however, are limited in addressing 
this “totality” by only studying one chemical or one chemical family at a time in one exposed 
population. In addition, studying the links between chemical exposures and health is challenging 
due to an incomplete understanding of how physiological responses are associated with adverse 
health outcomes. This challenge is further complicated due to how chemical exposures change 
with demographics such as age, sex, race, and occupation. Thus, this dissertation aims to address 
these challenges by applying an unbiased approach to datasets of chemical biomarker levels and 
physiological measurements to systematically identify susceptible populations using the National 
Health and Nutrition Examination Survey.  
 In the first project, I use quadratic regression models to characterize non-linear, age-based 
trends of chemical exposure in a sample comprised of 74,942 participants. I screen across 141 
chemicals to identify those of higher concentrations in children relative to the older population. 
Children exhibit higher exposures to chemicals in consumer products such as phthalates, 
brominated flame retardants, lead, and tungsten. In contrast, restricted and highly persistent 
chemicals such as polychlorinated biphenyls and dioxins are higher in the older population.  
 In the second project, I apply generalized linear models to evaluate exposure disparities 
by race/ethnicity for 143 chemicals in a representative sample of 38,080 US women. Compared to 
non-Hispanic White women, significant disparities are observed for non-Hispanic Black, Mexican 
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American, Other Hispanic, and Other Race/Multi-Racial women. These women have higher levels 
of pesticides, including 2,5-dichlorophenol and 2,4-dichlorophenol, compounds in personal care 
products, including parabens and mono-ethyl phthalate, and heavy metals, such as mercury and 
arsenic. These findings are being coupled with toxicological data to prioritize chemicals to 
evaluate their role in health disparities.  
In the third project, I develop a framework using hierarchical clustering to characterize 
occupational exposures and physiological responses among 26,186 blue- and white-collar workers 
across 20 employment sectors for 108 chemicals and 27 physiological indicators. Blue-collar 
workers have higher levels of toxicants such as lead, cadmium, volatile organic chemicals, and 
polycyclic aromatic hydrocarbons compared to white-collar workers. Moreover, blue-collar 
workers exhibit higher levels of alkaline phosphatase (indicative of liver disease) and C-reactive 
proteins (indicative of inflammation). Together, these results suggest that blue-collar workers are 
exposed to higher levels of toxicants, which may induce physiological dysfunction. 
 In the final project, I implement 10-fold cross-validated regression models to characterize 
the linear and non-linear associations between all-cause mortality and 27 physiological indicators 
to identify directionalities indicative of increased mortality risk in a sample of 45,032 participants. 
Twenty-four out of 27 indicators show non-linear associations, while height, triglycerides, and 60-
second pulse show linear associations. Cholesterol-related indicators and glomerular filtration rate 
unexpectedly show parabolic associations, implying that higher mortality risk is associated with 
measurements in either extreme of the distribution instead of in one extreme. These findings 
highlight a need to study associations between these indicators and other health endpoints to gain 
insights into the physiological profiles associated with adverse health outcomes. 
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Together, this thesis contributes to a better understanding of how chemical exposures can 
impact human health across multiple subpopulations. It also enables further exploration of how 




Chapter 1 Introduction 
 
1.1 Background and Motivation  
As early as the 1890s, factory workers were screened for lead in their blood and urine to 
prevent elevated levels from reaching the point of acute lead poisoning 1. Here is one of the earliest 
examples of tracking biomarker levels to characterize the impact of chemical exposures. While 
this example pertains to occupational exposures, we are exposed to thousands of environmental 
substances everyday based on where we live, where we work, what we drink, what we eat, what 
we use, etc. Some of these substances may be toxic, but it is challenging to know which ones and 
the levels at which an adverse effect would occur.  
In 2005, Christopher Wild termed the exposome as the totality of all exposures in an 
individual’s lifetime and its impact on human health 2. This totality of exposures can consist of, 
but is not limited to, ecosystem, lifestyle factors, social indicators, and physical-chemical factors. 
The concept of the exposome was developed as the complement to the genome, and that an 
integrated understanding of both the exposome and the genome would facilitate progress toward 
addressing chronic human health problems 3. Genetics account for only about 10%-40% of  the 
contribution to most diseases 4–6, suggesting that environmental exposures may play a greater role 
in understanding the etiology of disease compared to genetic factors alone.  
The chemisome is defined as the chemical components of the exposome and how it affects 
human health 7. Toxic chemicals can enter the body from exogenous sources such as air, water, 
and lifestyle behaviors such as dietary habits and medication use 8,9. Toxicants can also be 
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generated by endogenous processes such as inflammation, oxidative stress, diseases, and infection 
10,11. As environmental insult can perturb physiological functions conducive to disease 12, 
characterizing biologically active chemicals inside the human body will promote the discovery of 
exposures responsible for chronic disease 5,13. Thus, better understanding of how environmental 
pollutants relate to health problems requires human biomonitoring.   
Human biomonitoring is the measuring of chemicals or their metabolites in the human 
body to ascertain the extent of human exposure to environmental toxicants 14. A chemical 
biomarker is an indicator of environmental exposures quantified as the chemical, its metabolites, 
or the products of an interaction between the chemical and a biological target in an organism 15,16. 
The largest continuous source of data on chemical biomarkers in the United States (US) is the 
National Health and Nutrition Examination Survey (NHANES) 17. The Centers for Disease Control 
and Prevention (CDC) designed this survey to ascertain the nutritional and health status of children 
and adults in the US. NHANES deploys a complex, multistage, probability sampling design to 
ensure that the data is representative of the noninstitutionalized, civilian US population 18. Since 
1999, the CDC has conducted the continuous NHANES survey by inviting several thousands of 
volunteers every two years to participate in interviews, questionnaires, and examination. 
Biological samples are analyzed for indicators of disease, disorders, and chemical biomarkers. 
These data are publicly available online accompanied with data on demographics, questionnaire 
response, physiological measurements, and other laboratory tests 19.  
In our current, cleaned NHANES dataset, we have blood, serum, and urinary measurements 
available for 411 chemical biomarkers to analyze exposures and 60 physiological indicators to 
analyze the physiologic condition of a representative US sample of 82,091 participants. The 
diverse suite of chemical biomarkers are from 17 different chemical classes:  Acrylamide, 
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Brominated Flame Retardants (BFR), Phosphate Flame Retardants (PFR), Dioxins, Furans, 
Melamine, Metals, Other, Personal Care & Consumer Product Compounds, Pesticides, Phthalates 
& Plasticizers, Phytoestrogens, Polyaromatic Hydrocarbons (PAH), Polychlorinated Biphenyls 
(PCB), Per- and Polyfluoroalkyl Substances (PFAS), Smoking Related Compounds, and Volatile 
Organic Compounds (VOC). The physiological indicators comprise a wide range of human body 
systems including body composition, cardiovascular system, respiratory system, immune system, 
metabolic system, and nephrology. Such wealth of data is conducive to conducting exposome 
research to evaluate the impact of environmental insults on human physiology.  
While exposomic data such as NHANES provides hope to better understand the 
environmental contribution to disease and how to prevent such diseases, addressing this problem 
requires addressing the scale of exposomic data. Measuring techniques such as omics and sensor 
technologies will generate heterogenous, massive, and high-velocity data 20. Thus, there is a need 
to develop approaches to manage, analyze, and visualize these large-scale data to begin untangling 
the intertwining associations between genetics, exposures, and disease 3. Inspiration can be drawn 
by the approaches implemented in genome-wide association study (GWAS), which involves 
screening across millions of genetic markers to identify those that can be used to predict the onset 
of a particular disease 21. In fact, inspired by techniques used in GWAS, Patel et al. conducted an 
environment-wide association study (EWAS) on chemical, clinical, and questionnaire data from 
NHANES to evaluate the associations between 266 chemical biomarkers and type 2 diabetes 
mellitus and serum lipid levels, respectively 22. Patel et al. observed strong associations between 
the risk of type 2 diabetes and exposures to heptachlor epoxide, g-tocophperol, b-carotenes and 
polychlorinated biphenyls. Such results suggest the importance of implementing an unbiased 
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approach to gain insights on the role of the environment in disease onset and ultimately lead to the 
prevention of chronic disease 3. 
However, most current approaches tend to implement a one-chemical 23–27 or one-
chemical-family 28–34 when studying exposures, which is not only limited in addressing the totality 
of exposures but also limited in prioritizing chemicals for further study. Furthermore, addressing 
the totality of exposures is further complicated by the dynamic nature of an individual’s exposome 
3, since it changes with demographic factors such as age, sex, race, and occupation and other 
lifestyle factors such as dietary habits, physical activities, etc. However, this one-chemical or one-
chemical-family approach is commonly applied to one exposed subpopulation instead of multiple 
different subpopulations 35–38, thus hindering progress towards identifying populations vulnerable 
to chemical-mediated effects. While this approach is necessary for an in-depth, detailed analysis, 
this single-chemical or single-family approach can complement an unbiased approach that 
systematically identifies chemicals with high exposures in specific susceptible populations to 
provide wealth and depth in understanding the exposure profiles associated with vulnerable 
populations. Hence, I have organized sections 1.2, 1.3, and 1.4 to discuss limitations in current 
approaches for studying age-based trends, characterizing racial exposure disparities in women in 
the context of breast cancer, and evaluating the impact of occupational co-exposures on worker’s 
health, respectively. For section 1.3, I focused primarily on breast cancer disparities due to interest 
of the Colacino Lab to prioritize toxicants for further experimental work to understand their role 
in breast cancer disparities. 
There are also limitations in addressing how chemical exposures influence health. For ease 
of interpretation, most studies assume linearity when modelling the associations between chemical 
exposures and a given disease 22,39. Linear models cannot detect whether participants with either 
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higher or lower exposures are at increased risk, as these models are limited to only detecting one 
subpopulation at risk. For example, lower levels of vitamin A are associated with increased risk 
for blindness, infection, rashes, and higher levels are associated with bone pain, liver damage, and 
increase pressure on the brain 40. A linear model would suggest one of the following:  1) higher 
levels, 2) lower levels, or 3) no levels are associated with increased risk. This shows the limitations 
of the using a linear model to detect susceptible participants, especially in situations when 
participants with measurements in either extremes of exposures are at risk. Furthermore, while 
these studies provide evidence of environmental influence on human health 41–45, they do not 
provide insight on how exposure may perturb important physiological mechanisms conducive to 
increasing disease risk. Therefore, we first need to gain insights into understanding the 
physiological profiles associated with adverse outcomes 46–51. In addition, there is a need to 
develop a framework to study the linear and non-linear relationship between physiological 
indicators and adverse health outcomes. This framework will not only be useful in identifying 
directionalities associated with increased disease risk, but it will also enable further exploration on 
how chemical exposures perturb physiological profiles in a manner that increases risk for a given 
adverse outcome. In section 1.5, I further discuss the limitations of the current approaches to 
modeling the associations between physiological indicators and health outcomes.  
Figure 1.1 illustrates the contributions from studies published within the last two decades 
that characterized associations along the continuum of chemical indicators, physiological 
indicators, and health endpoints. These domains converge toward the high-throughput evaluation 
of chemical exposures to simultaneously prioritize chemicals and identify susceptible populations 





1.2 Need to Systematically Identify Highly Exposed Chemicals in Children 
Children are especially susceptible to toxicant exposures due to an assortment of 
physiological traits and normal development behaviors. For instance, children tend to have higher 
metabolic rate 52,53, which facilitates the absorption of toxicants. Infants often have higher body 
burdens of chemicals, with estimated half-lives of several chemicals being 3-9 times longer than 
those found in adults 54. These higher half-lives may be due to childrens’ developing metabolism 
pathways. Due their small body sizes, children are more susceptible to adverse effects if exposed 
to the same doses as adults 55. Children are rapidly growing and developing, leading to changes in 
their organ system functioning, which may modify the effects from toxicant exposures 56. For 
example, developing organ systems, such as the central nervous system 57 and respiratory system 
58, are more susceptible to environmental insults in children than in adults. Furthermore, children 
are especially sensitive to adverse effect of toxic exposures as childhood development is a crucial 
window of susceptibility 56. Children may also be susceptible to higher exposures via routes of 
exposures associated with behaviors linked to normal development such as crawling 59, mouthing 
60,61, and playing 62. Therefore, approaches to identify chemicals of higher biomarker levels in 
children will help prioritize chemicals for further toxicologic and epidemiologic assessment and 
implement policy or regulations to prevent such exposures and subsequent adverse effects.  
Children are exposed to a wide ensemble of chemicals 63. Commonly used as plasticizers, 
especially in toys, phthalates are found at higher concentrations in children with links to 
developmental and reproductive toxicity in animals 64. Brominated flame retardants such as 
Polybrominated Diphenyl Ethers (PBDEs) are also found at higher levels in children 65 and have 
been shown to affect the developing brain and thyroid homeostasis 66, thus affecting the regulation 
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of many body functions due to irregular release of thyroid hormones in the bloodstream. Blood 
lead concentrations are declining 67 but are still found at levels associated with neurotoxicity and 
intellectual impairment, as no safe level of lead has been identified 68,69. From a literature review, 
children tend to have higher biomarker levels of bisphenol A (BPA), phytoestrogens, perchlorate, 
and metabolites of PAHs and benzene 70. From a range of many different chemicals, which of 
these chemicals should be prioritized for further risk assessment and consideration for 
implementing legislation to prevent such exposures and related adverse outcomes? While these 
studies are informative for detailed analysis, studying one chemical or one chemical family at a 
time is limited in addressing the totality of chemical exposures in children. Hence, there needs to 
be an untargeted approach to prioritize chemicals by exposures and severity of health problems in 
children.  
Studying age-based trends is salient to applying an untargeted approach to identify a set of 
chemicals found at higher concentrations in children than in adults. Studying such trends are also 
informative into gaining insights on the history of exposures as age can be used as a surrogate for 
time. In addition, studying age-based trends enables us to observe the efficacy of legislation and 
policy on chemical productions and its subsequent effects 71,72. Furthermore, identifying the drivers 
of age-based trends of chemical exposures will help prioritize susceptible populations and guide 
intervention strategies to prevent chemical-mediated adverse health outcomes. Several 
mechanistic models have been developed to study the relationship between chemical exposures 
and age for PCBs 73,74, dioxins 75, and selected PFASs such as PFOS and PFOA 76,77. While these 
models have enabled the identification of biological half-lives, restriction dates, and change of 
intake as important drivers of age-based trends, these models have been limited to persistent and 
legacy chemicals such as PCBs and Dioxins and required a substantial amount of data to 
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parameterize. These stipulations create challenges in applying an unbiased approach to 
characterize drivers of age-based trends and identify high risk populations across a broad set of 
chemicals. Thus, using human biomonitoring data containing measurements for hundreds of 
chemicals will enable the characterization of age-based trends and their determinants to help 
prioritize chemicals in children. 
1.3 Role of Environmental Insult on Breast Cancer Disparities 
There are stark racial disparities in breast cancer among women in the US. For example, 
non-Hispanic Black women are 40% more likely to die from breast cancer compared to women of 
any other race 78. Furthermore, the incidence of non-Hispanic Black developing triple negative 
breast cancer, the most aggressive subtype of breast cancer, is three times higher compared to that 
of non-Hispanic White women 79,80. Therefore, understanding the etiology of these disparities is 
integral to design targeted interventions to ensure health equity.  
While the mechanisms driving these breast cancer disparities are likely due to complex 
interactions between genetic and environmental factors, the contribution of genetic variations 
appears minor in explaining cancer disparities 81–83. For instance, a meta-analysis found that 
genetic risk factors explain less than 5% of the variation in cancer disparities 84. Furthermore, high 
penetrance inherited genes contribute to only 5-10% of breast cancer 85, leaving a substantial 
proportion to be possibly explained by the environment and hence preventable with targeted 
intervention 86,87.  
Differences in chemical exposures have been hypothesized to be pertinent drivers in racial 
disparities of disease 78–83. The role of chemical exposures in breast cancer disparities is not well 
studied nor understood. Thus, understanding the etiology of environmental insults on breast cancer 
disparities require comprehensive characterization of differences in chemical exposures. 
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Furthermore, systematic characterization of exposure differences across a diverse set of chemical 
indicators will enable the identification of toxicants showing the highest disparities and hence the 
prioritization of these toxicants for further experimental work to better understand the role of 
environmental insult in increasing the risk of breast cancer.  
1.4 Susceptibility of Workers to Occupational Exposures and Related Effects  
Workers are vulnerable to chemical-mediated effects as occupational exposures have been 
identified as causal factors in a wide variety of disorders and diseases. Prolonged exposures to 
hazardous chemicals even at lower doses have been identified as a causal factor in cancer 88,89. 
According to the National Institute for Occupational Safety and Health (NIOSH), 13 million 
workers in the US are exposed to chemicals via dermal absorption, which can result in occupational 
skin diseases and systemic toxicity 90. According to the United Nations, a worker dies from toxic 
occupational exposure every 30 seconds 91.  
These statistics lend urgency to characterize the totality of exposures across different 
industries and occupations to identify workers most susceptible to chemical-mediated health 
effects. Despite these alarming statistics, most studies tend to characterize occupational exposures 
by implementing a one-chemical or one-chemical family approach in a selected group of workers 
30,35,37. Such approaches are limited in prioritizing chemicals for further analysis. They are also not 
representative of the totality of chemical exposures as individuals are exposed to multiple 
chemicals in an occupational setting. In addition, characterizing co-exposures is important in 
understanding the synergistic effect of chemical exposures on disease. For example, workers, who 
were exposed to asbestos but do not smoke, have a 70% higher risk of lung cancer compared to 
the reference group of non-smoking workers who were not exposed to asbestos. While an increased 
risk of 70% is substantial, this risk is minimal when compared to the case of workers, who are 
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exposed to asbestos and smoke, as the likelihood of having lung cancer for this group is 9 times 
higher compared to the reference group 92. Despite these findings, studying co-exposures have 
been limited to one chemical family 93–95, but populations are not only exposed to one chemical 
class. Thus, there is a need to develop a framework to characterize co-exposures across multiple 
chemical classes. This is essential to identify workers, whose exposure profiles are characterized 
by elevated biomarker concentrations of the most toxic substances as they would benefit from 
targeted intervention. 
Understanding how chemical exposures may elicit or diminish important physiological 
responses will be integral to better understand the role of occupational exposures in causing 
diseases. Physiological responses can be characterized by measurements of various biomarkers 
known as physiological indicators that characterizes the normal functioning or dysfunction of the 
different systems in the human body. While some have studied the associations between a chemical 
or chemical family and a physiological indicator 30,35,96, this is not representative of the totality of 
exposure on human health. Few have evaluated the impact of multiple chemical on physiological 
response, but this was limited to one physiological indicator 97. Physiological function is not solely 
characterized by only one physiological indicator. Thus, evaluating the impact of chemical co-
exposures on a diverse suite of physiological indicators is fundamental to better understand the 
influence of environmental insults on human health, especially in an occupational setting. 
1.5 Characterizing Associations Along the Spectrum of Chemical Exposures to Physiological 
Indicators to Adverse Health Outcomes 
While several studies have provided evidence of the influence of chemical exposures on 
disease onset 22,39,98, there are several limitations in these approaches. First, the sample size for 
some studies are low 99–102, leading to decreased statistical power in detecting significant 
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differences. In addition, these studies do not adjust for multiple comparisons, which may 
potentially lead to spurious findings 103. Second, most studies assume a linear association when 
modeling the relationship between chemical exposures and disease risk 22,39,98. Others do evaluate 
non-linear effects 104,105, but very few studies compare the prediction performance between linear 
and non-linear models to determine which type of association best describe the dose-response 
relationship 96,106. Finally, while these studies provide evidence of environmental influence on 
human health, they do not provide insight on how exposure may perturb important physiological 
mechanisms conducive to increasing risk for the disease. Furthermore, we need to first evaluate 
the physiological profiles associated with adverse outcomes, so that we can have the foundation to 
understand how chemical exposures can modulate the associations between physiological function 
and adverse outcomes.  
Understanding whether associations between physiological indicators and health outcomes 
are linear or non-linear will enable identification of populations prone to increase risk for adverse 
outcomes. Most association studies assume linearity 107–110 or non-linearity 111–115 separately. 
Furthermore, these studies do not quantitatively evaluate whether linearity or non-linearity better 
describes the associations between a given physiological indicator and a health outcome. While 
there are many studies that do compare the prediction performance of various models such as 
linear, quadratic, cubic, and logarithmic 116,117, these results are not validated on new data. Without 
any validation, the more flexible model, usually the non-linear model, is deemed better at 
characterizing the associations, which may reflect the actual relationship or show an overfitted 
model 118. Thus, these limitations emphasize the need for a statistical framework to establish the 
appropriate model to best characterize the association between a physiological indicator and a 
health outcome while also evaluating for overfitting by using cross-validation and metrics such as 
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the AIC or Bayesian Information Criterion to penalize for added complexity in the non-linear 
models. This framework will enable identification of directionalities of the physiological indicator 
associated with increased disease risk. In addition, it will be applicable to characterize the 
associations between chemical exposures and physiological indicators and health outcome, 
respectively. Such applications will lead to the identification of the chemical doses conducive to 
elicit a negative physiological response leading to an adverse outcome.  
1.6 Objectives and Specific Aims 
The main objective of this thesis is to better characterize the totality of chemical exposures 
and to gain insights into understanding how chemicals exposures perturb physiological function 
in a manner that increase onset risks for adverse health outcomes. More specifically, to address 
the aforementioned limitations and challenges, I define the following four specific aims.  
Specific Aim 1 (Chapter 2): Identify toxicants of higher biomarker levels in children by 
characterizing age-based trends in a representative sample of the US population. More specifically, 
this aim entails:  1) understanding the influence of temporal drivers, in particular time trends, 
biological half-lives, and restriction dates on age-based trends, 2) systematically defining an age-
based pattern to identify chemicals with ongoing and high exposure in children, and 3) 
characterizing how age-based trends for six PFASs are changing over time to evaluate the criteria 
indicative of legacy exposures. 
Specific Aim 2 (Chapter 3): Conduct a comprehensive analysis of racial disparities in 
chemical biomarker concentrations among US women to identify chemicals of higher exposures 
in Non-Hispanic Black women. More specifically, this aim involves: 1) evaluating chemical 
exposures disparities by race, 2) evaluating how these exposure disparities varies across the life 
stage, and 3) characterizing how these exposure disparities change over time.  
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Specific Aim 3 (Chapter 4): Characterize occupational exposures and physiologic 
dysfunction in a working US population comprised of NHANES participants from a broad range 
of industrial sectors and occupations. More specifically, this aim involves:  1) characterizing 
differences in chemical exposure and physiological response profiles across combinations of 
sectors and occupations, 2) identifying groups of workers with similar chemical exposure and 
physiological response profiles, and 3) characterizing the physiological dysfunction of workers 
who have similar chemical exposure profiles.  
Specific Aim 4 (Chapter 5): Characterize the relationships between all-cause mortality 
and 27 physiological indicators in the US population. All-cause mortality was selected as it is the 
ultimate health endpoint. More specifically, this aim includes:  1) comparing the prediction 
performance of linear and different nonlinear models by applying a machine learning approach, 2) 
assessing the robustness of the models by observing changes in prediction performance when 
extreme measurements are excluded, 3) describing the associations between the physiological 
indicator and mortality as characterized by the most appropriate model(s), and 4) determining the 
relevance of the current clinical thresholds by evaluating whether these values are indicative of 
increased mortality risk. 
1.7 Dissertation Outline  
This dissertation is organized based on the aforementioned specific aims with Chapter 2-5 
used to address each of the four specific aims. Chapters 2-5 are formatted as journal articles 
accompanied by supplemental information available in Appendices 1-4. Chapter 2 119 and 3 120 
were published in Environment International. Finally, Chapter 6 concludes the dissertation by 










Figure 1.1. General structure of association studies along the spectrum of chemical biomarkers, physiological indicators, and health 
endpoints. BFRs, Brominated Flame Retardants; BMI, Body Mass Index; CRP, C-Reactive Proteins; GFR, Glomerular Filtration Rate; 
PAHs, Polycyclic Aromatic Hydrocarbons; PBDEs, Polybrominated Diphenyl Ethers; PBBs, Polybrominated Biphenyls; PCBs, 
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Chapter 2 Characterization of Age-Based Trends of Chemical Biomarker Levels 
 
2.1 Abstract  
Background: Chemical biomarker concentrations are driven by complex interactions 
between chemical use patterns, exposure pathways, and toxicokinetic parameters such as 
biological half-lives. Criteria to differentiate legacy from current exposures are helpful for 
interpreting variation in age-based and time trends of chemical exposure and identifying chemicals 
to which children are highly exposed. A systematic approach is needed to study temporal trends 
for a wide range of chemicals in the US population. 
Objectives: Using NHANES data on measured biomarker concentrations for 141 
chemicals from 1999-2014, we aim to 1) understand the influence of temporal determinants, in 
particular time trends, biological half-lives, and restriction dates on age-based trends, 2) 
systematically define an age-based pattern to identify chemicals with ongoing and high exposure 
in children, and 3) characterize how age-based trends for six Per- and Polyfluoroalkyl Substances 
(PFASs) are changing over time.  
Methods: We performed an integrated analysis of biological half-lives and restriction 
dates, compared distributions of chemical biomarker concentrations by age group, and then applied 
a series of regression models to evaluate the linear (!!"#) and nonlinear (!!"#!) relationships 
between age and chemical biomarker levels.  
Results: For restricted chemicals, a minimum persistence of 1 year in the human body is 
needed to observe substantial differences between less exposed young population and historically 
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exposed adults. We define a metric (!!"#! !!"#⁄ > $%&.() that identifies several phthalates, 
brominated flame retardants, pesticides, and metals such as lead and tungsten to reflect elevated 
and ongoing exposures in children. While a substantial reduction in children’s exposures was 
reflected in PFOS and PFOA, levels of PFNA and PFHxS in children were higher in 2013-2014 
compared to those in 1999-2000.  
Conclusions: Integrating a series of regression models with systemized stratified analyses 
by age group enabled us to define an age-based pattern to identify chemicals that are of higher 
level in children.  
2.2 Introduction 
Characterizing an individual’s exposome requires understanding their lifelong chemical 
exposures, including how chemical exposures change over time and by age. Studies using 
population-level chemical biomonitoring data have observed a variety of chemical-specific time 
and age trends. Persistent chemicals such as polychlorinated biphenyls (PCBs) tend to show a 
strong decline over time and differentiated exposure patterns across life stages, which are linked 
to chemical persistency and changes in legislation 73,121. Relative to PCB exposures which derive 
mainly from the diet, characterizing exposures to chemicals in consumer products, such as 
phthalates, are more complex, since these chemicals are used in a range of products with varying 
usage patterns. As a result, very different age-based and temporal patterns can be observed even 
within the same chemical family. For instance, urinary concentrations of mono-ethyl phthalate, 
mono-n-butyl phthalate, mono-benzyl phthalate, and metabolites of di(2-ethylhexyl) phthalate 
showed a decline, whereas mono-isobutyl phthalate, mono(3-carboxypropyl) phthalate, mono-
carboxyoctyl phthalate, and mono-carboxynonyl phthalate increased from 2001 to 2010, implying 
that the latter phthalates may be substitutes for the former 28. Similar trends can be observed in 
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biomonitoring data for per- and polyfluoroalkyl substances (PFASs), such as perfluorooctane 
sulfonate (PFOS) and perfluorooctanoate (PFOA), where differences in population concentrations 
manifested following restrictions in 2000-2002 122,123. The exposure patterns of other PFASs from 
treated consumer products 124, water 125,126, and food contamination 127 are not as well understood 
and evoke the need to study how age-based trends for these substances are changing over time 76. 
While many studies have used biomonitoring data to identify a variety of chemical-specific time 
and age trends, expanding these analyses to a broader set of chemicals and chemical classes will 
enable us to understand the drivers behind these age-based trends.  
To better understand the relationship between chemical biomarker levels and age, several 
mechanistic models have been developed to investigate the potential determinants. These models 
have studied age relationships for specific chemical classes such as PCBs Ritter et al. 2011), 
dioxins 75, and selected PFASs 76,77, with most considering dietary exposure pathways. These 
models have enabled the identification of key potential determinants such as biological half-lives, 
restriction dates, and change of intake with age as important factors in understanding age-based 
trends. However, such models have mostly been applied to dietary exposures for persistent 
chemicals and require substantial amount of data on age-based exposure patterns, chemical 
properties, and chemical usage. Such stipulations make a systematic application across a broad set 
of chemical classes and exposure pathways complex and challenging. Thus, an overarching 
statistical approach anchored in biomonitoring data would complement mechanistic approaches 
by allowing us to screen age-based trends and main determinants across a larger number of 
chemicals, chemical classes and (even unknown) product usage, to identify subpopulations at risk 
of high exposure. 
 19 
 
Compared to adults, children are particularly susceptible to toxicant exposures due to 
factors such as higher metabolic rate 52,53, rapid growth, development of organs and tissues 56, and 
behaviors associated with normal development such as crawling 59, mouthing 60,61, and playing 62.. 
For example, higher concentrations of polybrominated diphenyl ethers (PBDEs) in younger 
individuals were attributed to lifestyle and activity  differences 65. Due to their increased 
susceptibility, it is imperative to identify chemicals to which children are highly exposed. 
Comparing geometric means of chemical levels across age groups enables the identification of 
chemicals that are higher in children. Such approaches do not account for confounders, however, 
nor do they inform the influence of potential determinants on age-based trends 128–130. There is a 
need integrate data on biological half-lives and restriction dates with cross-sectional biomonitoring 
data to understand age patterns and systematically identify ongoing exposures in children.  
While progress has been made to characterize temporal trends for a few chemical classes, 
an overarching screening approach has yet to be developed to systematically study age-based and 
temporal trends of biomarker data in context with temporal determinants such as half-lives and 
restriction dates for a wide range of chemicals in the US population. In this study, we therefore 
applied a systematic approach through a series of regression models to characterize chemical 
specific age-based patterns and identify highly exposed subpopulations for a broad set of 141 
chemical biomarkers from a 1999-2014 sample of the US population. More specifically, our 
objectives were to 1) understand the influence of temporal determinants on age-based trends, in 
particular time trends, biological half-lives, and restriction dates, 2) systematically define an age-
based pattern of concern to identify chemicals of ongoing and high exposures in the younger 
population, and 3) conduct a targeted analysis of six PFASs to characterize how age-based trends 
of these substances are changing over time.   
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2.3 Material and Methods 
The approach integrates four types of data: a large dataset of biomarker concentrations for 
multiple chemicals in a large sample of the US population, the corresponding demographic factors 
for the studied population, a dataset of human biological half-lives for the observed chemicals, and 
a dataset describing the year and type of restrictions imposed on the production, emission, sale or 
use of products containing these substances, if applicable. 
2.3.1 Study Population  
Since 1999, the Centers for Disease Control (CDC) has conducted the continuous National 
Health and Nutrition Examination Survey (NHANES) to collect cross-sectional data on 
demographic, socioeconomic, dietary, and health-related characteristics in the US population. For 
this analysis, we combined data from the chemical biomarker and demographic datasets between 
years 1999-2014 for an initial number of 82,091 participants. We then excluded participants for 
which corresponding data on chemical biomarkers do not exist (n = 7,149), resulting in a sample 
size of 74,942 study participants. On a chemical specific basis, we also excluded participants with 
missing information on any of the following covariates: age, NHANES cycles, sex, race/ethnicity, 
poverty income ratio, cotinine levels, and urinary creatinine. These exclusion and inclusion criteria 
are detailed in Figure 2.1.  
2.3.2 Chemical Biomarker Measurements 
We define chemical biomarker as an indicator of environmental exposure that can be 
measured in blood, serum, or urine. We replaced all measurements below the limit of detection 
(LOD) with the LOD divided by the square root of 2  131, as recommended by the CDC to produce 
reasonably unbiased means and standard deviations 132. At times, NHANES identified a problem 
of interference from molybdenum oxide that resulted in corrected concentration of urinary 
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cadmium recorded as 0 ng/mL (NCHS, 2005a, NCHS, 2005b). Log-transforming such data would 
be undefined, therefore such measurements were replaced with the LOD divided by the square 
root of 2 if the participant’s urinary cadmium level was under the LOD or otherwise excluded. We 
calculated detection frequencies for each chemical biomarker and excluded biomarkers with 
detection frequencies of 50% or less (n = 173). Across the NHANES cycles, improvements in 
laboratory technology can change the LOD and thus influence changes in detection frequencies by 
NHANES cycle. To prevent such influence, we calculated detection frequencies by NHANES 
cycle for each chemical biomarker and excluded measurements that showed drastic changes in the 
LOD and detection frequencies over time. For instance, percentages of participants with PCB 196 
measurements above LODs for Cycle 2 and Cycle 3 are 37.8% and 86.7%, respectively, and the 
LOD for Cycle 2 and Cycle 3 were 10.50 ng/g and 0.40 ng/g, respectively. As such, measurements 
from Cycle 2 for PCB 196 were excluded (Figures A1.1 and A1.2). Measurements from given 
cycles for all PCBs, Dioxins, and Furans along with 2-(N-methyl-PFOSA) acetate, 2,4-D, 
Paranitrophenol, and 1-pyrene (n = 134,453) were therefore also excluded based on these criteria 
(Table A1.1). We also excluded biomarkers that are not indicative of exposure (n = 30). We 
preferred lipid adjusted measurements for biomarkers indicated by 7- or 8-letter NHANES 
codename ending in “L” or “LA,” respectively, for which NHANES provided both lipid-adjusted 
and non-lipid adjusted measurements, and excluded non-lipid adjusted chemical biomarkers (n = 
79). Finally, transition from the early to recent NHANES cycles resulted in differences in 
NHANES chemical codenames, which we corrected to reflect a unique codename for each 
biomarker (n = 22). The final dataset for analysis consisted of 141 chemical biomarkers from 16 
different classes.  
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2.3.3 Half-Lives of Organic and Inorganic Substances in Humans 
The biological half-life of a chemical is an important factor to explain differences in 
chemical biomarker levels across the life-stages 73. To determine a set of relevant half-lives, we 
first developed a table of NHANES codenames and corresponding CAS No. for each chemical 
biomarker (Table A1.2). We then matched metabolite biomarkers to their corresponding parent 
compounds. For biomarkers that are metabolites of several parent compounds, we developed the 
composite half-life by summing the half-life of the metabolite with the maximum half-life of the 
corresponding parent substances. This assumes the parent substance or compartment with the 
highest persistence drives the persistency of the metabolic biomarker. We searched a database of 
empirically-based whole body elimination half-lives and identified 39 chemicals on the list 133. For 
an NHANES chemical biomarker that is a mixture of two substances, i.e. m-/p-Xylene, we applied 
the average of the substance’s half-life. Thirty nine of the 118 organic chemicals in this study have 
empirically-based whole body elimination half-lives available in the OECD QSAR ToolBox 
(https://www.qsartoolbox.org/). Since estimated persistency of PFASs showed high variability 
with estimates up to 220 years, empirically based half-lives were selected from literature for this 
chemical class (Text A1.1 and Table A1.3). For organic chemicals that are not in the empirical 
database, the total elimination (intrinsic) half-life was predicted using a screening-level 
Quantitative Structure-Activity Relationship (QSAR) 133. The model is a fragment-based QSAR 
that was developed and validated following OECD QSAR guidance 134,135. Since these QSARs are 
only applicable to organic substances, we identified the half-lives of inorganic substances in 
humans through a review (Table A1.4). In selecting literature half-lives, we preferred 1) human 
half-lives over those from animals, 2) half-lives from animal species that are anatomically similar 
to humans if human data were not available, and 3) slower elimination kinetics over rapid kinetics. 
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We selected the maximum half-life for 1) inorganic chemicals that have multiple half-lives for a 
given biological compartment, and for 2) chemicals with half-lives available for multiple 
biological compartments, e.g. body, bones, blood, or lungs. Table A1.5 tabulates the methods used 
to find or estimate half-life for each chemical biomarker.  
2.3.4 Restriction Dates  
It has been suggested that the time-lapse between a chemical’s restriction date and sample 
collection date is an important contributor to biomarker concentration time trends and age-based 
differentiations 73. To investigate this, we developed a database of restriction dates (years) in US 
commerce through an extensive review (Table A1.6 and A1.7). Some chemicals have several 
reported restriction dates, in particular those that were restricted from different products in 
different years, such as lead. Note that some chemicals were restricted in certain applications but 
not in others. For instance, the use of lead was banned in paint 136 and gasoline 137, but it is still 
used in cosmetic products 138 and plumbing 139,140. Also, some chemicals have been gradually 
phased out over several years, such as PFASs. For chemicals with dates recorded as a range, and 
for which we were unable to determine the relative importance of a given year, we applied the 
mean year. When there are several dates associated with a chemical biomarker, we applied the 
latest date to represent the most recent period that the substance was banned or phased out.  
2.3.5 Statistical Analysis  
We performed all analyses using R version 3.5.1. We first defined 11 different age groups 
to compare chemical biomarker differences by age and then partitioned the distribution of each 
chemical biomarker by age group and NHANES cycle. To aid data visualization, such as in Figure 
2.5, we adjusted concentrations of urinary chemical biomarkers by urinary creatinine levels 141. 
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For a given biomarker, we used ANOVA to test for differences among geometric means of 
chemical concentration across age groups. 
In NHANES, deliberate oversampling was commonly employed to detect susceptible 
subpopulations at risk for exposures and/or disease 142. As such, generalizing the results to the US 
population requires the application of survey weights to account for the sampling design, but this 
decreases statistical power in identifying associations within the susceptible and oversampled 
subpopulations 143. We applied the survey weights in our statistical models for a few chemical 
biomarkers and identified minor differences between the weighted and unweighted regression 
coefficients for age. Due to this minimal influence, survey weights were not included in our 
statistical analyses.  
We used multivariate regression models to evaluate the influence of age and time on the 
chemical biomarker concentrations in blood and urine after log-transformation of these data. We 
included log-transformed levels of cotinine as a covariate to represent smoking (Benowitz, 1999), 
and creatinine levels to adjust for urine dilution and flow differences (Barr et al., 2005). We 
modeled poverty income ratio (PIR), i.e., the ratio of household income and poverty threshold 
adjusted for family size and inflation, as a surrogate variable for socioeconomic status. First, we 
examined the influence of age and time on chemical biomarker concentrations by performing a 
series of chemical-specific regression models with the main predictors of age centered at $!"#%%%%%% 
(continuous), survey cycle (continuous), sex (categorical), race/ethnicity (categorical), PIR 
(continuous), and cotinine (continuous) as described in Equation 1 without the term for age 
squared:  &'(10($)*#+,-!.	)01-#123!2,014) = 	!!"#($!"# − $!"#%%%%%%) + 																																																																					!!"#!($!"# − $!"#%%%%%%)% + 																																																			!-5-.#$-5-.# + 
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																																													!4#6$4#6 + 																																																																																	!3!-#/#2*1,-,25$3!-#/#2*1,-,25 + 																																													!89:$89: + 																																																												!-02,1,1#$-02,1,1# + 																																																																				!-3#!2,1,1#$-3#!2,1,1# + 										1,																																																																			[1]  
where XChemical Concentrations is the log-transformed, unadjusted chemical biomarker 
concentration for all participants, Xi, where i ϵ {age, age2, cycle, sex, race/ethnicity, PIR, cotinine, 
creatinine}, is the i covariate for all participants, βi  is the linear regression coefficient for the i 
covariate, and α is the intercept. For urinary chemical biomarkers, we further corrected the 
regression models by adjusting for urinary creatinine levels (continuous). For cotinine, the 
regression models were not corrected for cotinine. Age coefficient (!!"#.,1#!3) and cycle coefficient 
(βcycle) are interpreted as the change in log-transformed chemical biomarker concentration due to 
a one-year increase in age or a one-survey-cycle increase in time, respectively. To account for 
multiple comparisons, we used a False Detection Rate (FDR) method on the p-values of the linear 
regression age-coefficients 103.  
To evaluate nonlinear relationships between chemical biomarker levels and age, and 
systematically identify chemicals that are of higher concentrations in children, we included age 
centered at $!"#%%%%%% squared as another main predictor as shown in Equation 1. Age was centered at $!"#%%%%%%  to reduce the collinearity between the linear and quadratic age predictors to assess the 
separate contribution of these terms. We denote the age coefficient of the nonlinear regression 
models as !!"# 	to differentiate it from that of the linear models, !!"#.,1#!3. It is interpreted as the 
change in log-transformed chemical biomarker concentration due to a one-year increase in 
age.	!!"#! is interpreted as the change in the slope relationship between chemical concentrations 
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and age for a one-year increase in age. We assumed a quadratic association between chemical 
biomarker levels and age to capture how biomarker levels may change non-monotonically across 
the life stage and for ease of interpretation.  
Using !!"# and 	!!"#!, we defined a metric (5-*,.;3#1) to rank the chemicals from most 
concerning to least concerning for children as described in Equation 2: 5-*,.;3#1 = !!"#($!"# − $!"#%%%%%%) + 	!!"#!($!"# − $!"#%%%%%%)%																																											[2] 
where $!"# is designated to 5 years old for this analysis (Table A1.8). A more positive 5-*,.;3#1 
is indicative of higher chemical biomarker levels in children followed by a downward, convex 
trend across the older age groups. 104"#$%&'() is interpreted as the fold difference in chemical 
biomarker levels between a child of 5 years and adult of 31.88 years. To define a boundary line to 
differentiate the chemicals of higher exposures in children compared to those in adults, we solved 
for !!"#! !!"#⁄  when 5-*,.;3#1 = 0 from Equation 2 and calculated the slope of the boundary line 
to be $<*+(=======><*+( = $%&.(. Any chemical with 5-*,.;3#1 = 0 implies that biomarker levels are the same 
between a child of 5 years and adult of 31.88 years. Using the regression coefficients, we predicted 
the log-transformed chemical biomarker levels for all participants with complete data on age, 
cycle, sex, race/ethnicity, PIR, and cotinine. Predictions are not available for children between one 
to two years of age, since measurements for blood cotinine in this age group were missing. 
To understand how differences in chemical biomarker concentrations between young and 
older individuals change over time, i.e., how age-based trends are changing over time, we 
conducted stratified analyses by NHANES cycle. We first partitioned life-stage changes in 
chemical biomarker concentrations by NHANES cycles and fitted these cycle-specific 
concentrations with smooth curves through LOESS (locally weighted scatterplot smoothing) 144. 
Then for each cycle with measurements, we performed a chemical-specific linear regression with 
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age (continuous) as the main predictor while adjusting for sex (categorical), race/ethnicity 
(categorical), PIR (continuous), and smoking (continuous) described in Equation 3:  						&'(10($)*#+,-!.	)01-#123!2,014[678&9 = :]) = 	!!"#,@$!"#[678&9 = :] + 																																																										!4#6,@$4#6[678&9 = :] + 																																																																																														!3!-#/#2*1,-,25,@$3!-#/#2*1,-,25[678&9 = :] + 																																																										!89:,@$89:[678&9 = :] + 																																																																									!-02,1,1#,@$-02,1,1#[678&9 = :] + 																																																																																!-3#!2,1,1#,@$-3#!2,1,1#[678&9 = :] + 																										1@ ,																																																																							 [3] 
where k is the available cycle number that can range from 1 to 8, XChemical Concentrations[Cycle 
= k] is the log-transformed, unadjusted chemical biomarker concentrations of participants in the 
kth cycle, Xm[Cycle = k], where m ϵ {age, sex, race/ethnicity, PIR, cotinine, creatinine} is the m 
covariate for all participants in the kth cycle, βm,k is the linear regression coefficient for the m 
covariate in the kth cycle, and αk is the intercept for the kth cycle. The linear regression age 
coefficient (βage,k) is interpreted as the change in log-transformed chemical biomarker 
concentration due to a one-year increase in age for a given kth cycle.  
2.4 Results 
2.4.1 Study population 
Table 2.1 presents population characteristics for the 74,942 NHANES participants from 
1999-2014. The mean age ($!"#%%%%%%) is 31.88 (SD 24.28) with approximately 42.1% of the population 
being 18 years old or younger. This indicates children are oversampled, since according to the US 
Census, 26% of the US civilian noninstitutionalized population are below 19 years of age. The 
number of participants across the cycles does not vary drastically. The population is evenly 
distributed by sex with approximately 51% of the population being female. All race/ethnicity were 
oversampled, except for Non-Hispanic Whites, since according to the US Census, the proportions 
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of Hispanics, Non-Hispanic Blacks, and Other Race are 17.8%, 13.3%, and 9.8%, respectively 145. 
The mean of PIR is 2.301 (SD 1.59). The means of cotinine and creatinine levels were 38.39 (SD 
103.80) ng/mL and 130.3 (SD 81.98) mg/dL, respectively.  
2.4.2 Age-Based Trends, Half-Lives, and Restriction Dates 
Figure 2.2A shows the number of biomarkers for each chemical class, and Figure 2.2B 
shows the range of log-transformed half-lives for each chemical class with a dashed line 
representing one year (Table A1.5). Chemical classes with half-lives in the range of 1 to 100 hours 
include Phthalates, Acrylamide, Other, Smoking Related Compounds (SRCs), Phytoestrogens, 
Polycyclic Aromatic Hydrocarbons (PAHs), Personal Care and Consumer Product Compounds 
(PCCPCs), Volatile Organic Compounds (VOCs), and Melamine, while classes with more 
persistent chemicals include Brominated Flame Retardants (BFRs), PFASs, PCBs, Dioxins, and 
Furans. Chemicals from the Metals and Pesticides classes demonstrate a wide range of persistency 
in the human body.  
Figure 2.2C shows ranges of !!"#.,1#!3′5 for each chemical class. These values are 
interpreted as the log change in chemical concentration for a one-year increase in age. The majority 
of chemicals from PCBs, Furans, Dioxins, Melamine, Metals, and Pesticides along with a single 
BFR (2,2',4,4',5,5'-hexabromobiphenyl) have high positive ranges of !!"#.,1#!3′5, indicating higher 
concentrations in the older population. In contrast, most of the phthalates, SRCs, and BFRs along 
with a few VOCs, PCCPCs, PAHs, and phytoestrogens have negative !!"#.,1#!3′5, reflecting higher 
concentrations in younger individuals. The majority of chemical biomarkers have !!"#.,1#!3′5 
between -0.01 and 0.01, suggesting small or no differences in chemical biomarker levels across 
the life-stages.  
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Figure 2.2D shows the proportions of unrestricted or restricted chemicals for each class, 
and Table A1.7 tabulates the restriction dates. Since the latest data were from 2013-2014, 
chemicals with restriction dates after 2014 are categorized as having no restriction. Chemical 
classes with higher proportions of unrestricted chemicals include Acrylamide, Other, SRCs, 
VOCs, and Melamine, and these have limited !!"#.,1#!3′5. In contrast, PCBs, Dioxins, and Furans 
show higher proportions of historically restricted chemicals and have the highest !!"#.,1#!3′5 and 
high half-lives. The majority of BFRs, PCCPCs, and PFASs have been restricted more recently 
and have limited !!"#.,1#!3′5 despite PFASs having high half-lives. The Metal and Pesticides classes 
demonstrate a wide variety of restriction types, with most of the persistent chemicals in these 
classes having been restricted before the turn of the century.  
Figure A1.3 and Text A1.2 further analyze changes in biomarker levels over the NHANES 
cycles, demonstrating a decrease in chemical biomarker levels over time for the majority of 
pesticides and PFASs show, while a few pesticides, phthalates, and PAHs have increasing time 
trends.  
2.4.3 Influence of Temporal Determinants on Linear Age-Based Trends 
To understand the influence of chemical persistence in the body, time trends, and restriction 
dates on differences in chemical biomarker concentrations across the life-stages, we examined the 
association between the !!"#.,1#!3′5 and human whole body elimination half-lives for all chemical 
biomarkers, color-coded by 1) restriction dates (Figure 2.3) and by 2) time trend trajectories 
(Figure A1.4). Chemical biomarkers with half-lives less than one year have !!"#.,1#!3′5 ranging from 
-0.01 to 0.01, indicating limited variation across life-stages. For these chemicals, cross-sectional 
biomonitoring data is primarily reflective of present exposures in different age groups or 
populations  73. In contrast, chemical biomarkers with half-lives greater than one year demonstrate 
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more variation across life-stages and show a positive association between the !!"#.,1#!3′5 and half-
lives. The majority of these persistent chemicals were banned or phased out between the 1970s 
and 1999 (blue markers in Figure 2.3). This implies exposures of the younger population have 
been strongly reduced, and that higher concentrations observed in the older population are likely 
due to historical exposures and long biological half-lives. Despite the long half-lives of BFRs and 
PFASs, !!"#.,1#!3′5 of these chemical classes are substantially lower than those of other persistent 
substances with similar half-lives. The lower 	!!"#.,1#!3′5 with age may be explained by the fact that 
these chemicals have been recently restricted or are still in use (red and yellow markers in Figure 
2.3) and that current exposures remain higher than exposures to legacy pollutants that were banned 
earlier. Of special concern are chemicals with negative	!!"#.,1#!3′5, since these chemicals are of 
higher levels in the younger population compared to the aged population. Most of these chemicals 
are unrestricted (red markers in Figure 2.3) and demonstrate an increasing or stable time trend 
(red and orange markers in Figure A1.4). 
2.4.4 Nonlinear Age-Based Pattern of Higher Levels in Children 
Since a linear relationship between age and log-transformed biomarker levels may not be 
representative for chemicals that display a nonlinear relationship with age, we refined the 
chemical-specific regression models to have age squared centered at $!"# as another main 
predictor to better characterize this relationship. Figure 2.4 summarizes the results for age from 
the quadratic regression model by presenting the association between !!"#! 	and !!"# for all 
chemical biomarkers. The chemical classes are indicated by difference shapes, while the colors 
show the different categories of fold difference in chemical biomarker levels between a child of 5 
years and adult of 31.88 years. For instance, mono-benzyl phthalate levels in 5-years-old children 
are on average 2.598 times higher compared to those for 31.88-years-old adults. A positive !!"#! 
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indicates a convex (or u-shaped) relationship between log-transformed chemical biomarker levels 
and age, while a negative !!"#! indicates a concave or (n-shaped) relationship.  
Chemicals in the upper left quadrant are of interest, since these are higher in 5-years-old 
children compared to 31.88-years-old adults by more than a factor of 2. Most of these chemicals 
are metals, pesticides, and phthalates used in building materials and articles. Based on Equation 2, 
the boundary line corresponds to equal biomarker levels for a child of 5 years and an adult of 31.88 
years. Chemicals above and to the left of the boundary line (!!"#! !!"#⁄ > $<*+(=======><*+( = $%&.() have 
a downward and convex trend across age groups, implying the highest biomarker levels for the 
youngest participants. The highest levels in children compared to adults of average age are 
observed for mono-benzyl phthalate, O-Desmethylangolensin (O-DMA), mono-(3-
carboxypropyl) phthalate, 2-amnothiazolne-4-carbxylic acid and tungsten. Table A1.8 provides a 
detailed list of chemicals ranked from highest to lowest relative value between children and adults 
of average age. 
To further compare chemical biomarker distributions across the different life-stages and 
identify linear and nonlinear age-based trends, we stratified these distributions into 11 age groups 
(Figure 2.5) and selected example chemicals to represent the specific age-group trends within a 
chemical class. The geometric mean of the measured chemical biomarker levels for each age group 
is represented by a gray circle, while the geometric mean of the predicted chemical biomarker 
levels is indicated by a brown triangle. Outliers are represented by dash marks outside of the 
distributions of chemical biomarker concentration. A residual standard error (RSE) of 0 implies 
the model perfectly predicts the log-transformed biomarker levels. Geometric mean of predicted 
chemical biomarker levels for the 1-2 age group is unavailable, since cotinine was not measured 
in these participants. 
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Overall, the nonlinear regression models predicted the measured geometric means fairly 
well, particularly for children, middle-aged adults, and the elderly. The models, however, 
overestimated biomarker levels for tungsten, phthalates, and parabens in the adolescent age group, 
and underestimated lead in the toddler age group, indicating the need for a higher order polynomial 
model rather than a parabolic regression model for these specific cases. 
The following section analyzes in further detail these age trends by chemical class and type 
of usage. 
2.4.5 Age-Based Trends by Chemical Class 
2.4.5.1 PCBs, Dioxins, and Furans 
For PCBs, there are three main age patterns: a slight downward and convex trend, a steep 
upward and concave trend, and no trend across the life stage (Figure 2.4). The PCBs with half-
lives less than one year (Figure 2.3) showed little or no variation in chemical biomarker 
concentrations by age. PCB 49 (Figure 2.5A) and PCB 44 are the only two PCBs for which the 
youngest participants have the highest biomarker levels, with their negative !!"# and positive !!"#! characterizing a slight downward and convex trend across the age groups. This might 
indicate children are exposed through a pathway specific to these two congeners. In contrast, the 
more persistent PCBs, dioxins and furans have higher concentrations in the older population, 
except for 1,2,3,4,6,7,8-Heptachlorodibenzofuran (half-life of 3.58 years), which has a βage of -
0.0021. This may indicate ongoing exposure despite this chemical having been banned much 
earlier. With the highest !!"# of 0.037 and a !!"#! of -0.00033, PCB 194 illustrated well (Figure 
2.5B) a steep upward and concave trend across the age groups with the oldest participants having 
at most a 100-fold difference in biomarker levels compared to the youngest age group. This 
tendency is confirmed in the pooled serum concentrations observed for four age groups (12-19, 
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20-39, 40-59, 60+) in 2005-2008 by different race-sex combinations (details in Text S3, Section 
4). Age is a good predictor of biomarker levels for the more persistent PCBs, with an adjusted 
correlation coefficient (R2) ranging between 0.37 and 0.72 for most PCBs, with the exception of 
PCB 28 (R2 = 0.035), PCB 44 (R2 = 0.036), and PCB 49 (R2 = 0.041). 
2.4.5.2 PFASs 
PFASs are also highly persistent, but their !!"#′5 do not vary as substantially as those of 
PCBs. Most of the PFASs have !!"#′5 close to 0, indicating there is little to no difference by age 
and implying ongoing exposures. PFNA shows little to no variation across age groups (Figure 
2.5C). On the other hand, PFOA and PFOS show a slight upward and convex trend across the age 
groups (Figure A1.5 and 2.5D). This is confirmed by a !!"# of 0.0029 and a !!"#! of 3.27E-05 
for PFOS, and by a !!"# of -5.80E-05 and a !!"#! of 2.97E-05 for PFOA. Since PFOS and PFOA 
were phased out in 2002 146–148, differences across the age groups are substantially smaller than 
those observed in PCB 194, which was banned in 1979. Such differences across the life-course, 
however, are expected to increase in the future as articles and materials containing PFASs will 
reach the end of their usable life. A specific trend analysis is presented in the next section for these 
PFASs to illustrate how the age-based trends vary across the different cycles. 
2.4.5.3 Metals  
Another class of highly persistent chemicals is the Metals. Although many of the metals 
demonstrate a stable trajectory over time (yellow markers in Figure A1.4), there are high 
variations in chemical biomarker levels across the life-stages, with three different types of age 
group patterns evident (Figure 2.3 and 2.4). Cadmium demonstrates higher urinary concentrations 
in the older population with a !!"# of 0.014 and a !!"#! of -9.22E-05, denoting a slight upward 
and concave trend across the age groups (Figure A1.6). Lead is one of the few chemicals with 
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measurements in children 1 to 4 years old. Although the βage of lead (0.0039) is not as high as that 
of cadmium, the convex trend of lead (!!"#! = 8.72E-05) across the age groups indicates the 
youngest and oldest age groups have the highest biomarker concentrations compared to the other 
age groups (Figure 2.5F). Although tungsten has similar persistency to cadmium and lead, it has 
a !!"# of -0.0069 and a !!"#! of 0.00015, indicating a downward, convex trend across the age 
groups (Figure 2.5E). This is also indicative of high and ongoing exposures in the younger 
population. 
2.4.5.4 Phthalate and Parabens 
Most phthalates are used as plasticizers. These phthalates show a similar age group pattern 
to that of mono-(3-carboxypropyl) phthalate - a metabolite of mono-n-butyl phthalate, di-n-butyl 
phthalate, mono-n-octyl phthalate, and di-n-octyl phthalate (Figure 2.5G), and mono-benzyl 
phthalate (Figure 2.5H), with the highest concentration apparent in the youngest age group, a 
decrease during adolescence and young adulthood, and then stabilization for older age groups. In 
contrast, mono-ethyl phthalate is mostly used in cosmetics and demonstrates a very different age 
group pattern from those in its chemical family (Figure 2.5I). It has a similar age group pattern to 
chemicals used in cosmetics such as methyl paraben (Figure 2.5J). Methyl paraben has a slight 
upward and concave trend across the 5-12, to 13-18, and 19-28 years-old participants. Its levels 
peak for the mature adults and show a slight decrease in older age groups.  
2.4.6 Change in Age-Based Trends of PFASs over Time 
To determine how the age-based trends are changing over time, we fitted smooth curves to 
the life-stage changes in chemical biomarker concentration for each available NHANES cycles 
and conducted a series of linear regression models stratified by cycle to extract the βage,k’s. The 
βage,k’s shows the overall difference in chemical biomarker concentration between the young and 
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aged populations for a given NHANES kth cycle. Understanding how these βage,k’s change over 
time provides insight on how the difference between the youth and elderly changes across the 
cycles. In addition, these βage,k’s will help determine how long a time lapse must occur between 
the restriction date and sample collection date in order to observe these life-stage differences.  
PFASs were further analyzed, since some have been recently phased out and have 
measurements spanning over six or more cycles. PFOS, Perfluorohexane sulfonic acid (PFHxS), 
PFOA, Perfluorodecanoic acid (PFDA), PFNA, and 2-(N-methyl-PFOSA) acetate were selected 
due to their high detection frequencies for each available cycle. Figure 2.6 presents how the age-
based trends are changing over time. Each curve represents the variation in chemical biomarker 
concentration by age for a given NHANES cycle. A vertical shift in an ith cycle curve indicates 
how the chemical biomarker concentrations have increased or decreased compared to those in the 
(i-1)th cycle. The steepness of the curve shows the rate at which the log-transformed chemical 
concentration is changing with each one-year increase in age for a given cycle, providing insight 
on how the differences in chemical biomarker levels between the youth and elderly are changing 
over time. An increase in the βage,k’s indicates the difference between the young and aged 
populations are expanding over time. 
Between 1999-2000, the βage,1 for PFOS is 6.51E-4 (p-value = 0.025). If we assume 
chemical biomarker concentrations change linearly with age, then this value implies a 1.13-fold 
difference (1080×6.51E-4 = 1.13) in chemical concentration between an 80-year old participant and a 
newborn (aged 0). Between 2013-2014, the βage,8 is 6.49E-3 (p-value = 2.63E-59) with a 3.3-fold 
difference. This suggests that a decade after the phase-out of PFOS, the aged population has 
approximately a 3-fold difference in PFOS levels compared to the youth (Figure 2.6A and 2.6G). 
As the biomarker levels of PFOS and 2-(N-methyl-PFOSA) acetate decrease across the cycles, 
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illustrated by the downward shifts in the concentration-age curves, the difference between the 
youth and elderly increases. This is evidenced by the increasing steepness of these curves (Figure 
2.6A and 2.6F) and the upward trend in βage,k’s (Figure 2.6G). These patterns imply the use of 
PFOSA stopped around the time of the restrictions on PFOS and PFOA in 2002. A similar pattern 
can be observed with PFHxS and PFOA concentrations, but the differences between the young 
and aged populations for these chemicals do not change as drastically they do for PFOS and 
PFOSA (Figure 2.6B, 2.6C, and 2.6G). These patterns suggest that as the time increases between 
the restriction and sample collection dates, the differences by age will become more prominent. 
On the other hand, PFHxS, PFDA, and PFNA display different trends over time. For 
instance, biomarker levels for PFHxS initially decrease during 1999-2006, increase in 2007-2008, 
and then decrease again for the more recent NHANES cycles. For PFDA, biomarker levels increase 
from 1999 to 2006 and then decrease afterward. Biomarker levels of PFNA increase during the 
early NHANES cycles and then decrease after 2009-2010, but the PFNA levels for 2013-2014 are 
on average higher than those between 1999-2000 especially for children. The cycle-specific age 
coefficients for PFNA fluctuate during the early NHANES cycles but then show a strictly 
increasing trend after 2007-2008 (Figure 2.6E and 2.6G). These fluctuations in biomarker levels 
suggest PFHxS, PFDA, and PFNA may have been used as substitutes for PFOS and PFOA and 
reflect ongoing exposure throughout the population.  
2.5 Discussions 
In this article, we present a comprehensive analysis of age-based and time trends in 
chemical biomarker concentrations in the US population. We have accounted for biological half-
lives of chemicals, type of usage, and historical events, i.e., dates of chemical bans and phase-outs, 
which are expected to influence population-level exposures. These results provide insight on 
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population exposure trajectories. They are also informative for differentiating legacy exposures 
from current exposures and for identifying chemicals of higher levels in the younger population.  
For restricted chemicals, our data confirm that a minimum persistence of 1 year in the 
human body is necessary to observe substantial differences between the young population and 
historically exposed adults. Biological half-life is not the only determinant of high chemical 
biomarker levels in the aged population, however. Studies on age-based and time trends of 
biomonitoring data have suggested the potential influences of bans, phase-outs, bioaccumulation, 
metabolic rates, and consumer product usage on such trends 28,65,121–123, with the most influential 
determinant for simulated longitudinal data being the time lapse between the peak of emission and 
the sample collection 73. Thus, elevated concentrations in the elderly population are primarily due 
to a combination of past exposure and slow elimination. Using measured biomonitoring data for a 
wide range of chemicals, we confirm that chemicals with high age coefficients primarily have a 
biological half-life longer than 1 year and have been banned or phased out for longer than the 
chemical’s half-life. This evidences the efficacy of public health interventions, such as the 
International Stockholm Convention on Persistent Organic Pollutant, to reduce or prevent high 
exposures and associated health outcomes for the younger population effects 71,72.  
PFASs are also persistent, with half-lives ranging from 1.6 years to 7.3 years, yet show 
minimal differences in biomarker concentrations across the life-stages. These substances 
demonstrate contrasting age-based patterns even within the same family. For instance, we 
observed a substantial reduction in PFOA and PFOS levels in children, but levels of PFNA and 
PFHxS in children during 2013-2014 are still higher or equal than those in the earlier NHANES 
cycles. This indicates ongoing and higher exposures for the younger population. Such exposures 
to PFASs may occur through breastfeeding 149–151 or drinking contaminated water 125,126. In 
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addition, this pattern could be due to the fact that some of these chemicals were recently phased-
out, or due to the short time lapse between the emission peak and the sample collection. The time 
lapse of a decade for PFASs is shorter than the time lapse of almost 30 years for PCBs. Thus, it 
can be inferred that as this time lapse increases, especially if it exceeds the half-life of the 
substance, the difference in PFASs concentrations by age will continue to increase (Quinn and 
Wania 2012, Gomis et al. 2017).  
While cadmium levels are lower in the younger population, this is not the case for lead and 
especially tungsten for which the younger population has surprisingly higher biomarker levels. 
Higher lead levels have been attributed to consumer products usage, such as toys and children 
jewelry 62,152, exposures to dust and soil 153,154, and exposures via maternal transfer in utero or 
during breastfeeding 155,156. For the older participants, high lead levels may be due to leaded 
gasoline combustion before tetraethyl lead in gasoline was banned 137. High tungsten levels in 
children may be due to exposures to contaminated soil, articles from parents’ workspace, and 
electrical devices 157,158 (ATSDR 2005; Kampmann et al. 2002). The overall trend of higher levels 
in the 5-12 years old followed by a downward, convex trend across the older age groups suggests 
exposures in children may be driven by factors specific to this susceptible population. Hence, 
further research is necessary to elucidate potential reasons for higher exposures in children. 
For several less-persistent chemicals, such as phthalates that are widely used in consumer 
products, younger individuals seem to have been highly exposed, in addition to some persistent 
chemicals such as the BFRs, PFASs and lead. Our results suggest age-based trends in biomarker 
levels reflect product usage trends. Most phthalates show a plasticizer age pattern with higher 
concentrations in the 5-12 years old age group followed by a downward, convex trend across older 
age groups, which is quantified by a positive !!"#! and negative	!!"#. Children may be highly 
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exposed to these chemicals through frequent contact with flooring materials 59,61,159 and toys 160, 
which are products that typically have high levels of plasticizers. Also, children may more readily 
absorb these compounds 161. Metabolic rate is known to vary across age with a peak occurring 
during childhood and then stabilizing or decreasing during the senior years 52,53. In contrast, mono-
ethyl phthalate is used in personal care products 162 and shows a different concave pattern similar 
to other personal care products such as parabens and triclosan. The increase in exposure from 
children to teenagers may be explained by a greater use of cosmetic and/or skin care products 
during the teenage years 163–165. Comparing chemical levels by age group and quantifying trends 
across the age groups with !!"#! 	and !!"# enables us to identify two interesting clusters:  1) a 
cluster of phthalates used as plasticizers and 2) a cluster of chemicals used in personal care 
products. Mono-ethyl phthalate was shown to cluster with PCCPCs instead of with those in its 
chemical family. These age-based clusters of chemicals with similar product usage suggest a 
possibility to develop product-specific archetypes of intake pattern with e.g. a concave age curve 
for personal care products versus a convex age curve for plasticizers in articles and building 
materials. These archetypes could then be used to help extend mechanistic modelling approaches 
to predict direct exposures to chemicals used in consumer products. 
The present study has a number of limitations. By comparing chemical biomarker levels 
by age group, we have identified several chemicals, such as lead, tungsten, and phthalates, to be 
of higher concentrations in the younger population than in the older population. Although we have 
identified a number of potential reasons for higher exposures in children, we have not accounted 
for differences in metabolic rate within our models. Future extensions could determine surrogate 
variables to develop a scoring system to quantitatively represent metabolic rate and understand 
how it could confound age and chemical biomarker concentrations. As another limitation, we 
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assumed a quadratic relationship between age and chemical biomarker levels, but we did not test 
for other higher order polynomials that may better describe the changes in chemical biomarker 
levels across the life stage. Thus, future studies can compare the cross-validated prediction 
performance between a quadratic and cubic polynomial and/or even other higher order 
polynomials to determine whether a higher order polynomial would substantially improve the fit 
of the model to the data. Finally, while we demonstrated an overarching, statistical approach to 
identify chemicals that are of higher concentrations in children, there is a need to understand 
toxicological effects of these chemicals along with identifying sources and pathways of exposures 
to prevent elevated chemical levels and the onset of adverse health effects 71,72,166. 
Though we defined an age pattern of concern for children, quantifying exposure for young 
children, especially those below the age of 4, was limited to a few chemical biomarkers such as 
lead, manganese, cadmium, methyl mercury, cotinine, acrylamide, and glycideamide. Due to the 
ban of legacy chemicals such as PCBs, Furans, and Dioxins, fewer measurements are available in 
children, and children have substantially lower levels of these persistent substances. This creates 
challenges in understanding sources of exposures for these legacy chemicals in children. Thus, 
future studies can use the 2001-2016 biomarker data of PCBs for pooled samples to characterize 
differences by age group to gain more insights on sources of exposures in children. However, a 
challenge of using pooled data is that demographic and questionnaire data are limited. As shown 
with lead, predictions were unavailable for children below the age of 2, since cotinine was not 
measured for these participants. Thus, when more measurements for children become available, 
future extensions could incorporate such data to better quantify and predict exposure for this 
susceptible population as well as understand sources of such exposures.  
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Geographical location has been identified as a confounder of chemical exposure disparities, 
particularly for heavy metals, but we did not consider this as a covariate in this study. Future 
studies could consider geospatial variations in chemical biomarker concentrations to 
systematically address geographical location as a confounder.  
For lipophilic chemicals, we preferred the lipid-adjusted measurements, since these 
measurements were normalized to the blood lipid content of the participants. In addition, adipose 
content tends to increase as a person age, which can potentially lead to higher concentrations of 
more lipophilic compounds in the aged population. Even though BMI could modulate the 
concentration-age associations, we did not consider it as a covariate, since we wanted to study the 
BMI mediated effect of age on chemical biomarker levels. Future extensions could further explore 
the confounding nature of BMI on age-based and time trends of chemical biomarker levels.   
2.6 Conclusions 
This study presents a framework for systematically analyzing and interpreting 
biomonitoring data, to better understand chemical biomarker differences across the life-stages. We 
suggest different criteria for determining which chemicals are reflective of legacy exposures vs. 
current exposures and identify an age pattern of concern when longitudinal data are unavailable or 
incomplete. We confirm the criteria indicative of legacy exposure as follows: 1) biological half-
life of at least one year, 2) decreasing average biomarker concentration over time due to the 
chemical being banned or phased out, and 3) the time lapse between emission peak and the sample 
collection exceeding the human elimination half-life. For chemicals below the one-year half-life 
mark, cross-sectional biomonitoring data mostly reflect recent intake rates. In addition to 
confirming the criteria for legacy versus relevant exposures, the complementary analysis 
combining a series of regression models with systemized stratified analyses by age group helped 
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us define an age-based pattern for identifying chemicals of higher and ongoing exposures in 
children. This is especially evident when a chemical biomarker has an increasing or stable time 
trajectory, demonstrates a convex relationship with age, and is of higher concentration in the 






Figure 2.1. Schematic description of the process to curate chemical biomarker measurements and 




Figure 2.2. Characteristics of the 141 NHANES chemical biomarkers for 16 classes, including (A) 
the number of chemical biomarkers for each colored-specific chemical class, (B) ranges of log-
transformed composite half-lives in hours, (C) ranges of linear age coefficients (!!"#.,1#!3′5), 
defined as the log change in chemical concentration due to a one-year increase in age, and (D) 
percentage of unrestricted or restricted chemicals per class. Colors of the restriction types only 
applied to (D) and are also used in Figure 2.3. BFRs, Brominated Flame Retardants; SRCs, 
Smoking Related Compounds; PAHs, Polycyclic Aromatic Hydrocarbons; PCCPCs, Personal 
Care and Consumer Product Compounds; VOCs, Volatile Organic Compounds; PFASs, Per- and 
Polyfluoroalkyl substances; PCBs, Polychlorinated Biphenyls. Models were adjusted for age 
centered at ($!"#%%%%%%), survey cycle, sex, race/ethnicity, poverty income ratio, blood cotinine 




Figure 2.3. Association between linear age coefficients (!!"#.,1#!3′5) and chemical persistency in the 
human body for 141 substances with symbols indicating the different chemical classes. The colors 
indicate the time period during which the compound was restricted (same as Figure 2.2D). Models 
are adjusted for age centered at $!"#%%%%%%, survey cycle, sex, race/ethnicity, poverty income ratio, blood 




Figure 2.4. Association between !!"#! 	and !!"# for 141 substances with symbols indicating 
chemical classes and colors indicating categories of fold difference in biomarker levels between a 
child of 5 years and adult of 31.88 years. The boundary line !!"#! !!"#⁄ > 1 26.9⁄  differentiates 
chemicals of higher levels in children from those of higher levels in the older population. Models 
were adjusted for age centered at $!"#%%%%%%, age centered at $!"#%%%%%% squared, survey cycle, sex, 
race/ethnicity, poverty income ratio, blood cotinine concentrations, and urinary creatinine 





Figure 2.5. Violin plots of chemical biomarker concentrations partitioned by age group to display 
the 5th, 25th, 50th, 75th, and 95th percentiles, indicated by the superimposed boxplot. The 
frequency of chemical biomarker levels are represented by the width of the violins for (A) PCB 
49, (B) PCB 194, (C) PFNA, (D) PFOS, (E) Tungsten, (F) Lead, (G) Mono-(3-carboxypropyl) 
phthalate, (H) Mono-benzyl phthalate, (I) Mono-ethyl phthalate, and (J) Methyl paraben. (●) 
geometric mean of measured data. (▲) geometric mean of predicted chemical biomarker levels. 
Colors differentiate age groups. Models were adjusted for age centered at $!"#%%%%%% , age centered at $!"#%%%%%% squared, survey cycle, sex, race/ethnicity, poverty income ratio, blood cotinine 




Figure 2.6. Chemical biomarker concentrations across the life-stages stratified by NHANES cycles 
for (A) PFOS, (B) PFHxS, (C) PFOA, (D) PFDA, (E) PFNA, and (F) 2-(N-methyl-PFOSA) 
acetate. (G) 95% confidence intervals for the cycle-specific age coefficients for PFOS, PFHxS, 
PFOA, PFDA, PFNA, and 2-(N-methyl-PFOSA) acetate. The cycle-specific age coefficients 
(βage,k’s) with age shows the adjusted rate at which the chemical concentration is changing for a 
one-year increase in age for a particular cycle. Models were adjusted for age, sex, race/ethnicity, 









Age Groups N (%) Cycle N (%) Sex N (%) 
      1-2 4714 (6.29)       1999-2000 (Cycle 1) 8832 (11.79)       Male 36941 (49.29) 
      3-4 3307 (4.41)       2001-2002 (Cycle 2) 9929 (13.25)       Female 38001 (50.71) 
      5-12 12741 (17.01)       2003-2004 (Cycle 3) 9179 (12.25) Race/Ethnicity  
      13-18 10793 (14.40)       2005-2006 (Cycle 4) 9440 (12.60)       Mexican Americans 17199 (23.95) 
      19-28 8391 (11.20)       2007-2008 (Cycle 5) 9307 (12.42)       Other Hispanics 5580 (7.45) 
      29-38 7129 (9.51)       2009-2010 (Cycle 6) 9835 (13.12)       Non-Hispanic Whites 
28555 
(38.10) 
      39-48 7168 (9.56)       2011-2012 (Cycle 7) 8956 (11.95)       Non-Hispanic Blacks 
18055 
(24.09) 
      49-58 6209 (8.29)       2013-2014 (Cycle 8) 9464 (12.62)       Other Races  5553 (7.41) 
      58-68 6528 (8.71)     
      69-78 4676 (6.24)     
      79-85 3286 (4.38)     
CONTINUOUS 
 N (%)                 5th Median Mean (SD) 95th 
Age (years)                  2 25 31.88 (24.28) 77 
PIR (-) 68192 (90.99)                 0.30 1.82 2.301 (1.59) 5.00 
Cotinine 
(ng/mL) 54513 (72.74)                 0.011 0.066 38.39 (103.80) 282.00 
Creatinine 
(mg/dL) 63457 (84.67)                 26 116 130.3 (81.98) 284 
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Chapter 3 Racial Disparities in Chemical Biomarker Concentrations in United States 
Women 
 
3.1 Abstract  
Background: Stark racial disparities in disease incidence among American women remain 
a persistent public health challenge. These disparities likely result from complex interactions 
between genetic, social, lifestyle, and environmental risk factors. The influence of environmental 
risk factors, such as chemical exposure, however, may be substantial and is poorly understood. 
Objectives: We quantitatively evaluated chemical-exposure disparities by race/ethnicity, 
life stage, and time in United States (US) women (n=38,080) by using biomarker data for 143 
chemicals from the National Health and Nutrition Examination Survey (NHANES) 1999-2014.  
Methods: We applied a series of survey-weighted, generalized linear models using data 
from the entire NHANES women population along with cycle and age-group stratified 
subpopulations. The outcome was chemical biomarker concentration, and the main predictor was 
race/ethnicity with adjustment for age, socioeconomic status, smoking habits, and NHANES cycle.  
Results: The highest disparities across non-Hispanic Black, Mexican American, Other 
Hispanic, and Other Race/Multi-Racial women were observed for pesticides and their metabolites, 
including 2,5-dichlorophenol, o,p’-DDE, beta-hexachlorocyclohexane, and 2,4-dichlorophenol, 
along with personal care and consumer product compounds, including parabens and mono-ethyl 
phthalate, as well as several metals, such as mercury and arsenic. Moreover, for Mexican 
American, Other Hispanic, and non-Hispanic black women, there were several exposure 
disparities that persisted across age groups, such as higher 2,4- and 2,5-dichlorophenol 
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concentrations. Exposure differences for methyl and propyl parabens, however, were the starkest 
between non-Hispanic black and non-Hispanic white children with average differences exceeding 
4-fold. Exposure disparities for methyl and propyl parabens are increasing over time in Other 
Race/Multi-Racial women while fluctuating for non-Hispanic Black, Mexican American, and 
Other Hispanic. Differences in cotinine levels are among the highest in Non-Hispanic White 
women compared to Mexican American and Other Hispanic women with disparities plateauing 
and increasing, respectively.  
Discussion: We systematically evaluated differences in chemical exposures across women 
of various race/ethnic groups and across age groups and time. Our findings could help inform 
chemical prioritization in designing epidemiological and toxicological studies. In addition, they 
could help guide public health interventions to reduce environmental and health disparities across 
populations. 
3.2 Introduction 
The stark racial disparities in disease incidence and health outcomes among American 
women remain a persistent public health challenge. For example, preterm birth incidence is 
approximately 60% higher in non-Hispanic Black women relative to non-Hispanic White women 
167. Non-Hispanic Black and Hispanic women are at increased risk of being diagnosed with 
developing dysglycemia 168 and diabetes 169, relative to non-Hispanic White women. Non-Hispanic 
Black women are also 2-3 times more likely to develop the most aggressive subtype of breast 
cancer, triple negative, compared to non-Hispanic White women 79,80. Furthermore, relative to non-
Hispanic White women, non-Hispanic Black women are also 2.4 times more likely to die of breast 
cancer after being diagnosed with the pre-invasive lesion, ductal carcinoma in situ 170. Recent 
statistics from the American Cancer Society also show variation in trends in breast cancer 
 52 
 
incidence rates by race/ethnicity in US women from 2005-2014. Specifically, breast cancer 
incidence rates are increasing in Asian (1.7% per year), non-Hispanic Black (0.4% per year), and 
Hispanic (0.3% per year) women, while rates remain stable in non-Hispanic White and American 
Indian/Alaska Native women 171. Dementia rates also vary by race/ethnicity, with rates highest in 
non-Hispanic black women, followed by American Indian/Alaskan native, Latina, Pacific Islander, 
non-Hispanic White, and lowest in Asian American women 172. These rates vary 60% between 
African American and Asian American women. Reproductive outcomes are also significantly 
different by race/ethnicity, with studies reporting increased incidence of gestational diabetes in 
South and Central Asian American women 173 and Black and Hispanic women 174. Collectively, 
these findings suggest profound racial disparities in disease outcomes that manifest throughout the 
life course. Understanding the etiological factors driving these health disparities is essential for 
informing public health interventions seeking to promote health equity. 
While health disparities are likely due to complex interactions between genetic, social, and 
lifestyle factors, the impact of genetic variation on disease disparities appears to be minor 81–83. 
For example, a meta-analysis of genetic factors underlying racial disparities in cardiovascular 
disease failed to identify heterogeneity of genetic risk factors by race/ethnicity 175. These findings 
of a modest genetic impact on differential cardiovascular disease risk by race/ethnicity are 
consistent with genome-wide association studies. A study found that variants with the strongest 
association with blood pressure explain, in aggregate, less than 5% of the phenotypic variance 176. 
Moreover, a meta-analysis of genetic risk factors and cancer disparities reported similar findings, 
with almost no heterogeneity in cancer risk alleles by race/ethnicity 84.  
The limited impact of genetic risk factors in explaining health disparities points towards 
environmental risk factors as major determinants. Indeed, estimates of environmental factors on 
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chronic disease suggest than 70-90% of risk is due to environmental exposures 12,177. A mechanistic 
understanding of racial disparities in disease therefore requires a characterization of differences in 
environmental risk factors. In particular, differences in chemical exposures have been 
hypothesized to be important etiologic factors in racial disparities in disease rates 178–182. 
To investigate the influence of environmental risk factors on health disparities, the goal of 
this study was to conduct a comprehensive analysis of racial disparities in chemical biomarker 
concentrations among US women. To accomplish this, we leveraged data from the National Health 
and Nutrition Examination Survey (NHANES), an ongoing population-based health study 
conducted by the US Centers for Disease Control and Prevention (CDC). Additionally, we 
developed visuals to highlight differences in biomarker concentrations across races, age groups, 
and time, by defining the relative magnitude of exposure disparities for individual chemicals and 
chemical families.  
3.3 Methods 
3.3.1 Study Population 
NHANES is a cross-sectional study designed for collecting data on demographic, 
socioeconomic, dietary, and health-related characteristics in the non-institutionalized, civilian US 
population. For this analysis, we used the continuous NHANES data on chemical biomarkers and 
demographics, which were collected from 1999-2014 with 82,091 participants initially. We 
excluded participants for not having any data on chemical biomarkers (N = 7,001), resulting in a 
sample size of 75,090 study participants. Since this analysis is focused on measuring chemical 
disparities in US women, we excluded male participants (N = 37,010), leading to a final sample 
size of 38,080 female participants. For a given chemical, we also excluded participants with 
missing data on any of the following covariates:  race/ethnicity, age, NHANES cycles, poverty 
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income ratio, cotinine levels, and urinary creatinine. These exclusion and inclusion criteria are 
delineated in Figure 3.1. 
3.3.2 Chemical Biomarker Measurements 
This section along with Figure 3.1 delineates the curation process for selecting chemical 
biomarkers to include for analysis. First, we excluded biomarkers that are not indicative of 
chemical exposures (n = 99). Next, we corrected for differences in chemical codenames by using 
a unique codename for each biomarker (n = 36). We gave preference to lipid-adjusted data and 
therefore excluded non-lipid adjusted chemical biomarkers (n = 79) when both types of data were 
provided for a given chemical. We replaced all measurements below the limit of detection (LOD) 
with @AB/√2 as recommended by the CDC 131. This approximates a lognormal distribution, so 
that reasonably unbiased means and standard deviations are produced 132. There were also 
instances in which urinary cadmium concentrations were recorded as 0 ng/mL due to interference 
with molybdenum oxide (NCHS, 2005a, NCHS, 2005b). We replaced such values with @AB/√2 
if the participant's urinary cadmium level was under the LOD or otherwise excluded. We calculated 
detection frequencies for each chemical biomarker and excluded biomarkers with detection 
frequencies of 50% or less (n = 182) across all study participants. As we have reported previously, 
across the NHANES cycles, improvements in laboratory technology can change the LOD and thus 
lead to differences in detection frequencies by NHANES cycle (Nguyen et al. 2019). To limit bias 
from these changing LODs over time, we calculated detection frequencies by NHANES cycle for 
each chemical biomarker and excluded measurements where the LOD changed by over an order 
of magnitude and detection frequencies over time (Nguyen et al. 2019). For instance, percentages 
of participants with PCB 199 measurements above LODs for Cycle 2 and Cycle 3 are 36.2% and 
84.9%, respectively, and the LOD for Cycle 2 and Cycle 3 were 10.50 ng/g and 0.40 ng/g, 
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respectively. As such, measurements from Cycle 2 for PCB 199 were excluded. Measurements 
from given cycles for several PCBs, Dioxins, Furans, Phytoestrogens, and VOCs along with 
Paranitrophenol, 2-napthol, 1-pyrene and 9-pyrene (m = 449,396 total data points) were therefore 
also excluded based on these criteria (Table A2.1). The final dataset for analysis consisted of 143 
chemical biomarkers from 16 different chemical classes (Table A2.2). These chemical classes 
were: Acrylamide, Brominated Flame Retardants (BFR), Phosphate Flame Retardants (PFR), 
Dioxins, Furans, Metals, Other, Personal Care & Consumer Product Compounds, Pesticides, 
Phthalates & Plasticizers, Phytoestrogens, Polyaromatic Hydrocarbons (PAH), Polychlorinated 
Biphenyls (PCB), Per- and Polyfluoroalkyl Substances (PFAS), Smoking Related Compounds, 
and Volatile Organic Compounds (VOC). 
3.3.3 Statistical Analysis 
We performed all analyses using R version 3.6.0. Given the NHANES complex sampling 
design, we applied appropriate survey weights in our statistical models to produce estimates 
representative of the non-institutionalized, civilian US population. Applying the appropriate 
survey weights involved selecting the weights of the smallest analysis subpopulation 183. For 
example, there are two types of survey weights that can be used for a conducting an analysis with 
total arsenic:  WTSA2YR or WTMEC2YR. WTMEC2YR is the NHANES codename for survey 
weights for all participants whose measurements were taken in a Mobile Exam Center (MEC). 
WTSA2YR is similar to WTMEC2YR with the exception that the survey weights are only for 
participants who belong to subsample A, which is a smaller subpopulation with measurements for 
total arsenic. Since WTSA2YR pertains to the smaller analysis subpopulation, WTSA2YR is the 
appropriate survey weight to apply for an analysis on total arsenic. The appropriate survey weights 
are listed in the original NHANES files containing the measurements for the chemical biomarker. 
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If the survey weights are not listed for a given chemical, then we use WTMEC2YR as the default. 
Conducting an analysis across several NHANES cycles may require the use of different survey 
weights 183. For instance, a statistical model for total arsenic requires using only one type of survey 
weights (WTSA2YR). But a statistical model for triclosan requires three different types of survey 
weights (WTSA2YR, WTSB2YR, WTSC2YR), since in each NHANES cycle, a different 
subpopulation of NHANES is measured for triclosan. To account for NHANES sampling design 
and use the appropriate survey weights, we developed two databases. The first was a database of 
codenames indicating the appropriate survey weights for each chemical biomarker and NHANES 
cycle (Table A2.3). For several of the Per- and Polyfluoroalkyl Substance (PFAS), there were two 
different type of survey weights available within the same cycle (one for children aged 3-11 and 
the other for participants aged 12 and older). Therefore, we developed another database of 
codenames indicating which additional survey weights to use when generalizing these results for 
PFASs (Table A2.4).   
Using multivariate regression models, we evaluated differences in biomarker 
concentrations in blood and urine by race after log-transforming the data. We included log-
transformed levels of cotinine as a covariate to represent smoking (Benowitz, 1999), and creatinine 
levels to adjust for urine dilution and flow differences (Barr et al., 2005). We modeled poverty 
income ratio (PIR) as a surrogate variable for socioeconomic status. PIR is the ratio of household 
income and poverty threshold adjusted for family size and inflation. First, we examined the racial 
differences in chemical biomarker levels by performing a series of chemical-specific regression 
models with the main predictor being race/ethnicity (categorical), adjusting for age (continuous), 
NHANES cycle (continuous), PIR (continuous), and cotinine (continuous) as described in Eq. (1): @'(10($)*#+,-!.	)01-#123!2,01) = !3!-#/#2*1,-,25,AE$3!-#/#2*1,-,25,AF +  
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Here, $)*#+,-!.	)01-#123!2,01 is the log-transformed, unadjusted chemical biomarker concentration 
for all participants, $,, where G ∈ 	 {JK89/9LℎNG8GL7, O, K(9, 59P, 878&9, QRS, 8'LGNGN9,8J9KLGNGN9}, is the G covariate for all participants, !, is the linear regression coefficient for the G 
covariate, and 1 is the intercept. $3!-#/#2*1,-,25,A, where O	U{V9PG8KN	WX9JG8KN5,ALℎ9J	YG5ZKNG85, ['N-YG5ZKNG8	\&K8:, ALℎ9J	SK89/V]&LGJK8GK&} for 1999-2014, is the race 
covariate for comparing the OLℎ race to the reference group of Non-Hispanic Whites. For chemical 
biomarkers which were measured in urine, we further corrected the regression models by adjusting 
for urinary creatinine levels (continuous). For the analyses where cotinine concentration was the 
outcome, the regression models were not further corrected for smoking. Prior to 2011, Asian 
Americans were categorized in Other Race/Multi-Racial category. Accordingly, to evaluate 
chemical exposure disparities in Asian American women, we also applied Eq. 1 to the 2011-2014 
data. Then to determine whether racial disparities are driven by differences in socioeconomic 
status, we conducted a sensitivity analysis to observe how the race coefficients change with and 
without adjustment for PIR in the regression models. The coefficient for OLℎ race represents the 
difference in log-transformed chemical biomarker concentration between the OLℎ race and the 
reference group of Non-Hispanic Whites. As we are making multiple comparisons across chemical 
biomarkers and races, we have an increased probability of detecting false positives, i.e. a high false 
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positive rate. To identify significant comparisons while maintaining a lower false positive rate, we 
used the False Detection Rate (FDR) method on the p-values of the linear regression race-
coefficients 103. 
We are interested in understanding how the racial disparities are influenced by reproductive 
and nutritional factors such as parity, breastfeeding, menopause/hysterectomy status, and iron 
deficiency, which may impact toxicant absorption and excretion. We used the reproductive health 
questionnaire on reasons for having period irregularities and another questionnaire on having 
regular periods in past 12 months to classify participants as having menopause/hysterectomy, 
otherwise with irregular periods, or otherwise with regular periods (reference). Parity (continuous) 
is defined from the questionnaire on the number of pregnancies resulting in live births. We used 
parity and a questionnaire asking whether the mother breastfed her children for at least a month to 
categorize participants into three categories: breastfed, did not breastfeed her children, and did not 
breastfeed as she does not have children (reference). We used sex-specific thresholds for 
hemoglobin levels (hemoglobin <13.5 g/dL for men and <12 g/dL for women) 184 to classify 
participants as iron deficient or not (reference).  To determine whether the frequency distribution 
of these variables differ by race, we conducted a Chi-Square test on the categorical variables and 
a one-way ANOVA test on parity. To characterize how the estimates of racial disparities change 
when a given reproductive or nutritional factor is included in the regression model, we conducted 
a series of regression models with the outcome variable as chemical concentrations and the main 
predictor as race/ethnicity (categorical) while adjusting for age (continuous), NHANES cycle 
(continuous), PIR (continuous), cotinine (continuous), creatinine (continuous), and an ^Lℎ 
reproductive or nutritional factor from the set of 
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For example, if ^ = ZKJGL7, the $B!-203,B refers the number of pregnancies resulting in live birth 
for all participants. !B!-203,BCD!3,25	is interpreted as the change in log-transformed chemical 
biomarker concentration for every successful pregnancy. Now, if ^ = GJ'N	r9^G8G9N87, then $B!-203,B indicates whether a participant is iron deficient or not for all participants. !B!-203,BC,301	;#B,-,#1-5 is interpreted as the difference in log-transformed chemical biomarker 
concentration between iron deficient participants and the reference group of participants who are 
not. The interpretations for menopause/hysterectomy status and breastfeeding status are similar to 
that of iron deficiency.  
To evaluate how these racial differences in chemical exposures differ by age group, we 
conducted stratified analyses by age groups in the 1999-2014 data. We defined 4 age groups:  0-
11, 12-19, 20-50, and 51-85. For each age group with chemical biomarker measurements, we 
performed a chemical specific linear regression with the main predictor as race/ethnicity 
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(categorical) and adjusted for age (continuous), NHANES cycle (continuous), PIR (continuous), 
cotinine (continuous), and creatinine (continuous), stratified by age group described in Eq. (3). @'(10($)*#+,-!.	)01-#123!2,01[K(9	(J']Z = :]) = !3!-#/#2*1,-,25,A,@E$3!-#/#2*1,-,25,A[K(9	(J']Z = :]F + !!"#,@E$!"#[K(9	(J']Z = :]F + !-5-.#,@E$-5-.#[K(9	(J']Z = :]F + !89:,@($89:[K(9	(J']Z = :]) + !-02,1,1#,@($-02,1,1#[K(9	(J']Z = :]) + !-3#!2,1,1#,@($-3#!2,1,1#[K(9	(J']Z = :]) + 1 
Here, : is an available age group from the set of {0-11, 12-19, 20-50, 51-85}, $)*#+,-!.	)01-#123!2,01[K(9	(J']Z = :] is the log-transformed, unadjusted chemical biomarker 
concentration for all participants with ages in the :Lℎ age groups, $,,@[K(9	(J']Z = :], where G ∈ 	 {JK89/9LℎNG8GL7, O, K(9, 59P, 878&9, QRS, 8'LGNGN9, 8J9KLGNGN9}, is the G covariate for 
all participants with ages with the :Lℎ age group, !,,@ is the linear regression coefficient for the G 
covariate and :Lℎ age group, and 1 is the intercept. $3!-#/#2*1,-,25,A,@, where O	U{V9PG8KN	WX9JG8KN5, ALℎ9J	YG5ZKNG85, ['N-YG5ZKNG8	\&K8:, ALℎ9J	SK89/V]&LGJK8GK&}, is the race covariate for comparing the OLℎ race to the reference group of Non-
Hispanic Whites in the :Lℎ age group. To account for multiple comparisons, we used an FDR 
method on the p-values of the linear regression race-coefficients across all age groups (Benjamini 
and Hochberg, 1995). 
To evaluate how racial disparities in chemical exposures changes over time, we conducted 
stratified analyses by NHANES cycles. We denote a 8Lℎ cycle as from a study period from the set 
 61 
 
of {1	(1999-2000), 2 (2001-2002), 3 (2003-2004), 4 (2005-2006), 5 (2007-2008), 6 (2009-2010), 7  
(2011-2012), 8 (2013-2014)}. We excluded measurements from Cycle 2 for Blood 
Bromodichloromethane, Cycle 2 for Blood Chloroform, and Cycle 6 for Blood Toluene due to 
having an error in the statistical program R when accounting for the sampling design. We excluded 
measurements from Cycle 2 for 3-fluoranthene as there is only one person with measurements for 
this chemical in Cycle 2. For each NHANES cycle with chemical biomarker measurements, we 
performed a chemical specific linear regression with the main predictor as race/ethnicity 
(categorical) and adjusted for age (continuous), PIR (continuous), cotinine (continuous), and 
creatinine (continuous) as described in Eq. (4). [878&9 = 8] denotes the inclusion of participants 
who have chemical biomarker measurements in the cth cycle. We used an FDR method on the p-
values of the coefficients to account for multiple comparisons across all races and NHANES 













Table 3.1 displays demographic characteristics of the study population. The study 
population includes 38,080 female study participants of ages 1-85 years, with a median age of 26. 
Using a series of covariate adjusted regression models, we first calculated the fold-difference in 
chemical biomarker concentrations by race across the entire study population. These regression 
results are presented in graphical format in Figure 3.2, where the letters in the plot reflect the fold-
difference in chemical biomarkers for each race/ethnicity, relative to non-Hispanic White women, 
who made up the largest portion of the study population. Pesticides and pesticide metabolites, 
including 2,5-dichlorophenol, o,p’-DDE, beta-hexachlorocyclohexane, and 2,4-dichlorophenol 
had amongst the highest average fold difference across non-Hispanic Black, Mexican American, 
Other Hispanic, and other race/multiracial women. On average, large differences by race are also 
apparent for personal care and consumer product compounds including methyl paraben, propyl 
paraben, monoethyl phthalate and metals, such as mercury and arsenic. Conversely, cotinine, 
PBDE-153, PBB-153, Equol, DEET, and bisphenol F were among the chemicals of which non-
Hispanic White women had the highest levels. 
In order to more clearly visualize the differences in chemical biomarkers by race/ethnicity, 
we generated volcano plots, which are displayed in Figure 3.3. The x-axis of these plots depicts 
the fold difference in average chemical biomarker concentration between each race/ethnicity and 
non-Hispanic White women. The y-axis depicts statistical significance, as reflected in the negative 
log10 transformation of the FDR-adjusted p-value from the regression analysis for that chemical 
biomarker, where chemicals with larger values on the y-axis are more statistically significant. As 
shown in Figure 3.3A, non-Hispanic black women have biomarker concentrations that are more 
than twice those of non-Hispanic White women for multiple chemicals, including 2,5-
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dichlorophenol, 1,4-dichlorobenzene, methyl paraben, monoethyl phthalate, 2,4-dichlorophenol, 
and propyl paraben. The heavy metals, mercury and lead, are also significantly higher in non-
Hispanic Black women. Conversely, levels of benzophenone-3, a UV blocker used in sunscreen, 
are significantly higher in non-Hispanic White women. In general, concentrations of PCBs tend to 
be modestly elevated in non-Hispanic Black women, while volatile organic compounds (VOCs) 
and phytoestrogen concentrations are higher in non-Hispanic White women. Figure 3.3B shows 
relative differences in chemical biomarker concentrations between Mexican American and non-
Hispanic White women. Pesticides, including 2,5-dichlorophenol, beta-hexachlorocyclohexane, 
and 2,4-dichlorophenol, along with the polycyclic aromatic hydrocarbon 2-napthol were on 
average higher in Mexican American women. Conversely, the smoking biomarker, cotinine is 
significantly lower in Mexican American women. Exposure patterns comparing Other Hispanic 
and non-Hispanic White women, displayed in Figure 3.3C, showed some similarities, with 
pesticides 2,5-dichlorophenol and p,p’-DDE elevated in Other Hispanic women. Multiple PFASs, 
including PFOS, PFHxS, and 2-(N-methyl-PFOSA) acetate, as well as cotinine, are significantly 
lower in Other Hispanic women. Figure 3.3D shows a distinct exposure pattern in women of other 
race/ethnicity or multiracial women. Here, levels of heavy metals, including cadmium, mercury, 
and multiple arsenic biomarkers, are significantly elevated relative to non-Hispanic White women. 
Conversely, the smoking biomarkers, NNAL and cotinine, are significantly lower.  
To understand whether socioeconomic status is a driver of racial disparities in chemical 
exposures, we generated a series of correlation plots, comparing how the differences in chemical 
biomarker concentrations by race/ethnicity change with the inclusion and exclusion of PIR in the 
regression models (Figure A2.1). For many of the chemicals, the fold differences for comparing 
chemical biomarker levels by race did not change drastically when including PIR as a covariate in 
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the regression models, implying that socioeconomic status is not the primary driver in explaining 
differences in chemical exposures. However, for cotinine, PCB 194, and several chemicals used 
in personal care products, the relative differences changed by greater than 25% when PIR was 
included as a covariate in the regression models. This suggests that either exposure differences 
between races for these chemicals are mediated by PIR, and/or exposure differences are explained 
by interactions between race and socioeconomic status. To visualize differences in chemical 
biomarker concentrations by race across a gradient of income for a few selected biomarkers, we 
generated violin plots of the chemical biomarker distribution stratified by categories of PIR for 
each race/ethnicity (Figure A2.2). For benzophenone-3 and cotinine (Figure A2.2A and A2.2B), 
the trends of biomarker concentrations across the PIR categories and the average concentrations 
within the same PIR categories differ by race. This is similar for ethyl paraben (Figure A2.2C), 
but differences are not as drastic. On the other hand, mercury (Figure A2.2D) along with other 
remaining chemicals demonstrated a very different pattern from those of the previously mentioned 
substances. Across all races, the trends across PIR categories are similar for mercury, but within 
the same PIR category, there are differences in biomarker concentrations by race, suggesting that 
many chemical exposures disparities by race are independent of PIR. 
We also characterized how reproductive and nutritional factors such as parity, 
breastfeeding, menopause/hysterectomy status, and iron deficiency may influence racial 
disparities in chemical exposures, as well as to account for racial variations in these factors in our 
models (Aliyu et al. 2005; Henderson et al. 2008; Zakai et al. 2008). There are significant 
differences by race in all studied reproductive and nutritional factors with the p-values listed as 
the following:  parity (p-value = 6.59e-95), breastfeeding (p-value = 4.71e-121), 
menopause/hysterectomy status (p-value = 6.14e-148), and iron deficiency (p-value = 9.24e-322). 
 65 
 
Contingency tables are provided to show the frequency distribution of these variables by race in 
Tables A2.5-A2.8. In addition, we compared how differences in chemical biomarker 
concentrations by race/ethnicity change with and without accounting for these factors by 
generating a series of correlation plots comparing regression coefficients from models that include 
or exclude these factors (Figure A2.3-A2.6). Adjusting for either iron deficiency or 
menopause/hysterectomy status resulted in four chemicals that have the relative differences 
changed by greater than 25%, implying that neither iron deficiency nor menopause are primary 
driver in explaining racial differences in exposure. On the other hand, adjusting for breastfeeding 
and parity showed 25 and 16 chemicals, respectively, with changes greater than 25%, which 
implies that racial disparities in chemical exposure are better explained by these factors. For 
cotinine, the changes in relative differences by race was among the highest at approximately two-
fold different when either menopause or breastfeeding was considered in the regression models. 
Starting in 2011, more detailed information on NHANES study participant race/ethnicity 
were collected, including specifically identifying individuals who report Asian ethnicity. To 
understand whether the results presented in Figure 3.3D predominantly reflect results in Asian 
women, who prior to 2011 were categorized in other race/multi-racial category, we assessed 
exposure disparities specifically in the Asian population. These results, presented in Figure 3.4A, 
show that, on average, multiple heavy metal biomarkers are more than 2-fold higher relative to 
non-Hispanic White women, including cadmium, mercury, lead, and arsenics. Additionally, the 
PFAS compound PFDA is significantly higher in Asian women, while cotinine and biomarkers of 
phosphate flame retardants (Bis(1,3-dichloro-2-propyl) phosphate, Dibutyl phosphate, Diphenyl 
phosphate) are significantly lower. We also calculated whether there were significant disparities 
in chemical biomarker concentrations in women of other or multi-race after excluding Asian 
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women. Figure 3.4B suggests relatively few differences in this regard, confirming that the other 
race effect in Figure 3.3D is indeed associated with Asian women.  
We have previously shown dramatic differences in the chemical “exposome” by age in 
NHANES study participants, not stratified by gender or race 185. Here, we tested for differences in 
chemical biomarkers by race, after stratifying by age group. Figure 3.5 displays these results 
across the entire study population from 1999-2014. Blue colors reflect chemicals where levels are 
higher in non-Hispanic White women, while red colors reflect chemicals that are of higher 
concentration in women of the labeled race/ethnicity. Here, there appear to be exposure disparity 
patterns that persist across age groups – such as higher 2,4- and 2,5-dichlorophenol concentrations 
in Mexican American, Other Hispanic, and non-Hispanic black women. Differences in 1,4-
dichlorobenzene concentrations are consistent across age groups, although this biomarker was not 
measured in the youngest individuals. Heavy metal concentrations are elevated in women of other 
race across age groups. Some exposure patterns differ by age, however. For example, differences 
in methyl and propyl paraben are most apparent between young non-Hispanic black and non-
Hispanic White women less than 12 years old. Increased levels of phosphate flame retardants and 
the insect repellent DEET in non-Hispanic White women are the most evident in women less than 
12 years of age. Reduced levels of brominated flame retardants (PBDE's) in levels in non-Hispanic 
White women are emphasized for adolescents, age 12-19 (all other races are higher, in red). 
Similarly, higher relative concentrations of benzophenone-3, bisphenol A, and bisphenol F occur 
in non-Hispanic White women less than 12. Elevated PCB levels in non-Hispanic black women 
shown in Figure 3.3A are most evident in women greater than 51 years of age. Overall, these 
results highlight racial exposure disparities that are either stable or that vary across age groups. 
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To characterize how racial disparities in chemical exposures changes over time, we 
conducted analyses stratified by NHANES cycles (Figure 3.6). There are exposure disparities 
patterns that persist across time for arsenics and its metabolites, chemicals used in personal care 
products, cotinine, 2,5−dichlorophenol, 2,4−dichlorophenol, and 1,4−dichlorobenzene. 
Differences in 2,5−dichlorophenol concentrations are consistent higher in Non-Hispanic Black 
women over time, while differences peaked at the turn of the century and towards the end of 2000s, 
respectively, for Mexican American and Other Hispanic women. Arsenic and its metabolite 
arsenobetaine show the highest disparities in Other Race/Multi-Racial women with the disparities 
peaking in 2007-2010. Disparities patterns for methyl and propyl parabens fluctuate over time in 
Mexican American, Other Hispanic, and Non-Hispanic Black women, while differences for these 
substances are slightly increasing in Other Race/Multi-Racial women. For mono-ethyl phthalate, 
a metabolite of DEP used in personal care products, differences over time are consistent in 
Mexican Americans, fluctuating in Other Hispanics, and increasing in non-Hispanic Black women. 
Differences in cotinine levels are among the highest in Non-Hispanic White women compared to 
Mexican American and Other Hispanic women with disparities plateauing and increasing, 
respectively 
3.5 Discussion 
Based on population based chemical biomonitoring generated as part of the 1999-2014 
NHANES, we performed a comprehensive analysis of racial disparities in biomarker 
concentrations of 143 chemicals in 38,080 participants. Specifically, we quantified the relative 
magnitude of racial disparities for individual chemicals and chemical families while utilizing 
appropriate regression weightings. This helped ensure that the results were as generalizable to the 
entire US population. These results highlighted striking differences in chemical biomarker 
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exposure patterns by race/ethnicity, independent of other demographic factors such as 
socioeconomic status and independent factors such as menopause/hysterectomy status, parity, 
breastfeeding, and iron deficiency. In particular, exposure patterns of pesticides, heavy metals, 
tobacco smoke associated compounds, and chemicals found in personal care products are found to 
be most disparate across race/ethnic groups. Stratified analyses revealed exposure patterns that 
persisted across age groups. For example, this was apparent in heavy metals exposure for women 
who identify as other race or multiracial, as well as in age-specific exposure patterns, such as 
elevated PCB, dioxin, and dibenzofuran exposure in older non-Hispanic black women. In some 
cases, average differences in chemical biomarker concentrations between race/ethnic groups 
exceeded 400%, such as for urinary propyl or methylparaben concentrations between the youngest 
non-Hispanic Black and non-Hispanic White women. Racial disparities were attenuated or 
emphasized after adjusting for reproductive and nutritional factors. For example, when adjusting 
for breastfeeding, the average differences in cotinine biomarker levels were attenuated two-fold 
between Hispanic and non-Hispanic White women, whereas accounting for variation in iron 
deficiency resulted in average differences in cotinine levels increasing by two-fold when 
comparing between non-Hispanic Whites and non-Hispanic Black women. Since parity, 
breastfeeding, menopause, and iron deficiency may influence the absorption or elimination of 
chemicals, and the rates of these potential confounders differ by race, these factors may lead to 
further attenuation or amplification of racial disparities in chemical biomarker concentrations. 
These findings contextualize racial disparities in chemical exposures across US women and 
highlight the vast differences in chemical exposomes between demographic groups with well 
characterized disparities in health outcomes. 
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Environmental injustice is the disproportionate exposure of individuals of color, lower 
socioeconomic status, or other politically disadvantaged groups to toxic chemicals in food, air, 
consumer products, at the workplace, or in their communities 186. Disproportionate chemical 
exposures have been hypothesized to be important drivers of health disparities, including obesity 
and neurodevelopmental outcomes 187. While the primary goal of this study was to quantify and 
compare chemical exposure disparities across racial/ethnic groups, independent of income, others 
have evaluated combined income and race related disparities in exposure. For instance, one 
analysis compared geometric mean concentrations of 228 chemical biomarkers between six groups 
stratified by income and race in NHANES and identified 37 chemicals as likely contributing to 
environmental justice 188. Some of these chemicals, including cotinine, lead, 2,4- and 2,5-
dichlorophenol, methyl paraben, and propyl paraben, were associated with the highest disparities 
across race/ethnic group in the present study. We also compared chemical exposures disparities 
across racial/ethnic groups with and without adjustment for income and found that cotinine, PCB 
194, methyl mercury, and chemicals used in personal care products such as benzophenone-3, the 
parabens, and triclosan show disparities across both race and socioeconomic status. However, for 
most of the studied chemicals, differences in chemical exposures were not driven by 
socioeconomic status but were instead primarily associated with race/ethnicity.  Furthermore, a 
study of racial and social disparities in exposure to BPA and PFAS examined differences in 
biomarker concentrations in NHANES study participants 189. The concentrations of the four PFAS 
chemicals examined, PFOA, PFOS, PFNA, and PFHxS, were inversely associated with household 
income, while BPA concentrations were higher in individuals who reported low food security 189. 
Here, we identified that, independent of socioeconomic status, as assessed by poverty-income 
ratio, non-Hispanic White women had the highest concentrations of PFOA, while non-Hispanic 
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Black and other race/multiracial women had the highest concentrations of PFDA. Major routes of 
exposure to PFAS compounds include contaminated drinking water 190, diet 127, and occupational 
routes 191. BPA concentrations were not strikingly different by race in our study, but non-Hispanic 
Black women had, on average, 93% higher BPS concentrations than non-Hispanic White women. 
Common routes of exposure to BPA and other bisphenol analogues are diet, thermal paper, and 
personal care products 192. Further research is necessary to identify the major routes of exposure 
which are driving racial disparities in PFAS and bisphenol chemicals biomarker concentrations. 
The findings of highly elevated monoethyl phthalate and methyl and propyl paraben 
concentrations in the non-Hispanic Black women are consistent with a personal care product route 
of exposure. A study assessing the chemical composition of hair products used by Black women 
consistently identified high levels of cyclosiloxanes, parabens, and the fragrance carrier diethyl 
phthalate 193. In our study, the concentrations of the diethyl phthalate metabolite monoethyl 
phthalate were approximately 78% higher on average in non-Hispanic black women of all ages 
relative to non-Hispanic White women, and 122% higher in non-Hispanic black women less than 
12 years of age. This is concerning, since urinary concentrations of monoethyl phthalate have been 
positively associated with odds of developing breast cancer in a case-control study of women from 
Northern Mexico 194. Differences in concentrations of methyl and propyl paraben biomarkers were 
among the highest observed in this study, particularly for the youngest non-Hispanic Black 
women. These differences were observed to remain consistently higher across the NHANES cycles 
in Mexican Americans, Other Hispanics, and non-Hispanic Blacks. These chemicals have been 
used as preservatives in personal care products, pharmaceuticals, and food additives, and have 
been found to promote cell growth through multiple mechanisms, including estrogenicity 195–197 
and epidermal growth factor receptor signaling 198. Particularly relevant to our findings of the 
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greatest methyl and ethyl paraben disparities in the youngest non-Hispanic Black women was the 
finding that early life paraben exposures can alter developing mammary gland morphology and 
induce gene expression that resembles an early cancer-like state 199. Use of hair products has been 
identified as a potential risk factor for breast cancer in non-Hispanic Black women 200. When we 
adjusted for breastfeeding in the regression models, parabens levels are higher in Non-Hispanic 
White women compared to Mexican American, Other Hispanics, and Other Race/Multi-Racial 
women. This implies that women of other races are breastfeeding more often 201, and/or they are 
eliminating parabens from their body but exposing their infants via breast milk 202.  Further 
research is needed to determine whether early-life exposure to potentially estrogenic compounds, 
like parabens, can induce biological alterations that increase risk of estrogen receptor negative 
breast cancers.  
One of the most apparent disparities in chemical biomarker concentrations by race was 
with the compounds 2,4-dichlorophenol, 2,5-dichlorophenol, and 1,4-dichlorobenzene. 1,4-
dichlorobenzene is used as a disinfectant, pesticide, and deodorant. 2,5-dichlorophenol is a 
metabolite of 1,4-dichlorobenzene, while 2,4-dichlorophenol is a metabolite of the antimicrobial 
triclosan or other pesticides. Elevated concentrations of these chemicals in non-Hispanic Black 
individuals has been noted previously 188,203  The concentrations of these three chemicals were up 
to 350% higher on average in non-Hispanic Black women, relative to non-Hispanic White women, 
and also elevated in Mexican American and Other Hispanic women. Importantly, these exposure 
disparities were consistent across all age groups. While 2,4-dicholorophenol concentrations were 
significantly elevated in non-Hispanic Black and Hispanic women, urinary triclosan levels were 
not significantly different by race/ethnicity. This suggests that either triclosan is not the main 
chemical exposure that explains the differences in concentrations of 2,4-dichlorophenol or that 
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there are differences in metabolism and excretion rates by race, which is less likely. 2,5-
dichlorophenol is of particular interest, since after adjusting for breastfeeding, the exposure 
disparity between Mexican American and non-Hispanic White women was further emphasized. In 
a study measuring environmental phenols in milk of lactating North Carolina women, 2,5-
dichlorophenol was undetectable in all milk samples 202. This suggests that either 2,5-
dichlorophenol is not absorbed into breast milk or it is hindering lactation, and therefore excretion 
through this pathway. 1,4-dichlorobenzene exposure has been associated with altered thyroid 
biomarkers in NHANES 204, altered immunologic and liver function parameters in occupationally 
exposed workers 205, and altered sperm production and increased prostate weight in exposed rats 
206. Understanding and mitigating exposure to these chemicals is therefore of importance to reduce 
disparate risk of these health outcomes. 
Heavy metals were among the chemicals most consistently different across racial/ethnic 
groups. In particular, women who identified as other race or multiracial had the highest 
concentrations of multiple metals, including cadmium, mercury, arsenics, lead, and manganese. 
Focusing on data from NHANES 2011-14, we identified that these elevated metals concentrations 
were restricted to women who identified as Asian. This is consistent with a previous finding of 
increased concentrations of a subset of these metals in Asian NHANES participants 36. 
Furthermore, elevated levels of mercury, lead, and arsenics were also identified in non-Hispanic 
Black women, relative to non-Hispanic White women. Mexican American women had elevated 
levels of uranium, lead, mercury, arsenics, and cadmium, while Other Hispanic women had higher 
concentrations of mercury, arsenics, and cadmium than non-Hispanic White women. Non-
Hispanic White women, however, had higher concentrations of urinary barium. In our temporal 
analysis, differences in biomarker levels between Other Race/Multi-Racial and Non-Hispanic 
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White women are increasing for cadmium, mercury, and dimethylarsonic acid. While studies have 
identified the interaction between iron deficiency and biomarker levels of heavy metals 207,208, we 
observed in our study that accounting for iron deficiency in the regression models did not influence 
the racial disparities for heavy metals. Previous research has linked diet, occupation, education 
level, and smoking status to elevated metals exposure 36, in addition to housing 209, air pollution 
210, and contaminated water 211. The well characterized toxicity of heavy metals exposure, even at 
low doses, makes identifying and ameliorating heavy metal exposures a top priority for addressing 
environmental health disparities. 
The oldest non-Hispanic Black women in our study had consistently higher concentrations 
of persistent organic pollutants, including dioxins, dibenzofurans, PCBs, and DDT metabolites. In 
addition, these stark disparities for the persistent organic pollutants were plateauing or increasing 
over time in non-Hispanic Black women when these chemicals were last measured in NHANES. 
This is consistent with a previous report of non-Hispanic Black individuals having an increased 
risk of having multiple persistent organic pollutants detectable their blood  212 or higher average 
levels of PCBs 121. In our study, biomarker levels of most PCBs were higher in women who were 
iron deficient. The less persistent PCBs were also of lower concentrations in women who breastfed 
or have higher parity, suggesting that the depuration of PCBs occurs through these excretion 
mechanisms 213. However, biomarker levels were shown to be higher for the more persistent PCBs. 
Biomarkers of persistent organic pollutants were quantified on an individual (non-pooled) basis in 
the 1999-2004 NHANES cycles. Elevated concentrations of these pollutants, such as the DDT 
metabolite, DDE, have been associated with an increased risk of breast cancer 214. Interestingly, 
racial differences in DDE further increased when either parity or breastfeeding was accounted in 
the regression models, suggesting that environmental insult from this substance may perturb 
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pathways associated with the reproductive system. A lack of disparities, and decreasing 
concentrations of these chemicals in younger individuals over time, generally reflect a public 
health success in decreasing population exposures to these toxic compounds 185. The long half-life 
of these chemicals suggests that the detected biomarkers predominantly reflect historical 
exposures. This could, however, be of substantial importance for children of non-Hispanic Black 
women, who could have been exposed to disproportionately high levels of these chemicals in the 
womb or early in childhood. For example, in utero exposure to the pesticide, DDT, has been 
associated with an increased risk of breast cancer in adulthood. Specifically, women in the highest 
quartile of in utero DDT exposure were found to have a 3.7-fold increased risk of developing 
breast cancer relative to women in the lowest quartile of exposure 215. Prenatal exposure to 
organochlorine compounds has also been associated with decreased lung function later in life 216, 
risk of infection in childhood 217, attention deficit hyperactivity disorder 218, and obesity 219. If 
these effects of elevated early life persistent organic pollutant exposure last throughout the life 
course, there could be continued adverse health consequences that manifest in those exposed for 
the foreseeable future.     
While differences in chemical exposures likely explain most of the variations observed in 
the human body, these variations in biomarker levels may also be a result of differences in 
physiological processing. Specifically, genetic factors may control the metabolism of these 
chemicals. For example, the enzyme, cytochrome P450 2A6 (CYP2A6) controls the metabolism 
of nicotine into cotinine and subsequently into 3-hydroxycotinine. In a diverse cohort of current 
smokers, CYP2A6 activity was  found to be the highest in Latinos, followed by White Americans, 
African Americans, Native Hawaiians, and Japanese Americans with relevant alleles varying 
significantly by race 220. Furthermore, lower CYP2A6 activity was associated with lower 
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concentrations of nicotine metabolites and subsequentially lower risk of lung cancer, which may 
explain the relatively lower risk of lung cancer found in Japanese smokers 220. As another example, 
single nucleotide polymorphisms (SNPs) in the arsenic (III) methyltransferase gene AS3MT have 
been shown to influence the metabolism of inorganic arsenic into monomethylarsonate and 
dimethylarsinate 221,222. A SNP in AS3MT was found to be associated with a decrease in inorganic 
arsenic in Non-Hispanic Whites but an increase in African Americans, Hispanics, and Chinese 
American. However, these associations were not significant 223, which is likely due to low sample 
size by race/ethnicity 223. These findings emphasize the need to conduct a GWAS on a larger 
multiethnic cohort to better understand how genetic variants mediate racial differences in 
metabolic activity. These examples elucidate a limitation of using NHANES, since data on 
chemical exposures are not available. Having both exposure and biomarker measurements for the 
same chemicals would enable the comparison of metabolic activity by race to understand whether 
chemical biomarker levels are better explained by the environment or by genetics. In addition, 
these findings also showcase the need for joint studies that incorporate both genetics and the 
environment to comprehensively characterize the genetic and environmental contribution to 
disease.  
While there are substantial health disparities between races, there may be variations within 
the same race. For example, the frequency of triple negative breast cancer (TNBC) was highest in 
West African/Ghanaian and African American women and lowest in Ethiopian and White 
American women 224. In addition, highest prevalence of ER-negative disease were found among 
African Americans and patients born in West Africa, while the lowest were seen among White 
Americans and patients born in East Africa 225. In another study, the highest prevalence of triple-
negative tumors was found in West African/Ghanaian, followed by African Americans, and then 
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White Americans 226. Furthermore, women with TNBC tend to be of West African ancestry 
compared to women who do not have TNBC 226. These results may highlight a gradient of risk for 
TNBC due to increased proportion of ancestry attributed to West Africa. Moreover, the 
DARC/ACR1 allele (commonly known as the “Duffy-null” variant) was associated with western 
sub-Saharan African ancestry and independently associated with likelihood of TNBC 226. This 
variant was selected due to its role in resisting malaria, and thus this mutation was largely fixed in 
regions of African affected by malaria 227. However, this variant has been identified as the 
genotype responsible for lower average white blood cell counts observed in patients with African 
ancestry and thus potentially also responsible for disparities in transplant rejection and other health 
conditions 228,229. This genetic predisposition combined with environmental insults, whether due 
to chemical exposures and/or social factors such as long-term stress, health access, etc., may 
exacerbate the risk for having TNBC, thus showing the consequences of forced migration on 
descendent of West Africans even after several generations have passed. Hence, these examples 
highlight the needs to conduct studies that integrate genetic and environmental data to identify 
population, who have a genetic and environmental predisposition to disease. Such results also 
highlight a limitation of using NHANES as there is no greater resolution on the race/ethnicity 
variable to study susceptibility due to differing degree of ancestry. Hence, future studies can 
incorporate the restricted genetic data from NHANES as well as use other datasets such as the UK 
Biobank to better understand the genetic and environmental contribution to disease that are 
attentive to race. 
Our study has important limitations. First, the cross-sectional nature of NHANES only 
allows biomarker measurement at one time point per individual. In addition, there are no available 
data on season, but should such data become available, then it would be interesting to study 
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chemical exposure trends across the seasons. Moreover, since the half-lives of the biomarkers 
assessed in this study are highly variable 185, the precision of estimates of long-term exposure 
largely varies across chemical family. Additionally, this study was not able to assess geographic 
variation in exposure. Others have identified that persistent organic pollutant exposures in the 
NHANES cohort varies geographically, with higher DDT metabolite concentrations in individuals 
residing in the West, and  elevated PCB concentrations in individuals residing in the Northeast 230. 
Future work is needed to precisely characterize exposure “hot spots,” in order to design 
intervention studies to reduce exposure disparities. Our study also focused on identifying average 
differences in biomarker concentrations. By ignoring the extremes of these distributions, we have 
likely not considered individuals at greatest risk of developing adverse health outcomes. Similarly, 
our analyses were limited by low detection rates, with 182 chemicals not meeting our inclusion 
threshold of at least 50% detection in the study population. A more in-depth analysis of differences 
in detection frequency by race/ethnicity could identify additional chemicals with significant racial 
disparities. For chemical biomarkers measured in urine, variations in the concentration of urinary 
creatinine, used as a correction factor for urine dilution, potentially confounds our comparison of 
exposures between individuals of different races. This is because increased average concentrations 
of urinary creatinine have been identified for non-Hispanic Black individuals, relative to Mexican 
American and non-Hispanic White individuals 231. While we adjusted for urinary creatinine as a 
covariate in our regression models, the still may be residual confounding. The large number of 
chemicals assessed also precluded an in-depth characterization of the various routes of exposure 
of individual chemicals – this is undoubtedly an essential future direction of research to develop 
strategies to eliminate exposure disparities. Finally, while we performed analyzed all chemical 
biomarkers available from NHANES 1999-2014, these chemicals only represent a small 
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proportion of the over 80,000 chemicals estimated to be used in commerce in the United States. 
Future studies could benefit from an unbiased metabolomics approach to identity disparities in 
chemical exposures which are not captured in NHANES.   
3.6 Conclusions 
The persistent health disparities between women of different races/ethnicities make 
understanding the etiological drivers of these disparities a pressing public health issue. A recent 
commentary highlighted a lack of knowledge regarding the molecular underpinnings of health 
disparities. It described how the vast majority of genome sequencing data had been generated in 
populations of European ancestry 232. Environmental exposures, however, are hypothesized to be 
the major driving risk factors for a vast suite of complex diseases 12. Even when genetic data has 
been generated in an equitable fashion, understanding gene-environment interactions and complex 
disease phenotypes will still require in-depth quantification of environmental exposures. In this 
study, we have comprehensively identified differences in biomarker of chemical exposure across 
women of various race/ethnic groups and across age groups. These findings can guide future 
efforts to understand chemical impacts on health disparities by helping to prioritize chemicals for 
assessment in epidemiological studies. Additionally, chemicals as identified as highly disparate 
here can be further prioritized for toxicological assessment relevant to disease outcomes of interest. 
Finally, these findings can inform public health interventions designed to reduce chemical 














with < 50% 
Detection Rate
(n = 182)












n = 541 biomarkers
n = 143 biomarkers
Exclude participants 




N = 82,091 participants

























Disparities in Asian 
American Women
1999-2014
N = 38,080 (100%)
2011-2014
N = 9,278 (24.3%)
Measurements 
excluded based on 








Analysis on Racial 












Figure 3.2. Alphabet soup plot displaying the covariate adjusted fold differences in chemical 
biomarker concentration by race, ranked by the average difference with non-Hispanic White 
individuals. Colors represent the chemical families. Shapes represent the comparison between a 
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Figure 3.3. Volcano plots representing the significance of the covariate-adjusted differences in 
chemical biomarker concentrations between non-Hispanic White women and (A) non-Hispanic 
Black women, (B) Mexican American women, (C) Other Hispanic women, and (D) Other 





Figure 3.4. Volcano plots representing the significance of the covariate-adjusted differences in 
chemical biomarker concentrations between non-Hispanic White women and (A) Asian women, 
and (B) Other Race /Multi-Racial women in NHANES 2011-2014. Colors and shapes represent 
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Figure 3.5. Heatmap displaying covariate adjusted fold differences in chemical biomarker 
concentrations by race, relative to non-Hispanic White women, stratified by age group and 
chemical family. Color reflects the log2 fold difference in chemical biomarker concentration. 
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Figure 3.6. Heatmap displaying covariate adjusted fold differences in chemical biomarker 
concentrations by race, relative to non-Hispanic White women, stratified by study period and 
chemical family. Color reflects the log2 fold difference in chemical biomarker concentration. 
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3.8 Tables  




Age N (%) Cycle N (%) Race/Ethnicity (%) N (%) 
      0-11 9392 (24.66)       1999-2000 (Cycle 1) 4535 (11.91)       Mexican American  8760 (23.00) 
      12-25 9555 (25.09)       2001-2002 (Cycle 2) 5127 (13.46)       Other Hispanic 2949 (7.74) 
      26-50 9330 (24.50)       2003-2004 (Cycle 3) 4732 (12.43)       Non-Hispanic White 14384 (37.77) 
      51-85 9803 (25.74)       2005-2006 (Cycle 4) 4834 (12.69)       Non-Hispanic Black 9116 (23.94) 
        2007-2008 (Cycle 5) 4628 (12.15)       Other Race  2871 (7.54) 
        2009-2010 (Cycle 6) 4946 (12.99)   
        2011-2012 (Cycle 7) 4493 (11.80)   
        2013-2014 (Cycle 8) 4785 (12.57)   
CONTINUOUS 
 N measured (% of population)  5
th %tile Median Mean (SD) 95th%tile 
Age (years) 38080 (100) 2 26 32.1 (24.2) 77 
PIR (-) 34968 (91.83) 0.29 1.73 2.2 (1.6) 5.00 
Cotinine (ng/mL) 31699 (83.24) 0.011 0.045 29.9 (91.4) 245.00 




Chapter 4 Biomarker-Based Occupational Exposome 
 
4.1 Abstract 
Background: According to the World Health Organization, occupational exposures to 
hazardous chemicals may be responsible for over 370,00 premature annual deaths. Hence, this 
lends urgency to characterize the totality of exposures across different industries and occupations 
to identify workers most susceptible to chemical-mediated health effects.  
Objectives: We 1) characterized differences in chemical exposures across 108 toxicants 
and physiological responses for 27 physiological indicators in a US sample of 26,361 blue- and 
white collar workers across 20 industrial sectors, 2) identified groups of workers with similar 
chemical exposure and physiological response profiles, and 3) evaluated differences in 
physiological measurements among the groups with similar chemical exposure profiles. 
Methods: We applied a series of generalized linear models with the outcome as chemical 
biomarker concentrations or physiological measurements and the main predictor as sector-collar 
combinations with adjustment for age, sex, and race to characterize differences in chemical 
exposures and physiological responses. We applied hierarchical clustering with Pearson’s 
correlation-based distance on the normalized regression coefficients to identify groups of sector-
collar combinations with similar chemical exposures and physiological response profiles.  
Results: White-collar workers had higher exposures to heavy metals such as mercury, 
arsenic, and their metabolites, along with a biomarker of sunscreen use, Benzophenone-3. Most 
blue-collar workers, especially those working in professional services, technical services, and 
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retail trade, have higher biomarker levels of heavy metals such as lead and cadmium, PAHs, 
PFASs, and VOCs such as toluene and benzene compared to their white-collar counterparts. 
Moreover, in blue-collar workers from the previously mentioned sectors along with agriculture, 
forestry, fishing and education services, alkaline phosphatase (biomarker of liver disease or bone 
disorder), white blood cell count (biomarker of inflammation), and glomerular filtration rate 
(biomarker of kidney function) showed higher values compared to white-collar workers. These 
results suggest that certain occupational exposures can diminish important physiological functions 
in blue-collar workers. 
Discussion: We systematically characterized similarity in chemical exposures and 
physiological response profiles in a population of blue- and white-collar workers from a wide 
range of industrial sectors. Our findings could guide efforts to design targeted interventions to 
reduce health disparities in susceptible occupations. 
4.2 Introduction 
The exposome is the totality of all exposures in a lifetime and its impact on human health 
2. While environmental exposures have been heavily studied to characterize an individual’s 
exposome, there needs to be more studies conducted on occupational exposures to help provide a 
more holistic characterization of an individual’s exposome. Data from the World Health 
Organization suggest that exposures to hazardous chemicals in an occupational setting are 
responsible for over 370,000 premature annual deaths 177,233. Despite this alarming statistic, a 
limited number of studies have characterized occupational exposures within the manufacturing 
sectors 30,35,37,234. Many of these studies have applied a one-chemical or one-chemical-family 
approach to evaluate occupational exposures 30,35,37. Few studies, however, aimed to analyze 
exposure to multiple chemicals across different industries and job titles, but they are based on 
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estimates of exposures 30 or air measurements at the workplace 234,235. These studies are limited in 
addressing the extent of exposures within the human body. Thus, there is a need for a 
comprehensive, untargeted approach to study occupational exposures for a wide range of 
chemicals across a variety of occupations. 
Since populations are not exposed to one chemical at a time but are exposed to several 
toxicants, there is a need to evaluate co-exposures of multiple chemicals. The biomarker dataset 
from the National Health and Nutrition Examination Survey (NHANES) has a wealth of blood, 
serum, and urine measurements on chemical contaminants, as well as data on occupation, but its 
sampling procedure creates challenges in quantifying co-exposures. Not all chemical biomarkers 
are measured in all study participants, rather different chemical biomarkers are quantified in 
different population subsamples 141. For instance, in 2003-2004, participants in subsample A were 
measured for heavy metals and Per- and Polyfluoroalkyl Substances (PFAS) but were not 
measured for chemicals from other classes 236,237. This means that analyses to quantify co-exposure 
in subsample A will be limited to only these two chemical classes. Furthermore, analyses will be 
limited to participants with measurements for all toxicants within in these two chemical classes. 
Due to this sampling procedure, NHANES is non-randomly sparse. This makes it especially 
challenging to use machine learning techniques to identify co-exposures as no participants have 
measurements for all chemicals. Imputation techniques are not applicable as these techniques work 
on the assumption that the dataset is randomly sparse 238. Hence, studying co-exposures have been 
limited to one chemical family 93–95, but populations are not only exposed to one chemical class. 
Some studies even selected a candidate set of chemicals without assessing if this combination of 
chemicals is relevant in a susceptible population 239,240. Very few studies, however, have managed 
to characterize co-exposure across different chemical classes 241,242. Thus, characterizing co-
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exposures across a wide range of toxicants is essential to better understand the chemical exposure 
profiles associated with vulnerable populations. 
To begin understanding how occupational exposures may lead to premature death 177, we 
first need to understand the associations between chemical exposures and physiological responses. 
Physiological responses can be characterized by measurements of various biomarkers known as 
physiological indicators that reflect function of the different human body systems. Several studies 
have evaluated differences in a physiological response between worker populations 243–247, but they 
do not link such a response to chemical exposures. Some have studied the associations between a 
chemical or chemical family and a physiological indicator 30,35,96, but this is limited in addressing 
the “totality” of exposure on human health. Others have studied the impact of co-exposures on 
physiological response, but such approaches have been limited to only one physiological indicator 
97. Human health is not well-described by a single physiological indicator, rather it should be 
described by many different indicators to provide a holistic view of physiological function. Thus, 
evaluating the influence of chemical co-exposures on several physiological indicators is integral 
to gain insights on the influence of exposure on human health, especially in an occupational setting. 
Overall, our goal is to characterize the chemical exposure and physiologic dysfunction in 
a working population comprised of NHANES participants from a wide range of industrial sectors 
and occupations. More specifically, our objectives are to 1) define differences in chemical 
exposure profiles based on sector-collar combinations, 2) group occupations based on their 
similarities in chemical exposure profiles, and 3) evaluate differences in physiological 




4.3.1 Study Population  
Since 1999, the Centers for Disease Control (CDC) has conducted NHANES to collect 
cross-sectional data on demographic, socioeconomic, dietary, and health-related information in the 
US population. For this analysis, we combined data from the chemical biomarker, demographic, 
and occupational datasets between years 1999-2014 for an initial sample of 82,091 participants 
with 411 chemical biomarkers and 60 physiological indicators measured. We categorized 
participants as white- or blue-collar workers in their corresponding industrial sector by using the 
publicly available industrial and occupational codes and the US Department of Labor definition of 
blue-collar 248. Blue-collar workers are defined as workers who perform repetitive tasks with their 
hands, physical skill, and energy. We tabulate the job occupation description and the collar 
category in Table A3.1. We then excluded participants for which corresponding data on chemical 
indicators (N = 7,001) and occupational descriptions (N = 48,729) were not available. We also 
excluded participants (N = 175) from the following sector-collar combinations as the median 
sample size across the included chemicals is less than 10 participants:  blue- and white-collar 
workers from armed forces and white-collar workers from private household, mining, and utilities. 
Thus, the sample size of our studied population is 26,186 participants. These exclusion and 
inclusion criteria are further detailed in Figure 4.1.  
4.3.2 Chemical Biomarkers of Occupational Exposures  
We defined chemical biomarker as an indicator of environmental exposure that can be 
measured in blood, serum, or urine. We replaced all measurements below the limit of detection 
(LOD) with the LOD divided by the square root of 2, as recommended by the CDC 14 to produce 
reasonably unbiased means and standard deviations 132. At times, NHANES identified a problem 
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of interference from molybdenum oxide that resulted in corrected concentration of urinary 
cadmium recorded as 0 ng/mL 249,250. Log-transforming such data would be undefined, therefore 
such measurements were replaced with the LOD divided by the square root of 2 if the participant’s 
urinary cadmium level was under the LOD or otherwise excluded. We excluded smoking and soy 
metabolites (Table A3.2) as biomarker levels of these substances are driven primarily by smoking 
or dietary behaviors instead of from occupational exposures (c = 8). We preferred lipid adjusted 
measurements for biomarkers indicated by 7- or 8-letter NHANES codename ending in “L” or 
“LA,” respectively, for which NHANES provided both lipid-adjusted and non-lipid adjusted 
measurements. Therefore, we excluded non-lipid adjusted chemical biomarkers (c = 79). We 
calculated detection frequencies for each combination of chemical biomarkers and sector-collars. 
Using these detection frequencies, we also calculated the fraction of sector-collars with detection 
frequency above 50% for each chemical and excluded chemical biomarkers where this fraction 
was less than 0.5 (c = 142). Then, we calculated the sample size for each combination of chemical 
and sector-collar, determine the median sample size across all sector-collars, and excluded 
chemical biomarkers with a median sample size of less than 90 participants (c = 174). We chose 
90 participants as the cut-off based on a power calculation to have a 70% chance of detecting a 
significance difference with a p-value of less than 5% and with a regression coefficient of 0.37 
(Table A3.3). The final dataset for analysis consisted of 108 chemical biomarkers from 11 classes 
(Figure A3.1). 
4.3.3. Indicators of Physiological Response  
We identified 60 biomarkers and anthropomorphic measures that characterize 
physiological response. We excluded those with measurements in fewer than six NHANES cycles 
(p = 10) and with a sample size of less than 9,000 participants (p = 21). We also excluded 
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physiological indicators that are categorical (p = 2). We calculated the mean measurement for 
participants with two or more measurements for systolic and diastolic blood pressure. The final 
dataset for analysis consisted of 27 physiological indicators. Descriptions, clinical thresholds, and 
sample size of each physiological indicator are provided in Table A3.4.  
4.3.4 Statistical Analysis 
The non-random sparsity of the chemical biomarker dataset in the worker population 
creates challenges in applying machine learning techniques, such as hierarchical clustering to 
group individual workers together based on similarity in chemical exposure profiles. Applying 
machine learning techniques requires a complete dataset 238. However, as no worker has data 
available for all studied toxicants (Figure A3.2), we cannot characterize the chemical profile for 
each individual worker. Instead, we addressed this sparsity issue by characterizing the profiles for 
each sector-collar combination to identify clusters of the sector-collar combinations with similar 
chemical exposure profiles. To further highlight the sparsity of the NHANES chemical biomarker 
dataset, we tabulated that number participants with a given number of measured chemical 
biomarkers in Table A3.5.  
We performed all analyses using R version 3.6.0. We used multivariate regression models 
to evaluate differences in the chemical biomarker levels and physiological indicators across the 
sector-collar combinations. We conducted a series of generalized linear regression models with 
the log10 transformed chemical measurements or physiological measurements as the outcome 
variable and the main predictor as the sector-collar combination with the reference group as white 
collars from public administration. The selection of the reference group was based on a priori 
assumption that white collars from public administration would be exposed to toxicants at low 
doses. We adjusted for age (continuous), sex (categorical), and race (categorical). We assume age 
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to have a linear association with a given chemical biomarker levels due to ease of interpretation. 
For ease of interpretation, the regression coefficients for the sector-collar combinations were 
converted to percent differences [10coefficient - 1] × 100%. To show exposures and response 
differences across the sector-collar combinations, we visualized the results of the regression 
models with two heatmaps of percent differences for all 108 chemicals and all 27 physiological 
indicators. To identify significant comparisons while maintaining a lower false positive rate, we 
used the False Detection Rate (FDR) method on the p-values of the regression coefficients 
pertaining to the sector-collar combinations (Benjamini and Hochberg, 1995). 
We performed two series of hierarchical agglomerative clustering analyses to identify 
groups of sector-collar combinations with similar chemical exposures and physiological response 
profiles. First, we normalized the regression coefficients across a given chemical biomarker or 
physiological indicator with the mean equal to 0 and the standard deviation equal to 1. Normalizing 
will make the chemicals or physiological indicators comparable to each other. Normalizing also 
prevent features, e.g. chemical biomarker or physiological indicator, with the highest variation 
from driving the clustering 251. Second, we used Pearson’s correlation-based distance as our 
distance measure 252,253. This distance measure calculates the similarity between the chemicals or 
physiological indicators of every pair of sector-collar combinations by using Pearson’s correlation. 
We preferred Pearson’s correlation-based distance to Euclidean distance as we are interested in 
identifying cluster of sector-collars with similar overall profiles 251 in chemical exposures or 
physiological response. Using Euclidean distance would cluster the sector-collar combinations 
based on magnitude of the regression coefficients, e.g. sector-collars with the highest chemical 
biomarker levels would cluster together. Third, we needed to decide which linkage method to use 
in order to best determine how the sector-collars combinations should cluster together based on 
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similarity in chemical exposures or physiological responses 251. Hence, we tested four difference 
linkage functions: single, complete, average, and McQuitty’s linkage method. We provided 
description of each linkage method in Table A3.6. Fourth, we selected the linkage method that 
generated the dendrogram that best preserves the dissimilarity between the sector-collar 
combinations. We evaluated this performance with the cophenetic correlation coefficient (Table 
A3.7-A3.8), which is a correlation coefficient between the original distance matrix and the distance 
matrix generated by the clustering configuration 254. A cophenetic correlation coefficient equal to 
1 implies that the clustering configuration perfectly preserves the dissimilarity between the objects, 
e.g. sector-collar combinations. Finally, we conducted hierarchical agglomerative clustering with 
1500 multiscale bootstrap replicates to calculate the approximately unbiased (AU) p-values 255. An 
AU p-value of 100 implies that all bootstrap replicates support the cluster, implying that the cluster 
is strongly supported by the data 255. We visualized the clusters of sector-collar combinations with 
dendrograms. For ease of interpretation, we used Euclidean distance to cluster the chemical 
indicators based having similar profiles on occupational groups. 
We performed two types of analysis to understand the impact of occupational chemical 
exposures on physiological function in the workers population. In the first method, we compare 
the chemical exposures profiles with the physiological response within the same sector-collar 
combination or clustered group. If the same sector-collar combinations clustered together due to 
having similar profiles in both chemical exposures and physiological responses, then this may 
indicate that occupational chemical exposures are drivers leading to physiological dysfunction. In 
the second method, we defined clustered occupational groupings based on similarity in chemical 
exposure profiles. We defined a clustered group based on the sample size ≥ 400 or AU p-value ≥ 
80. To link occupational co-exposures to physiological responses, we used these chemical 
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exposure-based clustered groups as the main predictor in a series of generalized linear regressions 
with the outcome variable as a given physiological indicator and the covariates as age (continuous), 
sex (categorical), and race (categorical). We defined the reference group to include the white 
collars from public administration and other sector-collar combinations who have a similar 
chemical exposures profile. Hence, the reference group is comprised of white collars from the 
following sector-collar combinations:  Manufacture: Durable Goods; Arts, Entertainment, 
Recreation; Information; Professional, Technical Services; Education Services; Finance, 
Insurance, Real Estate, Rental; Health Care, Social Assistance; and Public Administration. 
4.4 Results 
4.4.1 Study Population  
Table 1 presents population characteristics for the 26,186 NHANES participants from 
1999-2014. Figure A3.3 presents the sample size for each sector-collar combination. Figure A3.4, 
A3.5, and A3.6 show the percentage of categories for sex, race, and poverty income ratio, 
respectively, for each sector-collar combination. Figure A3.4 shows that blue-collar jobs are 
primarily occupied by males, while females tend to work in private household, health care, and 
education. Figure A3.5 shows that white-collar occupations are predominantly comprised of Non-
Hispanic White participants, while blue-collar occupations in agriculture, fishing, forestry, 
construction, and mining blue collars are mostly comprised of Mexican Americans. Figure A3.6 
shows a socioeconomic gradient with white-collar workers having higher poverty income ratio 
compared to blue-collar workers 
4.4.2 Chemical Exposure Profiles 
Figure 4.2 displays a heatmap of the percent differences of chemical biomarker levels 
relative to white collars from public administration to show differences in chemical biomarker 
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profiles across the sector-collar combinations. The dendrogram of the sector-collars is defined 
based on using the average linkage function with Pearson’s correlation-based distance. The white 
blocks indicate that chemical biomarker levels are the same between a given sector-collar 
combination and the reference group of white collars working in public administration. Red blocks 
represent higher positive percent differences to indicate higher biomarker levels in a given sector-
collar combination compared to the reference group, while blue blocks represent higher negative 
percent differences to indicate lower biomarker levels in a given sector-collar combination or 
higher biomarker levels in the reference group. For instance, the percent difference of 3-fluorene 
between blue-collar workers in mining and the reference group is 213%, which implies that on 
average, biomarker levels of 3-fluorene in blue-collar workers in mining are more than three times 
higher compared to those of white-collar workers in public administration.  
This heatmap also shows co-exposure patterns by sector-collar combination. For example, 
compared to white-collar workers in public administration, blue-collar workers in professional or 
technical services tend to have higher levels of some of the most toxic chemicals such as cadmium, 
lead, several polyaromatic hydrocarbons (PAHs), several phthalates such as metabolites of Di-2-
ethylhexyl phthalate (DEHP), and volatile organic chemicals (VOCs), including toluene, benzene, 
and 2,5-dimethylfuran. On the other hand, this occupational group, on average, have lower levels 
of arsenic and mercury metabolites and benzophenone-3 (BP-3), a UV blocker used in sunscreen. 
This heatmap also enables the comparison of chemical exposure profiles across the 
different sector-collar combinations. The chemical exposure profiles of blue-collar workers are 
similar to the profiles of other blue-collar workers than to their white-collar counterparts. Blue-
collar workers from professional services, technical services, and retail trade have some of the 
highest biomarker levels of heavy metals, such as cadmium and lead, phthalates, PFASs, PAHS, 
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and VOCs, including xylene, ethylbenzene, toluene, benzene, and 2,5-dimethylfuran, but have 
lower levels of arsenic and mercury metabolites. Within the “Food Services” cluster, which 
includes blue collars from transportation, warehousing, other services, accommodation, and food 
services along with white collars from agriculture, forestry, fishing, accommodation, and food 
services, the phthalates signal is stronger in the workers from transportation, warehousing, 
accommodation, and food services, suggesting that these workers are relatively more exposed to 
phthalates. White-collar workers from health care and social assistance have the most similar 
chemical exposure profiles to that of white-collar workers from public administration as the 
percent differences across all studied chemicals are near 0, i.e. the blue and red boxes are faded.  
4.4.3 Heavy Metals 
Within the same family, the heavy metals display different exposure patterns. Lead and 
cadmium, on average, are higher in most blue-collar workers compare to the other white-collar 
workers, i.e. the red blocks are darker for right half of the heatmap compared to the left half. When 
we compared the distribution of blood cadmium concentrations across the sector-collar 
combinations and the NHANES population (Figure 4.3), we also confirmed that cadmium levels 
are predominately and significantly higher in most blue-collar workers. In contrast, several white-
collar workers have lower cadmium levels that are even below the average cadmium levels in the 
NHANES population, which is labeled with a yellow boxplot. We observed a similar pattern in 
blood lead (Figure A3.7). 
In contrast, metabolites of mercury and arsenic display the opposite exposure patterns to 
those of lead and cadmium. White-collar workers tend to have higher biomarker levels of mercury 
and arsenic metabolites, whereas blue-collar workers have lower levels of these metabolites. 
Figure 4.4 shows that the total blood mercury levels of most blue-collar are substantially and 
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significantly lower compared to those of white-collar workers. Blue-collar workers from mining 
have the lowest levels of total mercury with their average being slightly lower than the average of 
the NHANES population. In Figure A3.8, total urinary arsenic levels are also substantially lower 
for blue-collar workers from utilities, mining, information, and public administration compared to 
white-collar workers but not significant.  
4.4.4 Polyaromatic Hydrocarbons (PAHs) 
The chemical class of PAHs show very similar exposure patterns to each other and with 
lead and cadmium. Blue-collar workers, on average, have significantly higher levels of PAHs as 
show with percent differences ranging from 0 to 213.1% (Figure 4.2 and 4.5). Blue-collar workers 
from mining show that highest difference of 1-napthol and 3-fluorene at 213.1%, suggesting that 
levels of 3-fluorene are over three times as high as biomarker levels found in white-collars working 
in public administration. Average 3-fluorene levels are highest in blue-collar workers, who levels 
are higher compared to average biomarker levels in the NHANES population (Figure 4.5). In 
contrast, most white-collar workers, on average, have some of the lowest biomarker levels of 3-
fluorene with their levels being under the average of the NHANES population. 
4.4.5 Benzophenone-3 (BP-3) 
Based on the linear regression results, biomarker levels for BP-3, a biomarker of sunscreen  
and cosmetic use, are among the three highest in the reference group of white-collar workers from 
public administration compared to all other sector-collar combinations. But upon examining the 
distributions of BP-3 (Figure 4.6), we observed that the mean measurements of white-collar 
workers from public administration are lower compared to nine other sector-collar combinations. 
Biomarker levels of BP-3 for these sector-collar combinations are also higher compared to the 
average for the NHANES population. On the other hand, blue-collar workers, especially those in 
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mining, manufacture of durable goods, professional, and technical services, have some of the 
lowest mean and median concentration of BP-3, well below the average of the NHANES 
population. 
4.4.6 Per- and Polyfluoroalkyl Substances (PFASs) 
Like the heavy metals, there are different exposures patterns within the chemical class of 
PFASs. Within blue-collar workers in professional services, technical services, and retail trade, 
the highest percentage differences are found in perfluorobutane sulfonic acid (PFBS) and 
perfluorododecanoic acid (PFDA), while slightly higher differences are found in 
perfluoroheptanoic acid (PFHpA), perfluorooctane sulfonic acid (PFOS), and perfluorooctane 
sulfonamide (PFOSA). These chemicals are clustered in the center of Figure 4.2. Blue collars 
from utilities, agriculture, forestry, and fishing have a similar exposure profile to the previously 
mentioned blue-collar workers but at lower magnitudes. Differences between the previously 
mentioned sector-collar combinations and white-collar workers from public administration are 
minimal for perfluoroundecanoic acid (PFUnA), perfluorodecanoic acid (PFDA), perfluorohexane 
sulfonic acid (PFHxS), and perfluorooctanoic acid (PFOA), which are clustered at the bottom of 
Figure 4.2. Interestingly, biomarker levels of perfluorononanoic acid (PFNA) are higher in the 
reference group. In Figure 4.7, blue collar workers in professional services, technical services, 
retail trade, agriculture, forestry, and fishing, on average, have substantially and significantly 
higher average biomarker levels of PFDA compared to the reference group and the NHANES 
population. 
4.4.7 Phthalates  
Even within the same chemical family, individual phthalates metabolites show very 
different exposure patterns. Metabolites of DEHP are higher in blue collars working in 
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professional services, technical services, and retail trade, who show the highest positive percent 
differences. On the contrary, other phthalates are lower in the same occupational groups with 
mono-isononyl and mono-isobutyl phthalates having negative percent differences (Figure 4.2). 
This suggests that biomarker levels of mono-isononyl and mono-isobutyl phthalates for these 
occupational groups are lower than those found in the reference group. All phthalate metabolites 
are generally higher in blue- and white-collar workers from accommodation and food services 
compared to the reference group. The exposure difference for mono-(2-ethyl)-hexyl phthalate 
(MEHP) is substantial and only significant for blue-collar workers in professional, technical 
services at 61% (p-value = 3.8e-02) and retail trade at 38.2% (p-value = 3.3e-02). In Figure 4.8, 
average MEHP levels were the highest for blue-collar workers in private household, professional 
and technical services, and utilities along with white-collar workers in arts, entertainment, and 
recreation.  
4.4.8 Differences in Physiological Stress Response   
Figure 4.9 displays the percent differences of physiological indicators to show differences 
in physiological response profiles across the sector-collar combinations. The interpretation is 
similar to that for Figure 4.2. 
This heatmap enables the comparison of physiological response profiles among the sector-
collar combinations. Like the chemical exposure profiles, hierarchical clustering nearly split the 
sector-collar combinations into two large groups: one comprised mostly of blue-collar workers on 
the right of Figure 4.9 and the other of most white-collar workers on the left. This implies that 
workers within the same collar class have similar physiological profiles. The profiles of the blue-
collar workers are predominantly characterized by lower C-reactive protein levels, which is 
indicative of decreased inflammation. The exception is found in blue collars working in mining, 
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transportation, and warehousing as the percent difference in C-reactive proteins levels are +57% 
and +6.3%, respectively, relative to the reference group of white collars from public 
administration. Compared to the reference group, most blue-collar workers have lower values in 
glucose control indicators such as Homeostatic Model Assessment of Insulin Resistance (HOMA-
IR) and the ratio of insulin to glucose, higher measurements of alkaline phosphatase (a biomarker 
of liver disease or bone disorder), and higher measurements of glomerular filtration rate, which is 
indicative of increased kidney filtration function. In addition, most blue-collar workers have lower 
values of markers describing body fat deposition including subscapular skinfold, triceps skinfold, 
relative fat mass index, waist circumference, body mass index (BMI), and weight, which may be 
indicative of their physical fitness or the physical demand of their jobs.  
The physiological profiles of the white-collar workers differ even within the same collar 
class. Values of HOMA-IR and ratio of insulin to glucose are lower or on par with those found in 
white collars from public administration. This contrast with white-collar workers from agriculture, 
forestry, fishing, and construction, who have higher values. Measurements of body fat deposition, 
alkaline phosphatase, GFR, and white blood cell count are very similar for most white-collar 
workers. 
4.4.9 Alkaline phosphatase 
Alkaline phosphatase is an enzyme found in blood that help break down proteins with 
important role in liver function and bone development 256. Biomarker levels below 20-44 U/L may 
indicate hypophosphatasia, a rare genetic disease that affects bones and teeth, while levels above 
116-147 U/L may indicate liver damage. Biomarker levels of alkaline phosphatase are significantly 
higher in several blue collars compared to the reference group and the NHANES population 
(Figure 4.10). Most of the workers in each sector-collar combination are within the normal range. 
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However, there is a high percentage of workers with biomarker levels outside the normal range for 
the blue collars, especially those working in agriculture, forestry, and fishing. On the other hand, 
the lowest average concentrations of alkaline phosphatase are found predominantly in white-collar 
workers, who averages are 3-7 U/L lower than that of the NHANES population.  
4.4.10 Indicators of Inflammatory Response 
White blood cells are cells of the immune system responsible for protecting the body 
against infectious disease and foreign invaders 257. C-reactive protein (CRP) is a protein made by 
the liver where increased levels are indicative of a condition causing inflammation in the body 258. 
After correcting for multiple comparisons, no results were significant for white blood cell count. 
CRP levels are significantly lower in white-collar workers from education services, professional, 
technical services, and arts, entertainment, recreation and in most blue collars as shown with 
negative percent differences. This is not the case for blue collars working in mining, however, who 
have the highest difference observed at 57.1% compared to the reference group of white collars 
from public administration. In Figure 4.11, while the unadjusted average mean concentration of 
CRP is not the highest for blue-collar workers from mining, 60.3% of these workers have CRP 
levels higher than the clinical threshold established at 0.1 mg/dL.  
4.4.11 Indicators of Insulin Resistance 
Insulin resistance occurs when the body’s cells do not respond normally to insulin to 
control blood glucose levels 259. On average, higher values of HOMA-IR are found in white collars 
from agriculture, forestry, fishing, and construction along with blue collars from information and 
private household, which is indicative of higher to insulin resistance. However, these results are 
not significant after adjusting for multiple comparisons. The only significant result was for blue 
collars working in construction, whose values of HOMA-IR are 18.8% lower compared to those 
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for white-collars from public administration. Interestingly, in Figure 4.12, 51% and 43.4% of the 
white collars from agriculture, forestry, fishing, and construction, respectively, along with 41.9% 
and 46.2% blue collars from information and private household, respectively, are above the clinical 
threshold for HOMA-IR. This suggests that approximately more than 40% of the workers in these 
occupational groupings are susceptible to insulin resistance.  
4.4.12 Glomerular Filtration Rate (GFR) 
GFR is a measure of kidney function with values below 90 mL/min/1.73 m2 indicative of 
kidney damage and higher values indictive of hyperfiltration 260. The effect sizes for several blue 
collars and only one white-collar group from transportation and warehousing remain significant 
after correcting for multiple comparisons. Interesting all these effect sizes are positive, indicating 
that average adjusted GFRs for these occupational groups are higher compared to the reference 
group. Moreover, less than 25% of the workers for these groups have GFRs indicative of kidney 
disease (Figure 4.13). The most susceptible occupational groups are the white collars from 
professional and technical services, agriculture, forestry, fishing, and construction, with at least 
2.9% of the population with GFR below 60 mL/min/1.73 m2.  
4.4.13 Indicators of Body Fat Deposition 
Indicators of body fat deposition include BMI, relative fat mass index, waist circumference, 
weight, subscapular skinfold, and triceps skinfold. Triceps skinfold is the thickness measured at 
the back side in the middle of the upper arm 261, while subscapular skinfold is measured under the 
lowest point of the shoulder blade 262. The thickness of the skinfold is a measure for subcutaneous 
fat. Several blue-collar workers, on average, have lower measurements of subscapular and triceps 
skinfold compared to the reference group, whereas most white collars show similar profiles with 
the reference group except for those working in agriculture, forestry, fishing, and manufacture of 
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non-durable goods. Almost all sector-collar combinations, on average, have lower measurements 
of subscapular skinfold compared the reference group of white collars from public administration. 
Several of these differences are significant within the blue-collar class. The effect sizes are 
concurrent with the unadjusted mean measurements for subscapular skinfold as the average 
measurement for the reference group was the highest (Figure 4.14). Blue collars working in 
construction have the lowest average measurements of subscapular skinfold.  
4.4.14 Influence of Occupational Exposure on Physiological Function 
Comparing the chemical exposure profiles (Figure 4.15) with the physiological response 
profiles (Figure 4.16) within the same sector-collar combination or clustered group may provide 
insights into the influence of occupational exposures on eliciting a physiological response. 
Interestingly, both clustering procedures first split the sector-collar combinations by collar class, 
implying that chemical exposures profiles and the physiological response profiles are similar for 
workers within the same collar class. More specifically, some of the sector-collar combinations 
that show the highest averages of alkaline phosphatase levels are blue-collars from agriculture, 
forestry, fishing, retail trade, education services, and professional, technical services. These same 
sector-collar combinations are in the same cluster for having similar chemical exposure profiles, 
which is characterized by higher biomarker levels of PFASs, heavy metals, VOCs, PAHs, and 
phthalates. As another example, blue-collar in mining have higher biomarker levels of some of the 
most toxic chemicals such as heavy metals including cadmium and lead, PAHs, and VOCs 
including benzene and toluene. They also have the highest levels of CRP, which may suggest that 
such occupational exposures may elicit an inflammatory response.  
As another method to understand the influence of chemical exposures on physiological 
function, we defined clustered occupational groupings based on similar chemical exposures 
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profiles (Figure 4.17) and compared the physiological response across these chemical exposure-
based clustered groups while adjusting for age, sex, and race (Figure 4.18). Like the results from 
comparing the clustered groups between the chemical exposures and physiological response 
profiles, blue-collar workers have similar chemical exposure profiles as well as physiological 
response profiles. In addition, the physiological responses profiles for the clustered occupational 
groups also suggest that blue collar workers, compared to the reference group of white collars, 
have higher levels of alkaline phosphatase, white blood cell count, and GFR while lower 
measurements of triceps and subscapular skinfold, weight, creatinine levels, and indicators of 
glucose control such as HOMA-IR and ratio of insulin to glucose. On the other hand, indicators of 
body fat deposition such as BMI, waist circumference, weight, subscapular skinfold, and triceps 
skinfold are comparable between the reference group of white collars and two clustered groups: 1) 
an occupational group comprised of white collars from construction, management, administration, 
waste services, transportation, and warehousing along with blue collars from private household 
and 2) blue collars from public administration and white collars from wholesale trade. In contrast, 
HOMA-IR, the ratio of insulin to glucose, and cardiovascular indicators such as the ratio of total 
to HDL cholesterol, ratio of LDL to HDL cholesterol, triglycerides, and LDL cholesterols are 
higher in the previous clustered groups compared to the reference group. 
4.5 Discussions 
In this study, we present an unbiased approach to characterize difference in chemical 
biomarker levels and physiological measurements across a diverse suite of chemical contaminants 
and physiological indicators. To our knowledge, this is the first application of hierarchical 
clustering on differences by chemical exposures to identify groups of workers with similar 
chemical exposure profiles. We applied the same procedure with the physiological responses. We 
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compared the chemical exposure profiles with the physiological response profiles within the same 
sector-collar combination or clustered group to gain insights into the influence of occupational 
exposures on eliciting a physiological response. These results provide insight on differences of 
occupational exposures and responses across a wide set of industrial sectors. They are also 
informative for identifying which workers are susceptible to higher occupational exposures and 
potential adverse health outcomes. 
We identified substantial differences in chemical biomarker levels across the different 
occupational groups. Blue-collar workers show higher biomarker levels of heavy metals such as 
lead and cadmium, PAHs, PFASs, and VOCs such as toluene and benzene compared to their white-
collar counterparts. Higher lead levels found in blue collars from construction, manufacture, 
wholesale trade, retail trade, professional, and technical services may be due to how lead can be 
found in old and commercial paint, car parts, batteries, glass, and consumer products made of 
plastics 263. In addition, this same group of workers may be exposed to cadmium via industrial uses 
of cadmium in making batteries, plating, pigments, and plastics 264. Sources of occupational PAH 
exposures to this group may be due to engaging in tasks that involved combustion emission, such 
as welding, firefight, metal refining, vehicle repairs, etc. 265–267. Higher biomarker levels of PFASs 
may be due to contact with products containing PFASs, which include food packaging, stain-
resistant furniture, non-sick cookware, water repellant clothing, and medical and automotive 
application 268. Similarly, higher VOCs levels may also be due to working with product containing 
VOCs such as building material, person care products, air fresheners, cleaning productions, fuel 
oil, and gasoline 269. Higher VOCs 270,271 and PAHs 272 levels may also be due to smoking habits. 
Overall, higher biomarker levels of heavy metals, PAHs, PFASs, and VOCs in predominantly 
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blue-collar workers may be due to contact with products containing these chemicals and/or higher 
smoking prevalence. 
On the other hand, most white-collar workers have higher levels of metabolites of arsenic 
and mercury along with a biomarker of sunscreen use, BP-3. While arsenic is used in many 
industries in the manufacture of paints, wood preservatives, agriculture chemicals, and in glass 273, 
it is less likely that higher biomarker levels of arsenic metabolites in white collars are due to 
occupational exposures. A similar argument can be made for mercury as industrial uses of mercury 
involve producing thermometers, barometers, batteries, and electrical switches 274, though health 
care workers may be exposed to mercury via medical or dental equipment 275. Higher mercury and 
arsenic biomarker levels among these white-collar workers may indicate higher fish consumption 
276. This could therefore be a surrogate for behaviors associated with higher socioeconomic status 
277 instead of an indicator of occupational exposures, since fish is expensive and is more accessible 
to those with higher socioeconomic status. It is also doubtful that white-collars are exposed to BP-
3 due to their occupation as this chemical is used to manufacture agricultural chemicals, 
pharmaceuticals, plastic packaging, and household cleaning products 278,279. Instead, as BP3 is used 
to prevent UV light from damaging scents and colors in personal care products 280, it more likely 
that higher levels of this chemical may suggest that cosmetics usage has a major role in strategic 
self-presentation, which may be integral in succeeding at the jobs of white-collar workers. 
Interestingly, unlike how the chemical biomarker levels of blue collars may be due to occupational 
exposures, the chemical exposure profiles of white collars may be indicative of behaviors or habits 
associated with their occupation and socioeconomic status. 
The physiological response profiles also differ between white- and blue-collar workers. 
We observed that alkaline phosphatase was significantly higher in blue-collar workers compared 
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to their white-collar counterparts in a representative US population. These findings are supported 
by a study characterizing alkaline phosphatase levels in a representative Korean population where 
most blue-collar workers have serum alkaline phosphatase levels greater than or equal to 264 U/L 
for men and 252 U/L for women compared to unemployed and white-collar workers 281. We 
observed an inflammatory response in blue collars via higher levels of white blood cell counts, 
and the signal was the strongest in mining blue-collars via CRP. This finding could be associated 
with occupational chemical exposures or with stress, as increased psychosocial job stress is 
associated with increased inflammatory markers 282,283. The physiological response profiles of 
blue-collar workers are also characterized by elevated GFR, indicative of hyperfiltration or 
improved kidney function. This contrasts with other studies that finding the lower GFR is 
associated with blue-collar jobs 284,285. Across markers of body fat deposition, these measurements 
were on average, significantly lower in blue collars from accommodation, food services, arts, 
entertainment, recreation, retail trade, construction, agriculture, forestry, fishing, and professional 
and technical services. Obesity prevalence has also been found to be lower in these occupational 
groups 286. These findings suggest that markers of body fat deposition may serve as surrogates of 
physical activity 287,288. We observed that the ratio of insulin to glucose was significantly lower in 
blue collars working in accommodation, food services, arts, entertainment, recreation, and 
construction compared to the reference group of white collars from public administration. While 
the higher ratios indicate insulin resistance in white collars from agriculture, forestry, fishing, and 
construction, the result was not significant. Interestingly, we observed that the workers with 
significantly lower ratio of insulin to glucose also have lower measurements on marker of fat 
deposition. This may suggests that insulin resistance is prevented by the physical activity required 
by the job for these blue-collar works 289. We observed a healthy worker effect in the blue-collar 
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workers for indicators of body fat deposition and kidney function but not for alkaline phosphatase. 
These results emphasize that using a broad set of physiological enable a more holistic 
characterization of human health.  
While we did not directly assess the impact of multiple chemical exposures on 
physiological response, we noticed potential links between the chemical exposures and 
physiological response profiles within the same occupational group. In our study, blue-collar 
workers in mining are exposed to some well characterized highly toxic chemicals including heavy 
metals such as cadmium and lead, the PAHs, and VOCs such as benzene and toluene. Furthermore, 
these workers also have a strong inflammatory response. Even after adjusting for age, sex, and 
race and correcting for multiple comparison, biomarker levels of C-Reactive Protein are 57.1% 
higher and significant compared to reference group of white collars from public administration. In 
fact, several studies have observed that cadmium exposures induce inflammation in mouse 290–293 
even at non-toxic levels 294. Similarly, lead exposures are also associated with inflammation 295–
297. One study assessed the association between CRP and blood lead levels in NHANES and found 
men are at increased risk of lead-induced inflammation than women 298. Interestingly, majority of 
mining blue collars in NHANES are men, thus occupational exposure to heavy metals like lead 
may elicit an inflammatory response in mining blue collars. In addition, PAHs 299–302 and VOCs 
such as toluene 303,304 and benzene 305,306 are also known to elicit an inflammatory response 
individually and in combination 97. Overall, our findings provide additional evidence to suggest 
that occupational co-exposures to lead and cadmium, PAHs, and VOCs may induce an 
inflammatory response in blue collar workers in the mining sector.  
As another example to link chemical exposures to physiological response, blue collars from 
agriculture, forestry, fishing, retail trade, education services, and professional, technical services 
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have the highest levels of alkaline phosphatase and have a chemical exposure profile characterized 
by higher levels of heavy metals such as lead and cadmium, PFASs, VOCs, PAHs, and phthalates. 
Numerous studies show that heavy metals do induce liver damage 307,308, which results in higher 
levels of alkaline phosphatase. PFASs have also been associated with altered liver function 309 and 
liver damage and cancer 310. Several studies have discovered significant associations between 
exhaled VOCs and liver disease 311,312, and thus exhaled VOCs can be used as diagnostic indicators 
of liver disease 313–315 Exposures to PAHs induce precancerous liver lesions and cancer in mice 316 
and chronic exposure to PAHs has been associated with liver damage in humans 317. Phthalates 
also modulate liver function 318,319. These findings emphasize that co-exposures of heavy metals, 
PFASs, VOCs, PAHs, and phthalates may induce liver damage and may explain the elevated levels 
of alkaline phosphatase observed in blue collars working in agriculture, forestry, fishing, retail 
trade, education services, professional services, and technical services. Since excess alcohol 
consumption can causes liver damage, the higher levels of alkaline phosphatase found in blue 
collars may be a signal for alcohol intake. Thus, future studies can adjust for alcohol consumption 
to help disentangle the association between occupational exposures and liver disease.  
The physiological profiles of these workers are also characterized by elevated GFR, 
indicative of hyperfiltration. Hyperfiltration has been linked to high exposures to cadmium 320 and 
lead 321,322. Moreover, exposures to lead or cadmium have been associated with an initial increase 
in GFR and then a decline 320,321,323. This suggests a physiological response to eliminate the 
toxicants and then the subsequent loss of kidney function. Reduced 324 and increased GFRs have 
also been associated with PFASs 325,326. While reduced GFR is concerning as it indicates kidney 
damage, increased GFRs have also been associated with higher risk of cardiovascular morbidity 
and mortality 327,328. Exposures to VOCs have also been associated with kidney dysfunction 329 
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with higher exhaled levels of VOCs observed in critically ill patients with acute kidney injury 
compared to their counterparts with normal renal function 330. But VOCs exposures have not been 
linked to hyperfiltration. PAHs may contribute to kidney dysfunction 331 by disrupting the balance 
between production of harmful free radicals and the ability of the body to counteract their harmful 
effects with antioxidants 332, leading to oxidative stress 333. Cigarette smoking is associated with 
elevated GFRs 334, and as PAHs are present in tobacco products 272, exposures to this chemical 
class may also be linked to hyperfiltration. Increase in phthalates, particularly DEHP metabolites, 
was associated with kidney disease 335. On the other hand, these phthalates are associated with 
elevated GFRs 336. Overall, evidence suggests that exposures to heavy metals, PFASs, VOCs, 
PAHs, and phthalates are associated with both reduced and elevated GFRs and may vary based on 
the dose and duration of exposure. But it is unclear whether chemical-mediated hyperfiltration is 
a precursor of hypofiltration and subsequently a primary factor in kidney dysfunction. Thus, future 
studies can observe how chemical exposures influence the temporal trends of GFR. 
Many studies using NHANES have been limited to studying co-exposures and its impact 
on human health in one chemical family 93–95. Our framework enabled the identification of co-
exposure across a wide range of chemicals not only limited to one chemical family. The primary 
limitation of this study is the non-random sparsity of the chemical biomarker data in the worker 
population. This sparsity prevented the application of hierarchical clustering on individual workers 
as we could not build a complete dataset with participants, who have measurements for all studied 
chemicals. While there are no participants with measurements for all 108 studied chemical 
indicators, there are participants with measurements for a subset of these substances as shown in 
Table 2. For example, there are 811 participants with occupational data and measurements 
available in at least 90 chemicals. Thus, future studies can determine the set of overlapping 
 112 
 
chemicals among these participants and conduct clustering analysis on the raw chemical biomarker 
dataset. By observing the similarity of the clustering configurations between using the regression 
statistics versus using the raw data, these future analyses will help substantiate the findings of this 
paper. As another way to address this sparsity challenge, we conducted clustering analysis on 
exposure differences among the different sector-collar combinations, i.e. we applied clustering 
analysis on statistics of the biomarker data instead of on the raw data. A dataset of statistics derived 
from the biomarker data is usually complete. By applying hierarchical clustering on a dataset of 
statistics that represents exposure or physiological differences, we identified group of workers with 
similar exposure or physiological response profiles. This framework can be applied in other 
settings to help cluster observations based on similar profiles especially in a non-randomly sparse 
dataset. This can be done without having to form a complete dataset of impute the missing values. 
However, our framework does have disadvantages. First, there is a substantial reduction in 
sample size, which will affect statistical power to detect significant differences. Second, there is a 
high chance that the dataset of statistics is singular, which makes applying machine learning 
techniques almost impossible. Our dataset of percent differences on chemical exposures was 
singular, due to biomarker levels of several VOCs being the same across all sector-collar 
combinations. A solution to this problem of having a singular matrix would involve removing 
these chemicals from the analysis. Finally, the main disadvantage of our framework is that we did 
not model the impact of co-exposures on physiological response. Thus, future studies can use 
statistics of a given physiological indicator as the outcome variable in a regression model with 
statistics of the chemical indicators as the main predictors to identify the most important set of 
chemicals responsible for explaining the variation of the physiological indicator. 
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The present study has several other limitations. First, the sample size for participants with 
occupational data is only 25% of that of the NHANES population. This 75% reduction in sample 
size is due to 50% of the participants agreeing to provide information on their occupation and then 
50% of those participants responding that they are not working at a job or business. The analysis 
was limited by the small sample size, which prevented us from establishing a direct link between 
multiple chemical exposures and physiologic dysfunction. As NHANES includes more 
occupational data with each study year, future analysis will have increased statistical power to 
model the associations between chemical exposures and associated effects across different 
occupational groups. Second, we assume a linear association between age and chemical biomarker 
levels, which may not reflect how the chemical biomarker levels changes across the life-stage. 
Hence, future studies can determine which higher order polynomial would best describe the 
association between age and chemical biomarker levels to best account for the confounding effect 
of age on chemical biomarker levels. Future work can also use Gaussian kernel regressions to 
model the non-linear associations of chemical biomarker levels for age or other continuous 
variable and chemical biomarker levels. A Gaussian kernel regression model involves taking a 
weighted average of the surrounding data points to predict a given data point 337 Third, we did not 
correct for physical activity, which may explain why measurements of body fat deposition in lower 
in blue collar workers compared to their white-collar counterparts. Thus, further studies can 
account for physical activity in their models by using metabolic equivalents. Fourth, the strong 
signal of VOCs and PAHs observed in blue-collar workers may be due to smoking habits, which 
we did not adjusting for smoking in our models. Future analysis can conduct a sensitivity analysis 
to observe how the results changes when smoking is accounted. Fifth, a limitation of using 
chemical biomarker data is that a delay between the time of exposure and time of data collection 
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may prevent the detection of higher occupational exposures. This limitation is especially salient 
for VOCs, which have short half-life ranging from 2 to 128 hours 134,135. Thus, differences observed 
between the occupational groups could be substantially higher if data collection occurred at the 
time of exposure, e.g. at the workplace. Hence, future directions can involve comparing biomarker 
levels of chemicals between workers who had their measurements taken on a workday versus those 
who were measured on an off day. Sixth, long-term stress and social factors such as social 
economic status, education, and health access may impact health as much or more than 
environmental exposures. In addition, these factors can modulate the effects of environmental 
exposures 338. Thus, future work can involve accounting for these confounders as well as studying 
the interaction effects to better understand the contribution of chemical exposures to adverse health 
outcomes. In addition, to identify which environmental factors are most important in explaining a 
health endpoint, future directions can incorporate feature selection techniques such as LASSO 
(least absolute shrinkage and selection operator), adaptive elastic net, random forest and feature 
extraction techniques such as partial least squares and principal component regression. Finally, we 
assessed physiological response by using individual physiological indicators instead of pooling 
them together to better evaluate overall physiological dysfunction. Therefore, future studies can 
use the studied physiological indicators to define an allostatic load score to characterize the overall 
physiologic dysfunction 339–341 associated with multiple chemical exposures across the 
occupational groups. 
4.6 Conclusions 
Evaluating the influence of multiple occupational exposures on the physiological 
functioning is essential to begin understanding how chemical exposures elicit physiological 
response associated with adverse health outcomes. We applied an unbiased approach to screen 
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across 108 chemical indicators and 27 physiological indicators to characterize the chemical 
exposure and physiological response profiles across white- and blue-collars from 20 different 
industrial sectors. We developed a framework using hierarchical clustering on differences of 
chemical biomarker levels and physiological measurements to identify clusters of workers with 
similar chemical exposure and physiological response profiles. This framework enabled us to 
identify similar clustering between chemical exposure and physiological response profiles to 
characterize the indirect impact of multiple chemical exposures on physiological response in the 
workers population. Our framework enabled 1) comprehensive characterization of chemical 
exposures and physiological responses across a wide variety of occupations, 2) evaluation of 
occupational co-exposures patterns, and 3) identification of occupations susceptible to high 
exposure and physiological dysfunction. These findings can also guide efforts to design targeted 
interventions to reduce health disparities in susceptible occupations.  
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4.7 Figures  
 
Figure 4.1. Schematic description on curation of chemical biomarker and physiological 
measurements and of the analytical methods used to characterize occupational variations in 
chemical exposures and physiological responses. Reference group for the analysis on the sector-
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Figure 4.2. Heatmap of percent differences in chemical biomarker concentrations by sector-
collar combinations, relative to Public Administration - White Collars. Chemical biomarkers in 
white color indicates that the concentrations are the same between the given sector-collar 
combination and the reference group. The color bar represents the collar categorization. Blue 
presents the blue-collar workers, while gray represents the white-collar workers. Results are 






Figure 4.3. Box plot of distribution of blood cadmium. Far-left statistics are the mean chemical 
biomarker concentration. The middle-left statistics are the percent differences except for the 
“reference” group of “Public Administration – White Collars” and the “NHANES population”. 
The NHANES population includes all participants with measurements for cadmium, including the 
sector-collar combinations. The middle-right statistics are the p-values corrected for multiple 
comparison with the Benjamini and Hochberg FDR procedure of 5%. Far-right statistics are the 
sample size of each sector-collar combinations. Purple triangle represents the mean concentration 





Figure 4.4. Box plot of distribution of total mercury in blood. Far-left statistics are the mean 
chemical biomarker concentration. The middle-left statistics are the percent differences except 
for the “reference” group of “Public Administration – White Collars” and the “NHANES 
population”. The NHANES population includes all participants with measurements for cadmium, 
including the sector-collar combinations. The middle-right statistics are the p-values corrected 
for multiple comparison with the Benjamini and Hochberg FDR procedure of 5%. Far-right 
statistics are the sample size of each sector-collar combinations. Purple triangle represents the 
mean concentration of total mercury for a given sector-collar combination. Results are adjusted 





Figure 4.5. Box plot of distribution of urinary 3-fluorene. Far-left statistics are the mean chemical 
biomarker concentration. The middle-left statistics are the percent differences except for the 
“reference” group of “Public Administration – White Collars” and the “NHANES population”. 
The NHANES population includes all participants with measurements for cadmium, including the 
sector-collar combinations. The middle-right statistics are the p-values corrected for multiple 
comparison with the Benjamini and Hochberg FDR procedure of 5%. Far-right statistics are the 
sample size of each sector-collar combinations. Purple triangle represents the mean concentration 






Figure 4.6. Box plot of distribution of urinary benzophenone-3 (BP-3), a biomarker of sunscreen 
use. Far-left statistics are the mean chemical biomarker concentration. The middle-left statistics 
are the percent differences except for the “reference” group of “Public Administration – White 
Collars” and the “NHANES population”. The NHANES population includes all participants with 
measurements for cadmium, including the sector-collar combinations. The middle-right statistics 
are the p-values corrected for multiple comparison with the Benjamini and Hochberg FDR 
procedure of 5%. Far-right statistics are the sample size of each sector-collar combinations. Purple 
triangle represents the mean concentration of urinary BP-3 for a given sector-collar combination. 






Figure 4.7. Box plot of distribution of perfluorododecanoic acid (PFDA). Far-left statistics are the 
mean chemical biomarker concentration. The middle-left statistics are the percent differences 
except for the “reference” group of “Public Administration – White Collars” and the “NHANES 
population”. The NHANES population includes all participants with measurements for cadmium, 
including the sector-collar combinations. The middle-right statistics are the p-values corrected for 
multiple comparison with the Benjamini and Hochberg FDR procedure of 5%. Far-right statistics 
are the sample size of each sector-collar combinations. Purple triangle represents the mean 





Figure 4.8. Box plot of distribution of urinary mono-(2-ethyl)-hexyl phthalate, a metabolite of the 
plasticizer Di-2-ethylhexyl phthalate, DEHP. Far-left statistics are the mean chemical biomarker 
concentration. The middle-left statistics are the percent differences except for the “reference” 
group of “Public Administration – White Collars” and the “NHANES population”. The NHANES 
population includes all participants with measurements for cadmium, including the sector-collar 
combinations. The middle-right statistics are the p-values corrected for multiple comparison with 
the Benjamini and Hochberg FDR procedure of 5%. Far-right statistics are the sample size of each 
sector-collar combinations. Purple triangle represents the mean concentration of urinary mono-(2-






Figure 4.9. Heatmap of percent differences in physiological indicator measurements by sector-
collar combinations, relative to Public Administration - White Collars. Physiological indicators in 
white color indicate that the measurements are the same between the given sector-collar 






Figure 4.10. Box plot of distribution of alkaline phosphatase. Far-left statistics are the mean 
concentrations. The middle-left statistics are the percent differences except for the “reference” 
group of “Public Administration – White Collars” and the “NHANES population”. The 
NHANES population includes all participants with measurements for alkaline phosphatase, 
including the sector-collar combinations. The middle statistics are the p-values corrected for 
multiple comparison with the Benjamini and Hochberg FDR procedure of 5%. The middle-right 
statistics are the sample size of each sector-collar combinations. The far-right statistics are the 
percentage of participants outside of the range of normality, i.e. percentage of participants whose 
measurements are beyond the pink boxes. Purple triangle represents the mean concentration of 






Figure 4.11. Box plot of distribution of C-reactive proteins (CRP). Far-left statistics are the mean 
concentrations. The middle-left statistics are the percent differences except for the “reference” 
group of “Public Administration – White Collars” and the “NHANES population”. The NHANES 
population includes all participants with measurements for alkaline phosphatase, including the 
sector-collar combinations. The middle statistics are the p-values corrected for multiple 
comparison with the Benjamini and Hochberg FDR procedure of 5%. The middle-right statistics 
are the sample size of each sector-collar combinations. The far-right statistics are the percentage 
of participants outside of the range of normality, i.e. percentage of participants whose 
measurements are beyond the pink boxes. Purple triangle represents the mean concentration of 






Figure 4.12. Box plot of distribution of Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR). Far-left statistics are the mean concentrations. The middle-left statistics are the 
percent differences except for the “reference” group of “Public Administration – White Collars” 
and the “NHANES population”. The NHANES population includes all participants with 
measurements for alkaline phosphatase, including the sector-collar combinations. The middle 
statistics are the p-values corrected for multiple comparison with the Benjamini and Hochberg 
FDR procedure of 5%. The middle-right statistics are the sample size of each sector-collar 
combinations. The far-right statistics are the percentage of participants outside of the range of 
normality, i.e. percentage of participants whose measurements are beyond the pink boxes. Purple 
triangle represents the mean concentration of HOMA-IR for a given sector-collar combination. 





Figure 4.13. Box plot of distribution of glomerular filtration rate (GFR). Far-left statistics are the 
mean concentrations. The middle-left statistics are the percent differences except for the 
“reference” group of “Public Administration – White Collars” and the “NHANES population”. 
The NHANES population includes all participants with measurements for alkaline phosphatase, 
including the sector-collar combinations. The middle statistics are the p-values corrected for 
multiple comparison with the Benjamini and Hochberg FDR procedure of 5%. The middle-right 
statistics are the sample size of each sector-collar combinations. The far-right statistics are the 
percentage of participants outside of the range of normality, i.e. percentage of participants whose 
measurements are beyond the pink boxes. Purple triangle represents the mean concentration of 






Figure 4.14. Box plot of distribution of subscapular skinfold. Far-left statistics are the mean 
concentrations. The middle-left statistics are the percent differences except for the “reference” 
group of “Public Administration – White Collars” and the “NHANES population”. The NHANES 
population includes all participants with measurements for alkaline phosphatase, including the 
sector-collar combinations. The middle-right statistics are the p-values corrected for multiple 
comparison with the Benjamini and Hochberg FDR procedure of 5%. The far-right statistics are 
the sample size of each sector-collar combinations. Purple triangle represents the mean 
concentration of subscapular skinfold for a given sector-collar combination. Results are adjusted 





Figure 4.15. Dendrogram of sector-collar combinations based on exposure profiles for 108 
chemical biomarkers. Pearson’s correlation-based distance is the dissimilarity metric. Average 
linkage method was used due to having the highest cophenetic correlation coefficient, i.e. using 
this linkage method generated the dendrogram that best preserves the dissimilarity between the 







Figure 4.16. Dendrogram of sector-collar combinations based on physiological response profiles 
for 27 physiological indicators. Pearson’s correlation-based distance is the dissimilarity metric. 
Average linkage method was used due to having the highest cophenetic coefficient, i.e. using this 
linkage method generated the dendrogram that best preserves the dissimilarity between the sector-






Figure 4.17. Dendrogram of sector-collar combinations based on exposure profiles for 108 
chemical indicators. Red text represents the sample size of the sector-collar combination. Red 
boxes indicate the clustered occupational groups defined based on of sample size ≥ 400 or AU p-
value ≥ 0.8. Pearson’s correlation-based distance is the dissimilarity metric. Average linkage 
method was used due to having the highest cophenetic correlation coefficient, i.e. using this 
linkage method generated the dendrogram that best preserves the dissimilarity between the sector-
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Figure 4.18. Heatmap of percent differences in physiological indicator measurements by clustered 
groups, relative to White Collars from Manufacture: Durable Goods; Arts, Entertainment, 
Recreation; Information; Professional, Technical Services; Education Services; Finance, 
Insurance, Real Estate, Rental; Health Care, Social Assistance; and Public Administration. 
Physiological indicators in white color indicate that the measurements are the same between the 
given sector-collar combination and the reference group. The color bar represents the collar 
gradient of the collar categorization. Dark blue indicates that the occupational cluster is comprised 
of all blue-collar workers. Lighter blue implies that the occupational cluster is comprised of a 
mixture of blue and white-collar workers. Gray implies that the occupational cluster includes only 





4.8 Tables  
 




Cycle                 N (%) Sex                 N (%) 
      1999-2000 
(Cycle 1)                 3020 (11.5)       Male                 14030 (53.6) 
      2001-2002 
(Cycle 2)                 3469 (13.2)       Female                 12156 (46.4) 
      2003-2004 
(Cycle 3)                 3036 (11.6) Race/Ethnicity  
      2005-2006 
(Cycle 4)                 3340 (12.8)       Mexican Americans                 5347 (20.4) 
      2007-2008 
(Cycle 5)                 3435 (13.1)       Other Hispanics                 2001 (7.6) 
      2009-2010 
(Cycle 6)                 3472 (13.3)       Non-Hispanic Whites                 11370 (43.4) 
      2011-2012 
(Cycle 7)                 3024 (11.5)       Non-Hispanic Blacks                 5437 (20.8) 
      2013-2014 
(Cycle 8)                 3390 (12.9)       Other Races                  2031 (7.8) 
      
CONTINUOUS 
 N (%) Minimum 5th 10th Median Mean (SD) 90
th 99th Maximum 
Age (years) 26186 (100) 16 18 19 39 
39.6 
(15.3) 61 75 85 
 135 
 
Chapter 5 Characterization of Linear and Non-linear Associations between Physiological 
Indicators and All-Cause Mortality 
 
5.1 Abstract 
Importance: Clinicians have used thresholds to prioritize high-risk patients usually 
without considering the linear or non-linear associations between a physiological indicator and a 
health endpoint. 
Objective: To determine whether the clinical thresholds align with values indicative of 
increased mortality risk by characterizing the linear and non-linear relationships with all-cause 
mortality for 27 physiological indicators. 
Design: We used the cross-sectional, biomarker data from the 1999-2014 National Health 
and Nutrition Examination Survey linked with National Death Index mortality data collected 
through December 31, 2015. 
Setting: Data were analyzed from January 2019 to April 2020. 
Participants: A nationally representative sample of 45,032 adults aged 18 years and older.  
Exposures: 9 cardiovascular, 7 body composition, 5 metabolic, 4 nephrological, and 2 
immune biomarkers  
Main Outcomes and Measures: All-cause mortality. We used Cox proportional hazards 
regression models adjusted for age, sex, and race to associate physiological indicators with all-
cause mortality. We used 10-fold cross validation to help select the most appropriate model using 
the Concordance Index, Nagelkerke R2, and Akaike Information Criterion. We compare the 
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clinical thresholds to association-based thresholds, defined as values where the hazard ratio is 10% 
higher than the minimum hazard ratio.  
Results: 24 out of 27 (88.9%) indicators show non-linear associations, while height, 
triglycerides, and 60-second pulse show linear associations. 13 out of 23 indicators (57%) showed 
some agreement between the association-based and clinical thresholds. Creatinine shows 
concordance for both bounds of the male thresholds. 12 indicators were concordant for one 
threshold with confirmation of the threshold for C-Reactive Protein (CRP). 14 indicators show no 
concordance. For 10 indicators which includes the cholesterol-related indicators, glucose control 
indicators, markers of body fat deposition, and Glomerular Filtration Rate, the parabolic 
associations suggest the need for two thresholds.  
Conclusions and Relevance: The systematic characterization of the relationships with all-
mortality confirmed that most of the studied physiological indicators show non-linear associations. 
It also confirms the relevance of the clinical threshold for half of the studied indicators; however, 
there is a need to reconsider the thresholds for indicators that show parabolic associations but only 
have one bound.  
5.2 Introduction 
Clinicians commonly use reference ranges342–344 or clinical thresholds to determine 
whether a patient’s test results are normal. A reference range is defined as a set of values between 
the 2.5th and 97.5th percentiles for a physiological indicator in a healthy population345, which is the 
case for albumin, blood urea nitrogen (BUN), creatinine, alkaline phosphatase, and C-reactive 
proteins (CRP). Using percentiles without consideration of a health outcome can be presumptuous 
about disease pathophysiology346,347. Some clinical thresholds, however, were established via 
association with an outcome348–350. For example, the classification of body mass index (BMI) was 
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calibrated to all-cause mortality in 1995348. While the associations between BMI and mortality has 
changed, the classifications still remained unchanged. For an indicator of kidney function, the 
lower threshold for Glomerular Filtration Rate (GFR) was established based on associations with 
all-cause mortality and cardiovascular disease350. But the restricted distribution of GFR in the 
studied population prevented an upper bound from being defined. Thus, there is a need to evaluate 
whether the current reference ranges and clinical thresholds are relevant in distinguishing high-
risk from low-risk patients.  
Improved risk stratification requires understanding whether associations between 
physiological indicators and health outcomes are described by linearity or non-linearity351–353. 
Most association studies consider linearity107–109 or non-linearity111,112 separately without 
quantitatively assessing which of the models better describes the relationship between a given 
physiological indicator and a health outcome. Many studies do compare the prediction 
performance of various models such as linear, quadratic, cubic, and logarithmic116,117 but have not 
validated the results on new data. This led to finding that the more flexible model is deemed better 
at characterizing the associations, which may reflect the actual relationship or show an overfitted 
model118. Since these gaps may lead to significant limitations in risk surveillance and management, 
there is a need to develop a statistical framework to compare models and identify the most 
appropriate linear or non-linear model while evaluating for overfitting.  
To address these limitations, the goal of this study is to characterize the relationships 
between all-cause mortality and 27 physiological indicators in the US population. We focus on all-
cause mortality as it is the ultimate health outcome. For each physiological indicator, we 
specifically 1) compare the prediction performance of linear and different nonlinear models by 
applying a machine learning approach, 2) assess the robustness of the models by observing changes 
 138 
 
in prediction performance when extreme measurements are excluded, 3) describe the associations 
between the physiological indicator and mortality as characterized by the most appropriate 
model(s), and 4) determine the relevance of the current clinical thresholds by evaluating whether 
these values are indicative of increased mortality risk. 
5.3 Methods 
5.3.1 Study Population  
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional 
study conducted by the Centers for Disease Control and Prevention (CDC) to characterize the 
health of a non-institutionalized, civilian US population19. For this analysis, we used the 
continuous 1999-2014 NHANES data and started with sample of 82,091 participants. We also 
used data linked with the National Death Index to ascertain mortality information collected through 
December 31, 2015354. We excluded participants for not having data on mortality status (N = 
37,046) and those who were not followed up (N = 13), leading to a sample of 45,032 participants. 
Figure A4.1 describes these exclusion criteria. 
5.3.2 Measurements of Physiological Indicators 
Figure A4.1 also describes the curation process on which physiological indicators to 
include in our analysis. We identified 60 biomarkers and anthropomorphic measures that 
characterize physiologic function. To exclude physiological indicators with low overlap with the 
mortality data, we excluded those with measurements in fewer than six NHANES cycles (n = 10) 
and with a sample size of less than 10,000 participants (n = 21). As we preferred continuous 
variables for studying linear and non-linear associations, we also excluded physiological indicators 
that are categorical (n = 2). The final dataset for analysis consisted of 27 physiological indicators. 
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Tables A4.1-A4.3 compare the observed characteristics between participants with complete and 
incomplete data.  
5.3.3 Database of Clinical Thresholds 
To characterize the relevance of the current clinical thresholds, we compiled a database of 
thresholds for 23 physiological indicators from literature. Thresholds were not available for height, 
subscapular skinfold, triceps skinfold, and weight. Since the same indicator may have several 
thresholds, we used the range of the thresholds. We used sex-specific thresholds when available.  
5.3.4 Statistical Analyses 
We performed all analyses using R version 3.6.0. To produce estimates that are 
representative of the non-institutionalized, civilian US population, we accounted for NHANES 
sampling designs by applying the survey weights to our statistical models18.  
We used Cox proportional-hazards regression models to characterize the associations 
between all-cause mortality and each physiological indicator355. For each physiological indicator, 
we assessed linear associations with all-cause mortality and tested two non-linear associations by 
discretizing each indicator into 9 quantiles (“novemtiles”) and by using a weighted sum of cubic 
polynomials (“spline”)284,356 with the latter considered the more flexible, non-linear model. The 
reference group for the novemtiles models is the novemtile with the minimum mean hazard ratio. 
We conducted 10-fold cross validation357 while adjusting for linear age (continuous), sex 
(categorical), and race/ethnicity (categorical) to compare the predictive capability of the linear 
versus non-linear models. We adjusted for linear age as it showed better prediction performances 
compared to non-linear age (Figure A4.2). We observed whether the association between 
mortality and BMI remains robust after adjusting for smoking with blood cotinine. We selected 
the model that best describes the association between mortality and each physiological indicator 
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by using the Akaike Information Criterion (AIC)358, Concordance Index359, and Nagelkerke R2360. 
We provide our justification for using these fits measures in Table A4.4. We defined confidence 
intervals around each measure by bootstrapping for 1000 replicates361. To account for multiple 
comparisons across the models, we used a False Detection Rate (FDR) method of 5% on the p-
values of the regression coefficients pertaining to the physiological indicators103.  
To assess the influence of extreme measurements on the prediction performance, we 
conducted sensitivity analyses on the distributions of each physiological indicator. We applied a 
series of Cox Proportional Hazard models on sample subsets restricted to the study participants in 
the 1st to 99th, 5th to 95th, and 10th to 90th percentiles of each indicator. 
To define clinical thresholds based on the associations with mortality, we used the spline 
model to identify values of the physiological indicator that show an increased mortality risk of 
10% from the minimum risk. To define sex-specific clinical thresholds, we applied the same 
procedure to each sex.  
5.3. Results 
Table 5.1 presents population characteristics for the 45,032 participants. Figure A4.3 
displays the distributions of each physiological indicator.  
Figure 5.1 displays the Concordance Index and Nagelkerke R2s across all the models and 
physiological indicators for two populations:  one with all participants and another with 
participants who have measurements within the 1st and 99th percentiles. Figure A4.4-A4.5 display 
the AICs and Concordance Index for the same populations, respectively. Across the fit measures, 
the non-linear models show better prediction performances compared to the linear models. The 
prediction performance of the novemtiles models were consistently high across all physiological 
indicators regardless of the extent of measurements exclusion and were also stable as reflected by 
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the narrower confidence intervals. In contrast, linearity shows low R2s for inflammatory (CRP, 
alkaline phosphatase, white blood cell counts), metabolic (HOMA-IR), and nephrological (BUN, 
Creatinine) biomarkers when all participants were included. The spline model R2s are also low for 
alkaline phosphatase and cardiovascular biomarkers involving LDL cholesterol. For these 
physiological indicators, exclusion of measurements outside the 1st and 99th percentiles resulted 
in improved prediction performance, particularly for the linear and spline models. The overfitting 
is due to the linear and spline models attempting to fit to the outliers. Figure A4.6 shows the 
correlations between decreased sample size and improved prediction performance. 
Figure A4.7-A4.9 compare the prediction performance on including all participants with 
those from the sensitivity analysis on restricting the distribution of the physiological indicators to 
the 5th to 95th and the 10th to 90th percentiles. Figure A4.10 displays the statistical significance of 
all models with respect to the prediction performances. While prediction performance and 
statistical significance improved when the distribution was restricted to the 1st and 99th percentiles, 
further exclusion did not lead to further improvement for the linear nor spline models. In contrast, 
the novemtiles models show consistent prediction performance and significance regardless of the 
restrictions. This implies that studying non-linearity with quantile-based models will result in 
stable predictions, as outliers do not heavily influence these models given enough participants in 
each quantile. In our case, we ensured at least 1100 participants in each novemtile.  
Figure 5.2 displays the relative risk for death through the hazard ratios across the 
distribution of BMI, Systolic Average Blood Pressure (SBP), Ratio of Total to HDL Cholesterol, 
CRP, HOMA-IR, and GFR for the different models. We select these examples to highlight 
expected and unexpected findings, challenges in model interpretation, and relevance of the clinical 
thresholds. To aid visualization, we show the associations when measurements outside the 1st and 
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99th percentiles were excluded. Figure A4.11 displays the associations for these physiological 
indicators in the entire population, while Figure A4.12-A4.16 show the relative mortality risk for 
the remaining physiological indicators. Figure A4.17-A4.22 present the sex-specific associations. 
These figures are available online [name of shiny app]. For BMI, while the non-linear models 
show a parabolic association with death in Figure 5.2A, the linear model suggests that mortality 
risk is the same across the entire distribution. The association-based thresholds for BMI are shifted 
higher compared to the current clinical thresholds. These findings were robust even after adjusting 
for smoking (Figure A4.23). Low and high BMI were strongly associated with all-cause mortality 
in males (Figure A4.18A) than in females (Figure A4.18B). For average SBP, the linear model 
identified increased risk with elevated blood pressure (Figure 5.2B). However, the non-linear 
models suggest a parabolic association between mortality and SBP. In Figure 5.2C, the non-linear 
models imply that lower and higher ratios of Total to HDL Cholesterol are associated with higher 
mortality risk. In contrast, the linear model shows a positive association between the ratios and 
mortality. Increased mortality risk aligns with the threshold for males (Figure A4.17I) but is 
higher than the threshold for females (Figure A4.17J). In Figure 5.2D, discretization of CRP 
levels into novemtiles shows that a sigmoidal function best characterizes this association compared 
to the linear model. Mortality risk becomes apparent for CRP at the current clinical threshold of 
0.1 mg/dL. In Figure 5.2E, all models agree that elevated HOMA-IR is associated with increased 
mortality risk but disagree with the interpretation of the mortality risks at lower HOMA-IR with 
the spline, novemtiles, and linear models suggesting increased risk, no effect, and lower risk, 
respectively. In Figure 5.2F for GFR, the linear model suggests that participants below the clinical 
threshold of 90 mL/min/1.73m2 362,363 are at higher risk to death. But the non-linear models suggest 
that participants with GFR below 65 or above 90 mL/min/1.73m2 are at risk.  
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Table 5.2 compares the current clinical thresholds with the association-based thresholds. 
Creatinine shows concordance for both bounds of the male thresholds. Twelve indicators were 
concordant for one threshold with Relative Fat Mass Index, Creatinine, HDL-Cholesterol, and 
Ratio of Total to HDL Cholesterol agreeing with one of the sex-specific thresholds. Fourteen 
indicators show no concordance. 
5.4. Discussions 
We present a data-driven approach to identify the models that most appropriately describe 
the association between physiological indicators and all-cause mortality in the US population. We 
applied a machine-learning based approach to test the prediction capability and robustness of linear 
and non-linear models while penalizing models that are more prone to overfitting. We observed 
that with exception of height, triglycerides, and 60-second pulse, the associations between the 
other indicators and mortality are non-linear. We used the “winning” model(s) to determine 
expected and unexpected directions associated with higher mortality risk for each physiological 
indicator. Results from the spline models can also be informative of whether the current clinical 
thresholds align with values identified at which mortality risk increases over baseline mortality 
risk.  
There are advantages and disadvantages of using the spline models as an alternative 
approach to model the non-linear association with the novemtiles model. The spline models 
provide relative mortality risk for each measurement along the distribution of a given physiological 
indicator, while the novemtiles models provide an average risk for measurements within the same 
novemtile. Thus, using the spline model enable us to observe a gradient of mortality risk that is 
not possible in the novemtiles models. Due this attribute, spline models have been commonly used 
to define the clinical thresholds for physiological indicators such as GFR350 and BMI348. A 
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disadvantage of the spline model was the overfitting to outliers, which resulted in lower and 
unstable prediction performance. The interpretations were also unstable as the confidence intervals 
for mortality risk was wide for participants with extreme measurements. However, an unexpected 
advantage of the spline model overfitting is the ability to find individuals with extraordinary risk 
at the tails of a biomarker distribution. This highlights the need for focused study of individuals 
with these extreme biomarker levels to build better predictive models. As another disadvantage, 
when all measurements were included, fitting a spline model created difficulties in interpretation. 
The relative risks for some extreme measurements were substantially higher, therefore making the 
relative risks associated with other measurements appear negligible. However, when 
measurements outside the 1st and 99th percentiles of a given physiological indicator were excluded, 
fitting a spline model on measurements improved the interpretation along with the prediction 
performance and its stability, making it at times on par with that of the novemtiles models. But 
excluding participants, especially those with extreme measurements, is not conducive to helping 
those who would be at most need for targeted interventions. Overall, while the spline models were 
prone to overfitting due to outliers, these models provide insights on the gradient of the mortality 
risk as well as showcase the need to sample for participants with extreme measurements in order 
to enhance risk stratification.  
We found non-linear associations for cholesterol-related biomarkers. The non-linear 
models support the growing literature on the associations between higher HDL levels and 
increased mortality risk364,365, possibly contradicting the impression of being the “good” 
cholesterol. The current notion of LDL being the “bad” cholesterol implies that higher LDL levels 
are associated with increased risk366. Hence, guidelines on cholesterol management recommend 
lipid-lowering therapy for patients who show high cardiovascular risk and have LDL levels of 70 
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mg/dL or higher367. Following the guidelines might lead to more patients being treated to 
abnormally low levels of LDL. Our non-linear results show a stronger association between 
mortality and lower LDL levels compared to higher levels, which are consistent with other 
studies368–372. It is unclear whether these associations are due to preexisting disease leading to low 
cholesterol levels370,372, adverse side effects from lipid-lowering medications369,371, or low LDL 
levels being a causal factor of mortality370,373. Thus, we advocate using longitudinal data to 
understand the risk associated with changing versus stable cholesterol levels to gain insights on 
the effects at low cholesterol levels. 
Obesity in the US is a major health problem as 71% of Americans are overweight or 
obese374. Eating disorders and being underweight are also important health problems, since 10-
15% of Americans are affected375,376. Participants with lower BMI are associated with an increased 
mortality risk compared to those with higher BMI, which may be attributed to efficacy of public 
health interventions or improvements in healthcare for obesity-related conditions377. In addition, 
the associations with mortality have shifted with the minimum risk found within 24-30 kg/m2 
instead of at 24 kg/m2 348. Our results are consistent with other studies378–380, suggesting additional 
investigation on other drivers leading to decreased risk associated with higher BMI. The 
associations with all-cause mortality in lower and higher BMI were attenuated in women than in 
men381, which may suggest residual confounding due to sex differences382 and/or the survival 
advantage of adipose distribution in females383. These findings emphasize the importance to 
understand the influence of caloric intake and adipose tissue mass on mortality risk. 
Our results support low GFR (hypofiltration384) and surprisingly elevated GFR 
(hyperfiltration385) as potentially reflecting renal injury. Interestingly, mortality risk for 
participants with hyperfiltration is twice as high as those with hypofiltration in the novemtiles 
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model. This result is especially pertinent to Native Americans386 and Non-Hispanic Black 
Americans387, who on average have elevated GFR, prompting the need to establish an upper 
threshold for GFR. Overall, these findings prompt the need to also study the associations of these 
biomarkers with other health endpoints to help reevaluate these pathophysiological mechanisms 
for better informed medical decision making.  
Precision prevention and precision medicine involve leveraging biologic, demographic, 
and epidemiologic data to develop personalized risk prediction models388,389. These models can be 
used to define a risk score to quantify a patient’s likelihood to a disease event. Some clinical risk 
scores are based on assuming a linear relationship between a given biomarker and a health 
outcome390–392. We observed, however, that when including all participants, linearity has the worst 
prediction performance when describing the associations between inflammatory, metabolic, and 
nephrological biomarkers and all-cause mortality. Other risk scores dichotomized the 
physiological indicators based on a cutoff393–396, such as a clinical threshold or a percentile. For 
physiological indicators that have parabolic associations with risk, using only one threshold to 
dichotomize the indicator will result in misclassifying the patients. This scoring methodology also 
assumes that risk is the same regardless of any deviation from the cutoff. However, our findings 
prompt the need to reexamine this assumption and suggest that estimating risk in this manner does 
not adequately represents patient’s risk, especially when the measurements are extreme. 
While some risk scores account for non-linear associations, some only penalize if 
measurements are in one unfavorable direction instead of in either direction397–399, which is 
particularly problematic for indicators showing a parabolic association with an outcome. For 
example, a score estimating cardiovascular risk penalizes for high Total Cholesterol and high 
SBP397 but not for low SBP. This suggests the need to better incorporate the non-linear associations 
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in the penalization. Our results may not be generalizable to the hospitalized population. Thus, 
future studies can use our framework to incorporate these associations in defining a more 
representative risk score to help clinicians provide tailored lifestyle and medical recommendations 
to high-risk patients.  
This study has several limitations. First, the cross-sectional nature of NHANES does not 
consider changes in physiological measurements over the follow-up period. Thus, more temporal 
measurements may better dissect the unexpected associations with mortality. Second, we did not 
evaluate how other demographic or lifestyle factors may influence the relationship between a 
physiological indicator and mortality. Future analyses can build upon our baseline model to 
quantify the type of influence e.g. mediating, moderating, or confounding that such factors have 
on these associations, but the effect of bias becomes increasing difficult to untangle with more 
complex models. Third, we observed that physiological indicators with smaller sample size 
showed better prediction performance, which was especially true for the AIC as it showed a strong 
positive correlation with sample size. Thus, we caution against using our results to infer the relative 
importance of the indicators on mortality. Hence, future studies can apply feature selection 
techniques on a complete dataset comprised of participants with measurements available for all 27 
physiological indicators to infer relative importance. Fourth, the spline model may not be the most 
optimized model, since we manually defined the interior knots to be at the 25th, 50th, and 75th 
percentile of the distribution of a given physiological indicator. Hence, future studies can compare 
the cross-validated prediction performance of spline models defined with different number and 
locations of interior knots to identify the optimum spline model. In addition, future work can use 
Gaussian kernel regression models, which involves taking a weighted average of the surrounding 
data points to predict a given data point 337. Such models may be a more automated alternative to 
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the spline models as the Gaussian kernel regression models do not require knots to be defined. 
Fifth, the discretization for the novemtiles model may not have led to the optimized quantile model, 
thus future directions can involve identifying the optimal number of discretization. Finally, we 
may not confidently characterize the morality risk for participants with extreme values due to lower 
sample size. Thus, there is a need to sample more participants with extreme measurements.  
5.5. Conclusions 
Accurate identification of high-risk patients requires systematic methodologies to 
characterize the linear and non-linear associations between a physiological indicator and any 
health outcome. In this study, we developed a machine-learning based framework to establish the 
appropriate model to best characterize the relationship with all-cause mortality for a wide variety 
of physiological indicators. Our framework led to 1) determining that non-linearity is better at 
charactering the relationships with death for most of the studied indicators, 2) identifying 
unexpected directionality in the relationships between GFR and cholesterol-related biomarkers and 
increased risk of death, and 3) observing the validity of the clinical thresholds for a few biomarkers 
and also the need for reevaluation for others. Our findings can guide future efforts in risk 
prioritization, so that preventative strategies can be personalized to promote better informed 








Figure 5.1. Alphabet soup plot displaying the AIC and Nagelkerke R2 for the associations with 
all-cause mortality for all physiological indicators, grouped by body system. The prediction 
performances are displayed for two populations: one with all participants and another with 
participants who have measurements within 1st and 99th percentiles for a given physiological 
indicator. Sample size for each physiological indicator is provided to indicate the number of 
participants who have data for mortality, age, sex, race, and the given indicator. Results were 




Figure 5.2. Stairway plots of hazard ratios relative to physiological indicators across all models to 
describe the relative mortality risk for A) Body Mass Index, B) Average Systolic Blood Pressure, 
C) Ratio of Total to HDL Cholesterol, D) C-Reactive Proteins, E) Homeostatic Model Assessment 
of Insulin Resistance, and F) Glomerular Filtration Rate. For visualization aid, participants with 
measurements between the 1st and 99th percentiles of a physiological indicator are included. 
Relative risks for mortality from the novemtiles model are represented by the boxes with the width 
representing the range of a novemtile and the height representing the 95% Confidence Interval of 
the hazard ratio. The mean hazard ratio for each novemtile is presented by a digit. The hazard 
compares participants in a novemtile to those in the reference group at the novemtile shown 
without a box. The purple dot represents the reference point and the measurement of a 
physiological indicator shown to have the lowest hazard ratio for the linear and spline models. The 
red and blue lines represent the relative mortality risk with respect to reference point for the linear 
and spline models, respectively. The black dot represents the median of a physiological indicator. 
The dashed navy line represents when the hazard ratio is 10% higher than the minimum hazard 
ratio, i.e. when the hazard ratio is 1.1. The navy diamonds indicate the concentration at which the 
hazard ratio shows a 10% increase from the minimum hazard ratio. The pink lines and rectangles 
represent the values of the clinical thresholds with the width of the rectangles representing the 
ranges of the threshold. The set of tick marks along the base of the plot represent the distribution 
of a physiological indicator with increased opacity implying increased number of participants. 





Table 5.1. Characteristics of 45,032 participants and distributions of the 27 physiological indicators in the NHANES population. 
 
Categorical Variables 
Mortality Status  N (%) Sex N (%) Race N (%) 
Deceased  5588 (12.4) Males 21737 (48.3) Mexican 8562 (19.0) 
Alive  39444 (87.6) Females 23295 (51.7) Other Hispanics 3286 (7.3) 
     Non-Hispanic Whites 20312 (45.1) 
     Non-Hispanic Blacks 9665 (21.5) 
     Other Race/Multi-Racial 3207 (7.2) 
Continuous Variables 
 N Min 1st 5th 10th Median Mean 90th 95th 99th Max 
Time of follow up (months) 45032 1 12 19 27 92 97.30 177 189 199 201 
Age (years) 45032 18 18 19 21 46 47.09 75 80 85 85 
Body Composition            
Body Mass Index (kg/m**2)  44047 12.04 17.72 19.81 21.2 27.43 28.52 37.1 40.937 49.92 130.21 
Standing Height (cm)  44288 123.3 145.7 151.3 154.3 166.9 167.32 180.8 184.4 190.3 204.5 
Subscapular Skinfold (mm)  26374 2.4 6.5 8.4 9.9 19.4 20.08 31.3 34.5 38.5 44 
Triceps Skinfold (mm)  29824 2.4 4.9 7 8.5 17.8 18.92 31.2 34.2 38.4 45 
Waist Circumference (cm)  42558 55.5 67.5 73.4 77.4 96.2 97.34 118.2 126 142.2 179 
Weight (kg) 44233 25.6 45.1 52.2 56.7 77.1 80.04 106.8 118 145.4 371 
Relative Fat Mass Index (-)  42425 2.82 15.26 20.17 23.49 34.40 34.91 46.63 48.67 51.89 58.41 
Cardiovascular System            
60 sec. pulse (30 sec. pulse * 2):  43147 32 48 54 58 72 72.84 90 96 106 224 
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Diastolic: Average blood 
pressure (mm Hg)  42647 3.33 39.33 50 54.67 70 69.88 84.67 89.33 100 132 
Systolic: Average blood 
pressure (mm Hg)  42881 64.67 91.33 98.67 102.67 120 123.74 149.33 161.33 186 270 
Direct HDL-Cholesterol 
(mg/dL)  42145 7 26 32 35 50 52.77 74 82 101 188 
LDL-cholesterol (mg/dL)  19696 9 45 62 72 112 114.81 161 177 213 629 
Ratio of LDL to HDL 
Cholesterol (-)  19696 0.15 0.70 1.01 1.21 2.15 2.31 3.6 4.08 5.15 33.11 
Ratio of Total to HDL 
Cholesterol (-)  42144 1.31 1.89 2.26 2.49 3.72 3.99 5.82 6.60 8.40 37.05 
Total cholesterol (mg/dL)  42147 59 112 133 144 192 195.39 250 270 313 813 
Triglycerides (mg/dL)  42018 9 34 46 56 116 148.28 269 347 589 6057 
Immune System            
C-reactive protein (mg/dL)  31478 0.01 0.01 0.02 0.04 0.21 0.45 1.06 1.63 3.77 29.6 
White blood cell count (1000 
cells/uL) 42703 1.5 3.5 4.31 4.8 6.9 7.27 10 11.2 13.798 99.99 
Metabolic System            
Alkaline phosphatase (U/L)  36827 7 32 41 46 68 71.86 101 115 153 1378 
Glucose, plasma (mg/dL)  20757 36 72.556 81 84.7 98 105.92 128 159 281 686.2 
Glycohemoglobin:(%)  42657 2 4.5 4.8 4.9 5.4 5.64 6.4 7.4 10.7 18.8 
Homeostatic Model Assessment 
of Insulin Resistance (-)  17659 0.05 0.40 0.74 0.98 2.43 3.81 7.24 10.31 24.72 204.47 
Ratio of Insulin to Glucose  17659 0.00 0.02 0.03 0.04 0.10 0.13 0.24 0.31 0.56 5.06 
Nephrology             
Albumin (g/dL)  42041 1.2 3.1 3.6 3.8 4.3 4.25 4.7 4.8 5 5.7 
Blood urea nitrogen (mg/dL)  42038 1 4 6 7 12 13.19 20 23 35 122 
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Creatinine (mg/dL)  36831 0.16 0.4 0.5 0.6 0.82 0.89 1.17 1.3 1.957 17.8 
Estimated Glomerular Filtration 





Table 5.2. Comparison of current clinical thresholds or reference ranges with association-based thresholds of the 27 physiological 
indicators. 
 
  Clinical Association-baseda Concordanceb 











Body Composition        
Body Mass Index (kg/m**2) all 18.5-19 24.9-25 23.48 32.97 No No 
Standing Height (cm) all   168.6    
Subscapular Skinfold (mm) all   29.9 37.1   
Triceps Skinfold (mm) all   22.6    
Waist Circumference (cm) females  80-88 73.6-86.8 105 No No 
Waist Circumference (cm) males  90-102 87.6 115.5 No No 
Waist Circumference (cm) all   86.6 113.3   
Weight (kg) all   78.6 104.8   
Relative Fat Mass Index (-) females 21-24 33-36 27.01 34.01-39.53 No Yes 
Relative Fat Mass Index (-) males 8-13 19-25 25.14 31.36 No No 
Relative Fat Mass Index (-) all   25.57 30.67   
Cardiovascular System        
60 sec. pulse (30 sec. pulse * 2) all 50-60 80-100  65 No No 
Direct HDL-Cholesterol (mg/dL) females 50  57 91 No No 
Direct HDL-Cholesterol (mg/dL) males 40  42 68 Yes No 
Direct HDL-Cholesterol (mg/dL) all   49 83   
LDL-cholesterol (mg/dL) all  100-130 107 168 No No 
Triglycerides (mg/dL) all  150 43 207 No No 
Total cholesterol (mg/dL) all  200 186 284 No No 
Diastolic: Average blood pressure (mm Hg) all 60 80-90 69.33 89.33 No Yes 
Systolic: Average blood pressure (mm Hg) all 90 130-140 107 129.33 No Yes 
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Ratio of LDL to HDL Cholesterol (-) all  1.4 1.51 3.62-5.15 No No 
Ratio of Total to HDL Cholesterol (-) females  4.4 2.42 5.02-8.38 No No 
Ratio of Total to HDL Cholesterol (-) males  5 3.07 5.74 No No 
Ratio of Total to HDL Cholesterol (-) all   2.77 5.36   
Immune System        
C-reactive protein (mg/dL) all  0.1-0.2 0.02 0.1 No Yes 
White blood cell count (1000 cells/uL) all 4-15 10-11 4.2 5.9 Yes No 
Metabolic System        
Glycohemoglobin (%) all  5.7-7 4.9 5.9 No Yes 
Glucose, plasma (mg/dL) all 60-70 99-126 95.4 107.9 No Yes 
Alkaline phosphatase (U/L) all 20-44 116-147  64 No No 
Homeostatic Model Assessment of Insulin 
Resistance (-) all 
 1.4-2.9 0.77 5.23 No No 
Ratio of Insulin to Glucose (uU*dL)/(mg*mL) all  0.2-0.3 0.07 0.15 No No 
Nephrology        
Albumin (g/dL) all 3.4-3.5 5.4-5.5 4.65 4.95 No Yes 
Blood urea nitrogen (mg/dL) all 6-10 20-21 12 19 No Yes 
Creatinine (mg/dL) females 0.5-0.6 1-1.1 0.6 0.81 Yes No 
Creatinine (mg/dL) males 0.6-0.9 1.2-1.3 0.92 1.12 Yes Yes 
Creatinine (mg/dL) all   0.63 0.93-1.15   
Estimated Glomerular Filtration Rate 
(mL/min/1.73 m2) all 60-90 
 64.61 89.89 No No 
a The association-based thresholds are values of the physiological indicator that that show an increased mortality risk of 10% from the minimum risk of the spline 
model. All models are adjusted for age, sex, and race, while the sex-specific models are adjusted for age and race. Participants with measurements between the 1st 
and 99th percentiles of the physiological indicator were used.  
b Concordance is achieved when the association-based threshold is within 10% of the clinical threshold. When there is a range for the clinical threshold, 
concordance is achieved when the association-based threshold is within the range or within 10% of the maximum clinical threshold. 




Chapter 6 Conclusion 
 
My dissertation research interfaces data science, epidemiology, and environmental health 
as I applied computational approaches to understand how the environment can influence human 
health. This research required addressing two challenges:  1) characterizing chemical exposure ad 
disparities for a wide range of chemicals to identify populations that are at risk for high chemical 
exposures and 2) characterizing associations along the spectrum of chemical exposures to 
physiological indicators to adverse health outcomes. Addressing these challenges is necessary for 
understanding how certain chemical exposures perturb physiologic function and thereby result in 
increased risk of adverse health effects. Motivated by this goal, I developed and applied unbiased 
approaches to systematically screen for chemical exposure disparities by age, sex, race, and 
occupation for a wide range of toxicants (Chapter 2-4), and characterize the types of associations 
between all-cause mortality for 27 indicators used to describe physiologic function (Chapter 5). 
Sections 6.1 to 6.4 present the key achievements, limitations, future directions, and 
contribution of the frameworks developed in the four studies (Chapter 2-5). Section 6.5 is an 
integrated discussion of the four studies. Finally, Section 6.6 presents my closing remarks about 
integrating these frameworks to ground exposome research in data science.  
6.1 Characterization of Age-Based Trends of Chemical Biomarker Levels 
This study focused on evaluating age-based exposure trends by applying a screening 
approach to a diverse suite of 141 chemical biomarkers in a representative sample of 74,942 
participants in the US. Specifically, I defined characteristics to distinguish chemicals indicative of 
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legacy exposures from those reflecting current, ongoing exposures. I conducted a targeted analysis 
of PFASs to further substantiate the criteria for legacy exposures. In addition, I developed a 
framework using a series of quadratic regression models to explore non-linear age-based trends in 
identifying chemicals of higher concentrations in children versus those in the older population.  
Summary and Insights: Childhood development is a crucial window of susceptibility for 
the effects of toxic exposures, so prioritizing chemicals that are more common in children can 
drive future work on studying the effects of these exposures. It can also lead to developing 
interventions to reduce exposures and prevent subsequent adverse outcomes. To systematically 
characterize age-based trends of chemical biomarkers, I defined a metric to rank chemical 
indicators from most to least concerning for children by using the first derivative and second 
derivative of the chemical biomarker levels with respect to age. The first derivative represents the 
association between age and the chemical biomarker levels, while the second derivative describes 
the curvature of the association. Using this metric, I identified several chemical contaminants of 
elevated and ongoing exposures in children: phthalates, brominated flame retardants, pesticides, 
and metals, such as lead and tungsten. On the other hand, there were several legacy chemicals such 
as PCBs and Dioxins of higher concentrations in adults. These legacy chemicals were 
characterized by having a minimum half-life of one year in the human body and being restricted 
in North American commerce due to legislation or a voluntary commercial phaseout. Moreover, a 
targeted analysis of highly persistent PFASs such as PFOS and PFOA with known phaseout dates 
further confirmed these characteristics of legacy chemicals, since the differences in their biomarker 
levels between the young and older populations continued to increase since the phaseout period. 
This implies that persistent chemicals, that have been banned or phased out for longer than their 
half-lives, have the potential to be legacy chemicals as time passes. This pattern was not observed 
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for all PFASs, especially those still in use, so we will still be exposed to particular PFASs such as 
PFNA and PFDA, which will require continued biomonitoring. 
Limitations and Future Directions: While I characterized the influence of several 
important factors in explaining age-based trends in chemical exposures, I did not study which 
factors among half-lives, time-trends, legislation, and consumer product usages, are most 
important in explaining these age-based trends. Thus, future work could use machine learning 
techniques such as feature selection to help identify the most important factors in explaining age-
based trends for legacy versus emerging chemicals. The second limitation is that I excluded 182 
chemicals that did not satisfy the inclusion threshold of at least 50% detection in the study 
population. As such, I may have excluded chemicals that exhibit low dose effects or that have 
exposures only in population subsets. The final limitation is that I did not incorporate toxicological 
data to prioritize chemicals based on both exposure and toxicity. Now, with the US Environmental 
Protection Agency Toxicity Forecaster (ToxCast) data on in vitro toxicity for thousands of 
chemicals 400, future work can integrate both biomonitoring and bioactivity data to prioritize 
chemicals that elicit low-dose and/or high-dose effects. 
Contributions: Applying an unbiased, screening approach to biomonitoring data enabled 
a characterization of age-based trends for a diverse suite of toxicants spanning 16 chemical classes. 
It also facilitated the ease of identifying chemicals of higher exposure in children versus the older 
population. My current framework can be coupled with toxicity data to help facilitate chemical 
prioritization and risk stratification. 
6.2 Racial Disparities in Chemical Biomarker Concentrations in United States Women 
This study was motivated by a need to understand whether environmental exposures can 
help explain why the incidence of triple negative breast cancer (TNBC) is approximately three 
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times higher in Non-Hispanic Black women than in Non-Hispanic White women 79,80. While the 
mechanisms driving this difference likely involve interactions between genetic and environmental 
factors, the influence of environmental risk factors such as chemical exposures may be substantial 
albeit poorly understood. Thus, I evaluated chemical exposure disparities by race in 38,030 female 
participants for 143 chemical contaminants using a series of generalized linear models to prioritize 
chemicals for further experimental work.  
Summary and Insights: Non-Hispanic Black women had significantly higher 
concentrations of many chemicals in their bodies relative to non-Hispanic White women. This 
included chemicals used in cosmetics such as methyl paraben (2.39-fold), propyl paraben (2.09-
fold), and mono-ethyl phthalate (1.74-fold). It also includes 1,4-Dichlorobenzene (3.26-fold), 
which is used as a disinfectant, pesticide, and deodorant in mothballs, and its metabolite 2,5-
dichlorophenol (4.56-fold). Overall, the results showed substantial differences in chemical body 
burden by race in a representative sample of US women. 
Limitations and Future Directions: A major limitation is that we excluded chemicals 
with detection frequencies below 50%, thereby potentially excluding chemicals that exhibit low 
dose effects that should have been prioritized. Future studies could therefore benefit from 
evaluating differences in detection frequency by race to identify additional chemicals that show 
substantial racial disparities. A second limitation is that this study did not link exposure disparities 
with toxicological data specifically to breast cancer. However, two ongoing studies are integrating 
these exposure disparities with ToxCast database on chemical bioactivity 400 and with the 
Comparative Toxicogenomics Database on chemical-gene interactions 401 to understand why 
TNBC 79,80 and preterm birth 402,403, respectively, occurs disproportionally in non-Hispanic Black 
women compared to Non-Hispanic White women. 
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Contributions: My framework is currently being integrated with ToxCast bioactivity data 
to enable prioritization of three chemicals, thiram, propyl paraben, and p,p’-DDE, to understand 
how chemical exposure at environmentally relevant doses in humans can change cell morphology 
in ways that can progress toward breast cancer in the wet lab. While my framework is being used 
in the context of breast cancer disparities, it can be coupled with other data characterizing any 
health effect. Thus, this coupling can help prioritize chemicals to facilitate data-driven 
experimental work to better understand how the environment drives health disparities. 
6.3 Biomarker-Based Occupational Exposome 
The main objective of this study was to understand the distribution of occupational 
exposures to 108 chemicals in a US sample of 26,361 workers across 20 industrial sectors and 19 
occupational job titles and the resultant impact on physiological function. I used these job titles to 
classify participants as blue- or white-collar workers. I then performed clustering analysis on the 
sector-collar combinations to define occupational groups with similar chemical exposure profiles. 
I used these exposure-based groups to characterize differences in 27 physiological indicators to 
identify which occupational groups are most susceptible to chemical-mediated effects on 
physiological function.  
Summary and Insights: I identified higher levels of heavy metals, VOCs, and PAHs in 
most blue-collar workers across the different sectors compared their white-collar counterparts. In 
contrast, the white-collar workers had higher exposures to certain heavy metals such as mercury, 
arsenic, and their metabolites, along with a biomarker of sunscreen use, benzophenone-3. Higher 
mercury and arsenic biomarker levels among these white-collar workers may indicate higher fish 
consumption 276. This could therefore be a surrogate for behaviors associated with higher 
socioeconomic status 277 instead of an indicator of occupational exposures, since fish is expensive 
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and is more accessible to those with higher socioeconomic status. Based on these differences in 
chemical exposures between white- and blue-collar workers, the defined clustered groups were 
almost mutually exclusive with few clusters including both blue- and white-collar workers. 
Interestingly, in the clustered groups of blue-collar workers, alkaline phosphatase (biomarker of 
liver disease or bone disorder), white blood cell count (biomarker of inflammation), and 
glomerular filtration rate (biomarker of kidney function) showed higher values compared to the 
reference group of white-collar workers. These results suggest that certain occupational exposures 
can diminish important physiological functions in blue-collar workers. 
Limitations and Future Directions: A primary limitation is the non-random sparsity of 
the chemical biomarker data in the worker population. As no participant has data available for all 
studied toxicants, I could not conduct unsupervised clustering of individual workers. Instead, I had 
to work with groups of workers via the sector-collar combinations. This challenge resulted in 
conducting clustering analysis on exposure differences among the different sector-collar 
combinations. These differences then were quantified with the regression coefficients to compare 
differences in chemical biomarker levels between a given sector-collar combination and the 
reference group of white-collar workers in public administration. Ideally, if the chemical 
biomonitoring data were not sparse, then I could compare the clustering method conducted on the 
regression statistics versus that performed on the raw data to help substantiate the results. Second, 
due to the sparsity of the occupational data, the analysis was limited by the small sample size, since 
a quarter of NHANES participants have data on industrial sectors and occupational titles. This 
prevented me from establishing a direct link between multiple chemical exposures and physiologic 
dysfunction. As NHANES includes more occupational data with each study year, future analysis 
could have increased statistical power to model the associations between chemical exposures and 
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associated effects across different occupational groups. Third, I could not directly compare the 
chemical biomarker levels to the permissible exposures limits (PELs) defined by the Occupational 
Safety and Health Administration (OSHA). This prevented me from calculating the percentage of 
workers above acceptable or safe exposure levels. Thus, future studies can incorporate exposure 
modeling to predict exposures levels from biomarker levels to enable the comparison to PELs to 
help identify workers susceptible to high exposures. Fourth, I did not account for confounders such 
as socioeconomic indicators, alcohol consumption, dietary habits, and smoking habits that may 
explain differences in occupational exposures across the sector-collars. Hence, future directions 
can include quantifying differences in these factors by occupation and then account for such 
differences by including these variables as covariates in the regression models or by conducting 
stratified analysis in order to better understand if health disparities are due to differences in 
occupational exposures. Finally, another limitation involved using individual physiological 
indicators instead of pooling them together to better evaluate overall physiologic dysfunction. 
Therefore, future studies can define an allostatic load score 339,340 to characterize the overall 
physiologic dysfunction associated with multiple chemical exposures across the occupational 
groups.  
Contributions: I developed a framework using clustering analysis to characterize the 
indirect impact of multiple chemical exposures on physiological indicators in the workers 
population. This method enables me to apply unsupervised learning techniques to non-randomly 
sparse data without having to define a complete dataset nor impute.  
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6.4 Characterization of Linear and Non-linear Associations between Physiological Indicators 
and All-Cause Mortality 
This study focused on characterizing linear and non-linear associations between all-cause 
mortality and each of the 27 physiological indicators, to identify locations in the distribution 
associated with increased mortality risk. This study is foundational to better understanding the 
influence of environmental exposures on physiological functions that can impact mortality risk. 
Summary and Insights: I observed that 24 out of 27 (88.9%) indicators show non-linear 
associations with all-cause mortality, while height, triglycerides, and 60-second pulse show linear 
associations. Unexpectedly, I observed parabolic associations between cholesterol levels and all-
cause mortality. Also, unexpectedly, the results showed a parabolic association between 
glomerular filtration rate (GFR) and mortality where participants with higher GFR had a higher 
mortality risk compared to those with lower GFR. The current clinical threshold for GFR, however, 
only suggests that a value less than 90 mL/min/1.73m2 implies kidney damage 362,363. As another 
unexpected finding, mortality risk for obese participants was lower compared to that for 
underweight participants.  
Limitations and Future Directions: The unexpected lower mortality risk observed in 
obese patients may indicate the efficacy of public health interventions or improvements in 
healthcare for obesity-related conditions 377, which was not accounted in our models. Thus, future 
analysis can study trends of medical and public health interventions for obesity to account for 
residual confounding, in order to better understand why mortality risk is lower for obese or 
overweight participants compared to underweight participants. Moreover, the higher mortality risk 
observed in participants with lower LDL cholesterol may be overestimated due to the inclusion of 
participants on lipid-lower medications 370,372. However, it is not well understood whether 
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mortality risk is higher in participants on lipid-lower medication versus those who are not, even 
though their LDL cholesterol levels are the same. Thus, future studies could conduct a sensitivity 
analysis to study whether the associations would change if participants on lipid-lower medications 
were excluded. Finally, some of the associations may be overestimated due to inclusion of 
unhealthy participants, who tend to have higher mortality risk. Therefore, future work can include 
a sensitivity analysis to observe whether these associations would change if unhealthy participants 
were removed. 
Contributions: I developed a machine-learning framework to establish the best model to 
characterize the relationship with all-cause mortality for a wide variety of physiological indicators. 
This framework enabled identifying both expected and unexpected directionalities in associations 
for all-cause mortality. Thus, the framework could be applied to study the associations of any 
physiological indicators and health endpoints for more accurate risk identification. Furthermore, 
this framework could be applied to study any associations along the continuum of chemicals 
indicators to physiological indicators to any health endpoints. 
6.5 Integrated Discussion 
Drawing inspirations from GWAS for screening across millions of genetic factors to 
identify those significantly associated with a particular disease, I screened across a wide range of 
chemicals to characterize biomarker levels across the life stage, race/ethnicity, sex, and occupation 
in order to identify population susceptible to high exposures, and I screened across a broad suite 
of physiological indicators to identify populations vulnerable to physiological dysfunction along 
with directionalities associated with increased mortality risk. I applied a range statistical 
techniques such as generalized linear regression models, splines models, quantiles model, 
hierarchical clustering, bootstrapping, and cross validation. Using these techniques, I confirmed 
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expected findings and identified unexpected findings that would not have been detected if I did 
not apply these techniques coupled with an untargeted approach. 
The chemicals that showed the highest disparities were those that are found in consumer 
products. In children, several phthalates, brominated flame retardants, pesticides, and metals such 
as lead and tungsten are found at higher biomarker levels 185. Phthalates are used as plasticizers to 
make vinyl flexible and pliant 404. Due to flexibility of this chemical family, phthalates are detected 
in flooring, walls, ceiling, food containers, and children’s toys 405. Brominated flame retardants 
reduce the flammability of product containing them, which includes but not limited to furniture, 
carpets, pillows, paints, upholstery, and kitchen applicants 406,407. Lead can be found in household 
dust, toy jewelry, old toys, plastic toys, cosmetics, and paints 62,408,409. Pesticides can be found in 
food, insect repellents, rodent control product, garden care products, and pet products 410,411. 
Tungsten is found in jewelry rings and in light bulb filaments 412,413. Children may be in contact 
with such products and thus exposed to these chemicals due to normal development behaviors such 
as crawling 59, mouthing 60,61, and playing 62. 
Studying racial disparities in women reiterates the theme of observing higher biomarker 
levels from chemicals used in consumer products. In non-Hispanic Black, Mexican American, 
Other Hispanic, and Other Race/Multi-Racial women, pesticides and their metabolites, including 
2,5-dichlorophenol, o,p’-DDE, beta-hexachlorocyclohexane, and 2,4-dichlorophenol and personal 
care and consumer product compounds, including parabens and mono-ethyl phthalate 120. 2,4-
dichlorophenol is a photo-degradation product of triclosan, which is a common antibacterial and 
antifungal agent used in soap and hand sanitizer 414,415. 2,5-dichlorophenol is a metabolite of 1,4-
dichlorobenzene, which has been used in moth balls, room and toilet deodorizers, and as an 
insecticidal fumigant 416,417. o,p’-DDE is a metabolite of DDT, which was developed as an 
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insecticide but has been banned in 1972 418,419. Beta-hexachlorocyclohexane is a byproduct of the 
production of the insecticide lindane and was deemed as a Persistent Organic Pollutant by the 
Stockholm Convention 420,421. Parabens are used as preservatives in personal care products 422,423. 
Mono-ethyl phthalate is a metabolite of diethyl phthalate, which is a plasticizer used in plastic 
packaging, toiletries, fragrance, and cosmetics. Diethyl phthalate is used to extend the aromatic 
strength of the fragrance, prevent brittleness in nail polishes, and enable hairspray to form a 
flexible film on the hair 162,424. Cotinine levels, which is a metabolite of nicotine 425, is the highest 
in non-Hispanic White women. Interestingly, similar to the findings in children, chemicals 
showing the highest biomarker levels are also the ones being used in common consumer products, 
highlighting how the products that we use on a daily basis drives an individual’s “chemosome”.  
Then, this theme is further emphasized when I studied the occupational exposome. Blue-
collar workers from retail trade, professional, and technical services show some of the highest 
biomarker levels of heavy metals such as lead and cadmium, PAHs, phthalates, PFASs, and VOCs 
such as toluene and benzene compared to any of the other occupations. Furthermore, these 
chemicals are some of the most toxic substances measured in NHANES. In addition, these blue-
collar workers from retail trade, professional, and technical services have a physiological profile 
characterized by liver damage and elevated kidney filtration, which are both indicative of increased 
risk for death. If these chemical biomarkers are indicative of occupational exposures and 
responsible for eliciting these physiological responses, then these findings would imply that 
handling or producing the consumer products are linked to elevated toxicant levels and 
subsequently physiological dysfunction conducive to increased risk of mortality.  
Every day, we come into contact with many out of the 80,000 chemicals on the market, but 
only about 1% of them have been evaluated for safety 426. Though these statistics are daunting, we 
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do not necessarily need to measure biomarker concentrations for all 80,000 toxicants. The findings 
in this dissertation suggest that the chemicals found at the highest biomarker levels are those that 
are used in consumer and personal care products. Thus, biomonitoring studies can measure for 
toxicants that are commonly used in consumer and personal care products to better prioritize which 
chemicals to use for further toxicological evaluation.  
While I did a comprehensive analysis of characterizing chemical exposure disparities 
across the life-stage, sex, race/ethnicity, and occupation, I did not ascertain the contribution of 
chemical exposures to adverse health outcomes nor did I compare these contributions to the 
contributions of other factors such as genetics, long-term stress, socioeconomic status, education, 
and health access. These factors are known to impact health outcomes and could even predispose 
individuals to adverse responses to environmental chemical exposures. This illustrates the need to 
measure genetic as well as a broad set of environmental factors in as many people as possible. 
Furthermore, how these genetic and environmental risk factors relate to health is further 
complicated by the intertwining associations among the risk factors. Thus, untangling this 
intertwining web will enable the identification of pertinent drivers of health disparities. This 
insight will be essential in identifying susceptible population and designing targeted intervention 
to mediate and prevent disease. 
6.6 Closing Remarks 
Throughout these studies, a quote from Dr. Eberhard Voit resonated with me: “Data 
generated from the exposome defy human intuition” 427. This quote was confirmed by the 
unexpected patterns I observed from applying unbiased approaches to large-scale biomonitoring 
data in the context of exposome research in data science. This systematic, screening approach is 
particularly salient to exposome research, as there are more than 80,000 chemicals estimated to be 
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used in commerce in the US 426. In addition, there continues to be an increasing availability of 
multiple layers of data on exposure, toxicity, and human health. Thus, integrating omics techniques 
with such data will be integral to deriving insights essential for more informed decision-making 










Appendix 1. Characterization of Age-Based Trends of Chemical Biomarker Levels 
Table A1.1.Indicator of excluded measurements by NHANES Cycles for chemical biomarkers. 
  Percentage of Participants below LOD by NHANES cycles 
Codename  Comment Name Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 
LBXD03    1,2,3,6,7,8-hxcdd 
(fg/g) 
X        
LBXD03LA 1,2,3,6,7,8-hxcdd 
Lipid Adj (pg/g) 
X        
LBXD05    1,2,3,4,6,7,8-hpcdd 
(fg/g) 
X        
LBXD05LA 1,2,3,4,6,7,8-hpcdd 
Lipid Adj (pg/g) 
X        
LBXD07    1,2,3,4,6,7,8,9-ocdd 
(fg/g) 
X        
LBXD07LA 1,2,3,4,6,7,8,9-ocdd 
Lipid Adj (pg/g) 
X        
LBXF03    2,3,4,7,8-pncdf 
(fg/g) 
X        
LBXF03LA 2,3,4,7,8-pncdf 
Lipid Adj (pg/g) 
X        
LBXF04    1,2,3,4,7,8-hxcdf 
(fg/g) 
X        
LBXF04LA 1,2,3,4,7,8-hxcdf 
Lipid Adj (pg/g) 
X        
LBXF08    1,2,3,4,6,7,8-hpcdf 
(fg/g) 
X        
LBXF08LA 1,2,3,4,6,7,8-hpcdf 
Lipid Adj (pg/g) 
X        
URXPAR    Paranitrophenol 
(ug/L) 
X        
LBXHXC   3,3',4,4',5,5'-hxcb 
(fg/g) 
X        
LBXHXCLA  3,3',4,4',5,5'-hxcb 
Lipid Adj (pg/g) 
X        
LBXPCB   3,3',4,4',5-pcnb 
(pg/g) 
X        
LBXPCBLA  3,3',4,4',5-pcnb 
Lipid Adj (pg/g) 
X        
LBX028   PCB28 (ng/g) X        
LBX028LA  PCB28 Lipid Adj 
(ng/g) 
X        
LBD199   PCB199 (ng/g) X X       
LBD199LA  PCB199 Lipid Adj 
(ng/g) 
X X       
LBX180   PCB180 (ng/g) X X       
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LBX180LA  PCB180 Lipid Adj 
(ng/g) 
X X       
LBX146   PCB146 (ng/g) X X       
LBX146LA  PCB146 Lipid Adj 
(ng/g) 
X X       
LBX170   PCB170 (ng/g) X X       
LBX170LA  PCB170 Lipid Adj 
(ng/g) 
X X       
LBX194   PCB194 (ng/g) X X       
LBX194LA  PCB194 Lipid Adj 
(ng/g) 
X X       
LBX187   PCB187 (ng/g) X X       
LBX187LA  PCB187 Lipid Adj 
(ng/g) 
X X       
LBX153   PCB153 (ng/g) X X       
LBX153LA  PCB153 Lipid Adj 
(ng/g) 
X X       
LBX196   PCB196 (ng/g) X X       
LBX196LA  PCB196 Lipid Adj 
(ng/g) 
X X       
LBX138   PCB138 (ng/g) X X       
LBX138LA  PCB138 Lipid Adj 
(ng/g) 
X X       
LBX118   PCB118 (ng/g) X X       
LBX118LA  PCB118 Lipid Adj 
(ng/g) 
X X       
LBX099   PCB99 (ng/g) X X       
LBX099LA  PCB99 Lipid Adj 
(ng/g) 
X X       
LBX074   PCB74 (ng/g) X X       
LBX074LA  PCB74 Lipid Adj 
(ng/g) 




  X      
URX24D   2,4-D (ug/L) X    X    
URXP10    1-pyrene (ng/L)        X 
URXPAR Paranitrophenol 
(ug/L) 





Table A1.2. Corresponding NHANES codename, CAS NO., and chemical classification for each 
chemical biomarker. 
Codename Chemical Name CAS NO. Chemical Class Chemical 
Class 
Shortened 
LBXGLY Glycideamide (pmoL/G Hb) 5694-00-8 Acrylamide Acrylamide 
LBXACR Acrylamide (pmoL/G Hb) 79-06-1 Acrylamide Acrylamide 
LBXBB1LA 2,2',4,4',5,5'-hexabromobiphenyl 






LBXBR2LA 2,4,4'-tribromodiphenyl ether 




















LBXBR3LA 2,2',4,4'-tetrabromodiphenyl ether 
lipid ad (ng/g) 






















LBXD07LA 1,2,3,4,6,7,8,9-ocdd Lipid Adj 
(pg/g) 
3268-87-9 Dioxins Dioxins 










LBXF03LA 2,3,4,7,8-pncdf Lipid Adj (pg/g) 57117-31-
4 
Furans Furans 





SSMEL Melamine (ng/mL) 108-78-1 Melamine Melamine 
SSCYA Cyanuric acid (ng/mL) 108-80-5 Melamine Melamine 
LBXBPB Lead (ug/dL) 7439-92-1 Metals Metals 
LBXBCD Cadmium (ug/L) 7440-43-9 Metals Metals 
LBXTHG Mercury, total (ug/L) 7439-97-6 Metals Metals 
URXUHG Mercury, urine (ng/mL) 7439-97-6 Metals Metals 
URXUBA Barium, urine (ng/mL) 7440-39-3 Metals Metals 
URXUCO Cobalt, urine (ng/mL) 7440-48-4 Metals Metals 
URXUCS Cesium, urine (ng/mL) 7440-46-2 Metals Metals 
URXUMO Molybdenum, urine (ng/mL) 7439-98-7 Metals Metals 
URXUPB Lead, urine (ng/mL) 7439-92-1 Metals Metals 
URXUSB Antimony, urine (ng/mL) 7440-36-0 Metals Metals 
URXUTL Thallium, urine (ng/mL) 7440-28-0 Metals Metals 
URXUTU Tungsten, urine (ng/mL) 7440-33-7 Metals Metals 
URXUUR Uranium, urine (ng/mL) 7440-61-1 Metals Metals 
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URXUAS Urinary total Arsenic (µg/L) 7440-38-2 Metals Metals 
URXUAB Urinary Arsenobetaine (µg/L) 64436-13-
1 
Metals Metals 
URXUDMA Urinary Dimethylarsonic acid 
(µg/L) 
75-60-5 Metals Metals 
URXUCD Cadmium, urine (ng/mL) 7440-43-9 Metals Metals 
LBXBMN Blood manganese (ug/L) 7439-96-5 Metals Metals 
LBXSCU Serum Copper (ug/dL) 7440-50-8 Metals Metals 
LBXSZN Serum Zinc (ug/dL) 7440-66-6 Metals Metals 
LBXBGM Mercury, methyl (ug/L) 22967-92-
6 
Metals Metals 
URXSCN Urinary thiocyanate (ng/mL) 302-04-5 Other Other 
URXUIO Iodine, urine (ng/mL) 7553-56-2 Other Other 
URXNO3 Urinary nitrate (ng/mL) 14797-55-
8 
Other Other 
URXUP8 Perchlorate, urine (ng/mL) 14797-73-
0 
Other Other 
URXTRS Urinary Triclosan (ng/mL) 3380-34-5 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXBPS Urinary Bisphenol S (ug/L) 80-09-1 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXMPB Methyl paraben (ng/ml) 99-76-3 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXPPB Propyl paraben (ng/ml) 94-13-3 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXBPH Urinary Bisphenol A (ng/mL) 80-05-7 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXBPF Urinary Bisphenol F (ug/L) 620-92-8 Personal Care & Consumer 
Product Compounds 
PCCPCs 
URXBP3 Urinary Benzophenone-3 
(ng/mL) 
131-57-7 Personal Care & Consumer 
Product Compounds 
PCCPCs 





Oxychlordane Lipid Adj (ng/g) 27304-13-
8 
Pesticides Pesticides 
LBXPDELA p,p'-DDE Lipid Adj (ng/g) 72-55-9 Pesticides Pesticides 
LBXDIELA Dieldrin Lipid Adj (ng/g) 60-57-1 Pesticides Pesticides 
LBXBHCLA Beta-hexachlorocyclohexane 
Lipid Adj (ng/g) 
319-85-7 Pesticides Pesticides 
URXCPM 3,5,6-trichloropyridinol (ug/L) 6515-38-4 Pesticides Pesticides 
URXOP3 Dimethylthiophosphate (ug/L) 1112-38-5 Pesticides Pesticides 
URXOPM 3-phenoxybenzoic acid (ug/L) 3739-38-6 Pesticides Pesticides 
URX14D 2,5-dichlorophenol (ug/L) 583-78-8 Pesticides Pesticides 
URXDCB 2,4-dichlorophenol (ug/L) 120-83-2 Pesticides Pesticides 
URXPAR Paranitrophenol (ug/L) 100-02-7 Pesticides Pesticides 
URX24D 2,4-D (ug/L) 94-75-7 Pesticides Pesticides 
URXDEA DEET acid (ug/L) 72236-23-
8 
Pesticides Pesticides 

















URXMIB Mono-isobutyl pthalate (ng/mL) 30833-53-
5 
Phthalates Phthalates 
URXMHP Mono-(2-ethyl)-hexyl phthalate 
(ng/mL) 

















URXMBP Mono-n-butyl phthalate (ng/mL) 131-70-4 Phthalates Phthalates 
URXMEP Mono-ethyl phthalate (ng/mL) 2306-33-4 Phthalates Phthalates 
URXMNM Mono-n-methyl phthalate 
(ng/mL) 

























URXP05 3-phenanthrene (ng/L) 605-87-8 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP06 1-phenanthrene (ng/L) 2433-56-9 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP07 2-phenanthrene (ng/L) 605-55-0 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP19 4-phenanthrene (ng/L) 7651-86-7 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP25 2 & 3-Hydroxyphenanthrene 
(ng/L) 
605-55-0 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP10 1-pyrene (ng/L) 129-00-0 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP01 1-napthol (ng/L) 90-15-3 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP02 2-napthol (ng/L) 135-19-3 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP17 9-fluorene (ng/L) 484-17-3 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP03 3-fluorene (ng/L) 6344-67-8 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 
URXP04 2-fluorene (ng/L) 2443-58-5 Polyaromatic Hydrocarbons 
(PAH) 
PAHs 












LBX209LA PCB209 Lipid Adj (ng/g) 2051-24-3 Polychlorinated Biphenyls 
(PCB) 
PCBs 






























































LBX028LA PCB28 Lipid Adj (ng/g) 7012-37-5 Polychlorinated Biphenyls 
(PCB) 
PCBs 










LBXPFDE Perfluorodecanoic acid (ng/mL) 335-76-2 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXMPAH 2-(N-methyl-PFOSA) acetate 
(ng/mL) 
2355-31-9 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXPFNA Perfluorononanoic acid (ng/mL) 375-95-1 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXPFHS Perfluorohexane sulfonic acid 
(ng/mL) 
355-46-4 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXPFOA Perfluorooctanoic acid (ng/mL) 335-67-1 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXPFOS Perfluorooctane sulfonic acid 
(ng/mL) 
1763-23-1 Per- and Polyfluoroalkyl 
Substances (PFAS) 
PFASs 
LBXCOT Cotinine (ng/mL) 486-56-6 Smoking Related 
Compounds 
SRCs 





LBXVXY Blood m-/p-Xylene (ng/ml) 108-38-
3/106-42-
3 
Volatile Organic Compounds 
(VOC) 
VOCs 
LBXVDB Blood 1,4-Dichlorobenzene 
(ng/ml) 





LBXVBM Blood Bromodichloromethane 
(pg/ml) 







Volatile Organic Compounds 
(VOC) 
VOCs 










106-99-0 Volatile Organic Compounds 
(VOC) 
VOCs 





















79-06-1 Volatile Organic Compounds 
(VOC) 
VOCs 














Volatile Organic Compounds 
(VOC) 
VOCs 











Volatile Organic Compounds 
(VOC) 
VOCs 




Volatile Organic Compounds 
(VOC) 
VOCs 
URX2MH 2-Methylhippuric acid (ng/mL) 42013-20-
7 




























Volatile Organic Compounds 
(VOC) 
VOCs 
LBXVTO Blood Toluene (ng/ml) 108-88-3 Volatile Organic Compounds 
(VOC) 
VOCs 
LBXNM Blood Nitromethane (pg/mL) 75-52-5 Volatile Organic Compounds 
(VOC) 
VOCs 





Text A1.1. Overestimation of QSARs half-lives for PFASs and Other Estimation Methods 
The estimated persistency of QSAR PFASs varies drastically from 3.5 years to 220 years. 
The half-lives of PFOS (4.80 years) and PFOA (5.42 years) from Arnot et al, 2014 Training 
Dataset are comparable with other estimated half-lives such as 5 years for PFOS  and 2.3  to 4 
years  for PFOA. In addition, the QSAR-estimated half-life of PFHxS (7.29 years) is comparable 
to 8.5 years. A one-compartment model was used to estimate the half-lives for PFASs in a sample 
of Chinese volunteers in Shijiazhuang and Handan and estimated to be 0.38 to 20 years for the 
half-life of PFNA  and 1.2 to 60 years for PFDA, which are very different from the QSAR-
estimated half-lives of PFNA (45.03 years) and PFDA (205.82 years). There are no measured or 
estimated half-lives for 2-(N-methyl-PFOSA) acetate in human.  
This model is a screening-level, fragment-based QSAR that for instance, focuses on 
“fragments” of the compound i.e. F-C bond. Since PFNA have several of these bonds and such 
bonds are associated with high persistency, the QSAR predicted a higher persistency for these 
cases. In addition, half-life of PFOS, PFOA, and PFHxS were the only ones used in the training 
set to train the QSAR model to predict half-lives for PFASs. So all of these stipulations can lead 
to overestimations on some of the predictions.  
Thus, to address these overestimations, we looked at different literature sources for the 
half-lives and defined a hierarchy to determine more reasonable half-lives for these substances. 
When multiple human biomonitoring-based half-lives are available for a given chemical, the 
median of all available half-lives is used, or else we perform an extrapolation from animal data 
using the ratio of the half-life of PFOSA to the half-life of PFOS from rat (10.6 and 30 days, 
respectively) and rainbow trout (6 and 16.9 days, respectively). So, the extrapolation factors were 




Table A1.3. Authorship for half-lives of PFASs with other estimation or extrapolation methods. 
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Table A1.4. References for half-lives of inorganic substances for which the half-life could not be 
estimated by the QSAR models. Half-Lives (hours) were used in the analysis. 
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Arsenobetaine Lehmann B, Ebeling E, Alsen-Hinrichs C. 
2001. Kinetics of arsenic in human blood 
after a fish meal. Gesundheitswesen 
(Bundesverband der Arzte des 
Offentlichen Gesundheitsdienstes 
(Germany)) 63:42-48. 




















CDC. 2009. Fourth national report on 










Antimony ATSDR. 2017. Toxicological profile for 













Gerhardsson L, Brune D, Nordberg GF, 
Wester PO. 1982. Antimony in lung, liver 
and kidney tissue from deceased smelter 
workers. Scandinavian journal of work, 





















Ayres DC, Hellier DG. 1997. Dictionary of 









AEITjAI#v=onepage&q=barium half life 
blood&f=false. 
50 days 1200 Bones 





















CDC. 2009. Fourth national report on 




450 days 10800 Bones 
Cacodylic Acid National Center for Biotechnology I. 
Pubchem compound database cid=2513: 















Cadmium Scoullos M, Vonkeman GH, Thornton I, 
Makuch Z. 2001. Mercury — cadmium — 
lead handbook for sustainable heavy 
metals policy and regulation. 1st 
ed:Springer Netherlands.  
30 years 262800 Body 
Bernhoft RA. 2013. Cadmium toxicity and 






































































CDC. 2009. Fourth national report on 












Cobalt Tvermoes BE, Unice KM, Paustenbach 
DJ, Finley BL, Otani JM, Galbraith DA. 
2014. Effects and blood concentrations of 
cobalt after ingestion of 1 mg/d by human 
volunteers for 90 d. The American journal 














99.50 days 2388 Body 
CDC. 2009. Fourth national report on 










Copper Johnson PE, Milne DB, Lykken GI. 1992. 
Effects of age and sex on copper 
absorption, biological half-life, and status 
in humans. The American journal of 







Lyon TDB, Fell GS, Gaffney D, McGaw 
BA, Russell RI, Park RHR, et al. 1995. 
Use of a stable copper isotope in the 
differential diagnosis of wilson's disease. 














27 years 236520 Bones 
ATSDR. Toxguide for lead. Available: 
https://www.atsdr.cdc.gov/toxguides/toxgu
ide-13.pdf. 
30 days 720 Blood, Serum, 
Plasma 
National Research Council Committee on 
Measuring Lead in Critical P. 1993. 4, 




25 days 600 Blood, Serum, 
Plasma 
Barbosa F, Tanus-Santos JE, Gerlach RF, 
Parsons PJ. 2005. A critical review of 
biomarkers used for monitoring human 









and future needs. Environmental Health 
Perspectives 113:1669-1674.  



















Oregon Department of Human Services. 


























NCHS. 2012. Laboratory procedure 
manual: Cadmium, Lead, Manganese, 




30 days 720 Blood, Serum, 
Plasma 
Swedish Chemicals Agency. 2012. 
Proposal for harmonised classification and 
labelling: Lead. Available: 
https://echa.europa.eu/documents/10162/1
3626/lead_clh_proposal_en.pdf. 
40 days 960 Blood, Serum, 
Plasma 
Dobbs MR. 2009. Clinical 





36 days 864 Blood, Serum, 
Plasma 
Manganese O’Neal SL, Zheng W. 2015. Manganese 
toxicity upon overexposure: A decade in 
review. Current environmental health 







Santamaria AB. 2008. Manganese 
exposure, essentiality & toxicity. The 










Mayo Foundation for Medical E, Research. 





40 days 960 Body 
O’Neal SL, Hong L, Fu S, Jiang W, Jones 
A, Nie LH, et al. 2014. Manganese 
accumulation in bone following chronic 
exposure in rats: Steady-state 
8.50 years 74460 Bones 
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concentration and half-life in bone. 
Toxicology Letters 229:93-100. 
Mercury ATSDR. 2000. Managing hazardous 

























Hyman MH. 2004. The impact of mercury 






























1 week 168 Blood, Serum, 
Plasma 
University of Minnesota E, Occupational 
H. Mercury: Dose, absorption, distribution, 




50 days 1200 Body 
Methyl 
Mercury 
Jo S, Woo HD, Kwon H-J, Oh S-Y, Park J-
D, Hong Y-S, et al. 2015. Estimation of 
the biological half-life of methylmercury 
using a population toxicokinetic model. 
International Journal of Environmental 






















1.5 months 1080 Blood, Serum, 
Plasma 












CDC. 2009. Fourth national report on 




50 days 1200 Body 
Inorganic 
Mercury 














ATSDR. 2000. Managing hazardous 






















6.60 hours 6.60 Blood, Serum, 
Plasma 
 
Vyskočil, Adolf, and Claude Viau. 
"Assessment of molybdenum toxicity in 
humans." Journal of Applied Toxicology 
19.3 (1999): 185-192. 
19 hours 19 Body 
Perchlorate Srinivasan A, Viraraghavan T. 2009. 
Perchlorate: Health effects and 
technologies for its removal from water 
resources. International Journal of 











Crump KS, Gibbs JP. 2005. Benchmark 
calculations for perchlorate from three 
human cohorts. Environmental Health 
Perspectives 113:1001-1008.  
7.50 hours 7.50 Blood, Serum, 
Plasma 
 




8 hours 8 Blood, Serum, 
Plasma 
 
WHO. 2004. Perchlorate in Drinking-
water Background document for 
development of WHO Guidelines for 














Platinum Herr CEW, Jankofsky M, Angerer J, 
Kuster W, Stilianakis NI, Gieler U, et al. 
2003. Influences on human internal 
exposure to environmental platinum. 
Journal of exposure analysis and 
environmental epidemiology 13:24-30. 
720 days 17280 Body 
Thallium  AcuteTox. Thallium sulfate. Available: 
http://www.acutetox.eu/pdf_human_short/
66-Thallium sulphate revised.pdf.  
8 days 192 Blood, Serum, 
Plasma 
 













Thiomersal Burbacher, Thomas M. et al. “Comparison 
of Blood and Brain Mercury Levels in 
Infant Monkeys Exposed to 




Methylmercury or Vaccines Containing 
Thimerosal.” Environmental Health 
Perspectives 113.8 (2005): 1015–1021. 
PMC. Web. 6 Sept. 2018.  
Tungsten Lemus R, Venezia CF. 2015. An update to 
the toxicological profile for water-soluble 
and sparingly soluble tungsten substances. 





















































Nriagu J. 2007. Zinc deficiency in human 
health. School of Public Health. 
280 days 6720 Body 
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Table A1.5. Maximum composite half-life in hours, log-transformed half-life, and types of 













to Find or 
Estimate Half-
Lives 
LBXGLY Glycideamide (pmoL/G Hb) 4.716143 0.673587 Estimated by 
QSARs 
LBXACR Acrylamide (pmoL/G Hb) 2.238721 0.35 Estimated by 
QSARs 
LBXBB1LA 2,2',4,4',5,5'-hexabromobiphenyl lipid adj 
(ng/g) 
56940 4.755417 Arnot et al., 
2014 Training 
Set 
LBXBR2LA 2,4,4'-tribromodiphenyl ether lipid adj 
(ng/g) 
26400 4.421604 Arnot et al., 
2014 Training 
Set 
LBXBR8LA 2,2',4,4',5,6'-hexabromodiphenyl ether lipid 
adj (ng/g) 
18214.72 4.260422 Arnot et al., 
2014 Training 
Set 
LBXBR6LA 2,2',4,4',6-pentabromodiphenyl lipid adj 
(ng/g) 
14831.67 4.17119 Arnot et al., 
2014 Training 
Set 
LBXBR3LA 2,2',4,4'-tetrabromodiphenyl ether lipid ad 
(ng/g) 
13818.15 4.14045 Arnot et al., 
2014 Training 
Set 
LBXBR5LA 2,2',4,4',5-pentabromodiphenyl lipid adj 
(ng/g) 
12699.6 4.10379 Arnot et al., 
2014 Training 
Set 
LBXBR7LA 2,2',4,4',5,5'-hexabromodiphenyl lipid adj 
(ng/g) 
6194.411 3.792 Estimated by 
QSARs 
LBXD03LA 1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) 244555 5.388377 Arnot et al., 
2014 Training 
Set 
LBXD07LA 1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) 66104.34 4.82023 Arnot et al., 
2014 Training 
Set 
LBXD05LA 1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) 39400.41 4.595501 Arnot et al., 
2014 Training 
Set 
LBXF04LA 1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) 60954.86 4.785008 Arnot et al., 
2014 Training 
Set 
LBXF03LA 2,3,4,7,8-pncdf Lipid Adj (pg/g) 51002.33 4.70759 Arnot et al., 
2014 Training 
Set 
LBXF08LA 1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) 22792.4 4.35779 Arnot et al., 
2014 Training 
Set 
SSMEL Melamine (ng/mL) 3.404082 0.532 Estimated by 
QSARs 




LBXBPB Lead (ug/dL) 262800 5.419625 Literature 
LBXBCD Cadmium (ug/L) 262800 5.419625 Literature 
LBXTHG Mercury, total (ug/L) 157680 5.197777 Literature 
URXUHG Mercury, urine (ng/mL) 157680 5.197777 Literature 
URXUBA Barium, urine (ng/mL) 1200 3.079181 Literature 
URXUCO Cobalt, urine (ng/mL) 17520 4.243534 Literature 
URXUCS Cesium, urine (ng/mL) 3600 3.556303 Literature 
URXUMO Molybdenum, urine (ng/mL) 19 1.278754 Literature 
URXUPB Lead, urine (ng/mL) 262800 5.419625 Literature 
URXUSB Antimony, urine (ng/mL) 2400 3.380211 Literature 
URXUTL Thallium, urine (ng/mL) 192 2.283301 Literature 
URXUTU Tungsten, urine (ng/mL) 201480 5.304232 Literature 
URXUUR Uranium, urine (ng/mL) 5760 3.760422 Literature 
URXUAS Urinary total Arsenic (µg/L) 60 1.778151 Literature 
URXUAB Urinary Arsenobetaine (µg/L) 98 1.991226 Literature 
URXUDMA Urinary Dimethylarsonic acid (µg/L) 2243 3.350829 Literature 
URXUCD Cadmium, urine (ng/mL) 262800 5.419625 Literature 
LBXBMN Blood manganese (ug/L) 78840 4.896747 Literature 
LBXSCU Serum Copper (ug/dL) 792 2.898725 Literature 
LBXSZN Serum Zinc (ug/dL) 12000 4.079181 Literature 
LBXBGM Mercury, methyl (ug/L) 3360 3.526339 Literature 
URXSCN Urinary thiocyanate (ng/mL) 4.477442 0.65103 Estimated by 
QSARs 
URXUIO Iodine, urine (ng/mL) 744 2.871573 Literature 
URXNO3 Urinary nitrate (ng/mL) 1.588547 0.201 Estimated by 
QSARs 
URXUP8 Perchlorate, urine (ng/mL) 9.3 0.968483 Literature 
URXTRS Urinary Triclosan (ng/mL) 254.0973 2.405 Estimated by 
QSARs 
URXBPS Urinary Bisphenol S (ug/L) 7.144963 0.854 Estimated by 
QSARs 
URXMPB Methyl paraben (ng/ml) 2.09894 0.322 Estimated by 
QSARs 
URXPPB Propyl paraben (ng/ml) 2.09894 0.322 Estimated by 
QSARs 
URXBPH Urinary Bisphenol A (ng/mL) 2 0.30103 Arnot et al., 
2014 Training 
Set 
URXBPF Urinary Bisphenol F (ug/L) 1.96336 0.293 Estimated by 
QSARs 
URXBP3 Urinary Benzophenone-3 (ng/mL) 1.202264 0.08 Estimated by 
QSARs 
LBXTNALA Trans-nonachlor Lipid Adj (ng/g) 685510.4 5.836014 Estimated by 
QSARs 




LBXPDELA p,p'-DDE Lipid Adj (ng/g) 77236.13 4.887821 Arnot et al., 
2014 Training 
Set 
LBXDIELA Dieldrin Lipid Adj (ng/g) 36525.47 4.562596 Arnot et al., 
2014 Training 
Set 
LBXBHCLA Beta-hexachlorocyclohexane Lipid Adj 
(ng/g) 
3365.348 3.52703 Estimated by 
QSARs 
URXCPM 3,5,6-trichloropyridinol (ug/L) 197.6464 2.295889 Estimated by 
QSARs 
URXOP3 Dimethylthiophosphate (ug/L) 117.1998 2.068927 Estimated by 
QSARs 
URXOPM 3-phenoxybenzoic acid (ug/L) 67.02382 1.826229 Estimated by 
QSARs 
URX14D 2,5-dichlorophenol (ug/L) 39.88466 1.600806 Estimated by 
QSARs 
URXDCB 2,4-dichlorophenol (ug/L) 35.81212 1.55403 Estimated by 
QSARs 
URXPAR Paranitrophenol (ug/L) 13.95087 1.144601 Estimated by 
QSARs 
URX24D 2,4-D (ug/L) 32.9997 1.51851 Arnot et al., 
2014 Training 
Set 
URXDEA DEET acid (ug/L) 9.29979 0.968473 Estimated by 
QSARs 
URXCNP Mono(carboxynonyl) phthalate (ng/mL) 10.35214 1.01503 Estimated by 
QSARs 
SSURHIBP Mono-2-hydroxy-iso-butyl phthlte (ng/mL) 5.936395 0.773523 Estimated by 
QSARs 
URXCOP Mono(carboxyoctyl) phthalate (ng/mL) 5.176068 0.714 Estimated by 
QSARs 
URXMIB Mono-isobutyl pthalate (ng/mL) 1.75945 0.245377 Estimated by 
QSARs 
URXMHP Mono-(2-ethyl)-hexyl phthalate (ng/mL) 1.117285 0.048164 Estimated by 
QSARs 
URXMOH Mono-(2-ethyl-5-oxohexyl) phthalate 
(ng/mL) 
1.117285 0.048164 Estimated by 
QSARs 
URXMZP Mono-benzyl phthalate (ng/mL) 1.093676 0.038889 Estimated by 
QSARs 
URXMHH Mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(ng/mL) 
1.022749 0.009769 Estimated by 
QSARs 
URXECP Mono-2-ethyl-5-carboxypentyl phthalate 
(ng/mL) 
0.990511 -0.00414 Estimated by 
QSARs 
URXMBP Mono-n-butyl phthalate (ng/mL) 0.951643 -0.02153 Estimated by 
QSARs 
URXMEP Mono-ethyl phthalate (ng/mL) 0.951643 -0.02153 Estimated by 
QSARs 
URXMNM Mono-n-methyl phthalate (ng/mL) 0.951643 -0.02153 Estimated by 
QSARs 
SSURMHBP Mono-3-hydroxy-n-butyl phthalate (ng/mL) 0.866928 -0.06202 Estimated by 
QSARs 
URXMC1 Mono-(3-carboxypropyl) phthalate (ng/mL) 0.837084 -0.07723 Estimated by 
QSARs 




URXETL Enterolactone (ng/mL) 0.820352 -0.086 Estimated by 
QSARs 
URXETD Enterodiol (ng/mL) 0.412098 -0.385 Estimated by 
QSARs 
URXP05 3-phenanthrene (ng/L) 10.13458 1.005806 Estimated by 
QSARs 
URXP06 1-phenanthrene (ng/L) 10.13458 1.005806 Estimated by 
QSARs 
URXP07 2-phenanthrene (ng/L) 10.13458 1.005806 Estimated by 
QSARs 
URXP19 4-phenanthrene (ng/L) 10.13458 1.005806 Estimated by 
QSARs 
URXP25 2 & 3-Hydroxyphenanthrene (ng/L) 10.13458 1.005806 Estimated by 
QSARs 
URXP10 1-pyrene (ng/L) 8.830799 0.946 Estimated by 
QSARs 
URXP01 1-napthol (ng/L) 6.424005 0.807806 Estimated by 
QSARs 
URXP02 2-napthol (ng/L) 6.424005 0.807806 Estimated by 
QSARs 
URXP17 9-fluorene (ng/L) 5.480988 0.738859 Estimated by 
QSARs 
URXP03 3-fluorene (ng/L) 1.689685 0.227806 Estimated by 
QSARs 
URXP04 2-fluorene (ng/L) 1.689685 0.227806 Estimated by 
QSARs 
LBD199LA PCB199 Lipid Adj (ng/g) 2023998 6.30621 Arnot et al., 
2014 Training 
Set 
LBX180LA PCB180 Lipid Adj (ng/g) 451554.3 5.65471 Arnot et al., 
2014 Training 
Set 
LBX209LA PCB209 Lipid Adj (ng/g) 303598.5 5.4823 Arnot et al., 
2014 Training 
Set 
LBX146LA PCB146 Lipid Adj (ng/g) 233539.3 5.36836 Arnot et al., 
2014 Training 
Set 
LBX170LA PCB170 Lipid Adj (ng/g) 226996.9 5.35602 Arnot et al., 
2014 Training 
Set 
LBX194LA PCB194 Lipid Adj (ng/g) 170215.9 5.231 Estimated by 
QSARs 
LBX187LA PCB187 Lipid Adj (ng/g) 136442.9 5.134951 Arnot et al., 
2014 Training 
Set 
LBX153LA PCB153 Lipid Adj (ng/g) 129038.7 5.11072 Arnot et al., 
2014 Training 
Set 
LBX196LA PCB196 Lipid Adj (ng/g) 101199.9 5.00518 Arnot et al., 
2014 Training 
Set 





LBXHXCLA 3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) 73872.02 4.86848 Arnot et al., 
2014 Training 
Set 
LBX118LA PCB118 Lipid Adj (ng/g) 45459.01 4.65762 Arnot et al., 
2014 Training 
Set 
LBX099LA PCB99 Lipid Adj (ng/g) 30359.85 4.4823 Arnot et al., 
2014 Training 
Set 
LBXPCBLA 3,3',4,4',5-pcnb Lipid Adj (pg/g) 14646.56 4.165736 Arnot et al., 
2014 Training 
Set 
LBX074LA PCB74 Lipid Adj (ng/g) 8552.045 3.93207 Arnot et al., 
2014 Training 
Set 
LBX028LA PCB28 Lipid Adj (ng/g) 5284.107 3.722972 Arnot et al., 
2014 Training 
Set 
LBX049LA PCB49 Lipid Adj (ng/g) 1046.887 3.0199 Arnot et al., 
2014 Training 
Set 
LBX044LA PCB44 Lipid Adj (ng/g) 948.7452 2.97715 Arnot et al., 
2014 Training 
Set 
LBXPFDE Perfluorodecanoic acid (ng/mL) 58692 4.768578909 Conglomerated 
Estimation 
LBXMPAH 2-(N-methyl-PFOSA) acetate (ng/mL) 14582.35905 4.163827787 Animal-
Human 
Extrapolation 
LBXPFNA Perfluorononanoic acid (ng/mL) 21900 4.340444115 Conglomerated 
Estimation 
LBXPFHS Perfluorohexane sulfonic acid (ng/mL) 63948 4.805826966 Conglomerated 
Estimation 
LBXPFOA Perfluorooctanoic acid (ng/mL) 20586 4.313571968 Conglomerated 
Estimation 
LBXPFOS Perfluorooctane sulfonic acid (ng/mL) 41172 4.614601964 Conglomerated 
Estimation 
LBXCOT Cotinine (ng/mL) 17.30103 1.238072 Arnot et al., 
2014 Training 
Set 
URXNAL NNAL , urine (ng/mL) 2.203265 0.343067 Estimated by 
QSARs 
LBXVXY Blood m-/p-Xylene (ng/ml) 31.62105 1.499976 Arnot et al., 
2014 Training 
Set 
LBXVDB Blood 1,4-Dichlorobenzene (ng/ml) 21.9786 1.342 Estimated by 
QSARs 
LBXVBM Blood Bromodichloromethane (pg/ml) 18.40772 1.265 Estimated by 
QSARs 
URXHEM N-Ace-S-(2-Hydroxyethyl)-L-cys (ng/mL) 7.353935 0.86652 Estimated by 
QSARs 
URXPHG Phenylglyoxylic acid (ng/mL) 4.400217 0.643474 Estimated by 
QSARs 






4.477442 0.65103 Estimated by 
QSARs 
URX34M 3-methipurc acd & 4-methipurc acd 
(ng/mL) 
4.824392 0.683443 Estimated by 
QSARs 
URXBMA N-Acetyl-S-(benzyl)-L-cysteine (ng/mL) 4.594688 0.662256 Estimated by 
QSARs 




4.477442 0.65103 Estimated by 
QSARs 








3.992602 0.601256 Estimated by 
QSARs 
URXATC 2-amnothiazolne-4-carbxylic acid (ng/mL) 3.992602 0.601256 Estimated by 
QSARs 
URXCYM N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL) 3.992602 0.601256 Estimated by 
QSARs 
URXTTC 2-thoxothazlidne-4-carbxylic acid (ng/mL) 3.992602 0.601256 Estimated by 
QSARs 
URX2MH 2-Methylhippuric acid (ng/mL) 3.867926 0.587478 Estimated by 
QSARs 








3.483236 0.541983 Estimated by 
QSARs 
URXDHB N-Ace-S-(3,4-Dihidxybutl)-L-Cys (ng/mL) 3.213711 0.507007 Estimated by 
QSARs 
LBXVTO Blood Toluene (ng/ml) 2.576321 0.411 Estimated by 
QSARs 
LBXNM Blood Nitromethane (pg/mL) 2.238721 0.35 Estimated by 
QSARs 





Table A1.6. References on regulation, legislation, and restriction dates of substances. 
 
Chemical References for Ban/Phase-out Dates 
Acephate US EPA. 2017. Food and pesticides. Available: 
https://www.epa.gov/safepestcontrol/food-and-pesticides. 
Aldrin/Endrin ATSDR. 2011. Toxic substances portal - aldrin/dieldrin. Available: 
https://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=56.  
US EPA. 2006. Procedures for the derivation of equilibrium partitioning sediment 





Azinphos-Methyl Gilbert S. 2014. Azinphos-methyl. Available: 
http://www.toxipedia.org/display/toxipedia/Azinphos-Methyl. 
Bisphenol A (BPA) Houlihan J, Lunder S, Jacob A. 2008. Timeline: Bpa from invention to phase-out. 
Available: https://www.ewg.org/research/timeline-bpa-invention-phase-
out#.WjsfefmnEdU. 
Cadmium Spencer J. 2008. Toys 'R' us, mattel phase out cadmium batteries. The Wall Street 
Journal. 
Carbofuran Foley S. 2009. Carbofuran. Available: 
http://www.toxipedia.org/display/toxipedia/Carbofuran.  
US EPA. 2011. Carbofuran cancellation process. Available: 
https://archive.epa.gov/pesticides/reregistration/web/html/carbofuran_noic.html#revo
cation. 
Carbon Tetrachloride ATSDR. 2015. Toxic substances portal - carbon tetrachloride. Available: 
https://www.atsdr.cdc.gov/phs/phs.asp?id=194&tid=35. 
Chlorobenzene ATSDR. 2011. Toxic substances portal - chlorobenzene. Available: 
https://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=87. 
Chlordane ATSDR. 2015. Toxic substances portal - chlordane. Available: 
https://www.atsdr.cdc.gov/phs/phs.asp?id=353&tid=62. 
Chlorpyrifos US EPA. 2017. Ingredients used in pesticide products: Chlorpyrifos. Available: 
https://www.epa.gov/ingredients-used-pesticide-products/chlorpyrifos. 
Chlorpyrifos-Methyl US EPA. 2000. Chlorpyrifos-methyl facts. Available: 
https://www3.epa.gov/pesticides/chem_search/reg_actions/reregistration/fs_PC-
059102_1-Oct-00.pdf. 
Cyanide Jensen J. Ban on cyanide mining in montana with initiative 137. Available: 
http://meic.org/issues/mining-in-montana/hardrock-and-cyanide-mining-in-
montana/ban-on-cyanide-mining-in-montana-with-initiative-137/.  
Representatives of Wisconsin. 2001. 2001 Assembly Bill 95. Available: 
http://docs.legis.wisconsin.gov/2001/related/proposals/ab95. 










US EPA. 1975. DDT regulatory history: A brief survey (to 1975). Available: 
https://archive.epa.gov/epa/aboutepa/ddt-regulatory-history-brief-survey-1975.html.  
Dioxins and dioxin-like 
compounds 





US EPA. 2000. 1,2-dibromo-3-chloropropane (DBCP). Available: 
https://www.epa.gov/sites/production/files/2016-09/documents/1-2-dibromo-3-
chloropropane.pdf.  
1,2-Dibromoethane ATSDR. 2011. Toxic substances portal - 1,2-dibromoethane. Available: 
https://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=131. 
Dichlorvos (DDVP) US EPA. 1995. Dichlorvos (ddvp); deletion of certain uses and directions. Available: 
https://www.federalregister.gov/documents/1995/04/19/95-9166/dichlorvos-ddvp-
deletion-of-certain-uses-and-directions. 
Ethyl Chloride US EPA. Ethyl chloride (chloroethane). Available: 
https://www.epa.gov/sites/production/files/2016-09/documents/ethyl-chloride.pdf. 
Ethylene Oxide Gilbert S. 2009. Ethylene oxide (eto). Available: 
http://www.toxipedia.org/pages/viewpage.action?pageId=2822700. 
Formaldehyde Thomas K. 2014. The ‘no more tears’ shampoo, now with no formaldehyde. New 
York Times.  
Heptachlor ATSDR. 2015. Toxic substances portal - heptachlor/heptachlor epoxide. Available: 
https://www.atsdr.cdc.gov/phs/phs.asp?id=743&tid=135.  
Extension Toxicology Network. 1996. Pesticide information profile - heptachlor. 
Available: http://extoxnet.orst.edu/pips/heptachl.htm.  
Gilbert S. 2014. Heptachlor. Available: 
http://www.toxipedia.org/display/toxipedia/Heptachlor#Heptachlor-
ATSDRPublicHealthStatement. 
Hexachlorobenzene ATSDR. 2015. Toxicological profile for hexachlorobenzene. Available: 
https://www.atsdr.cdc.gov/ToxProfiles/tp90.pdf. 
Hexachlorocyclohexanes ASTDR. 2005. Toxicological profile for alpha-, beta-, gamma-, and delta-
hexachlorocyclohexane. Available: https://www.atsdr.cdc.gov/toxprofiles/tp43.pdf.  
ATSDR. 2005. 5. Production, import/export, use, and disposal: 
Hexachlorocyclohexane. Available: https://www.atsdr.cdc.gov/ToxProfiles/tp43-
c5.pdf. 
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LBXGLY Glycideamide (pmoL/G Hb) #N/A No 
Restrictions 
No Restrictions 
LBXACR Acrylamide (pmoL/G Hb) #N/A No 
Restrictions 
No Restrictions 
LBXBB1LA 2,2',4,4',5,5'-hexabromobiphenyl lipid adj 
(ng/g) 
1979 1970s 1970-1984 
LBXBR2LA 2,4,4'-tribromodiphenyl ether lipid adj 
(ng/g) 
2004 2000s 2000-2014 
LBXBR8LA 2,2',4,4',5,6'-hexabromodiphenyl ether 
lipid adj (ng/g) 
2004 2000s 2000-2014 
LBXBR6LA 2,2',4,4',6-pentabromodiphenyl lipid adj 
(ng/g) 
2004 2000s 2000-2014 
LBXBR3LA 2,2',4,4'-tetrabromodiphenyl ether lipid ad 
(ng/g) 
2004 2000s 2000-2014 
LBXBR5LA 2,2',4,4',5-pentabromodiphenyl lipid adj 
(ng/g) 
2004 2000s 2000-2014 
LBXBR7LA 2,2',4,4',5,5'-hexabromodiphenyl lipid adj 
(ng/g) 
2004 2000s 2000-2014 
LBXD03LA 1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) 1995 1990s 1985-1999 
LBXD07LA 1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) 1995 1990s 1985-1999 
LBXD05LA 1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) 1995 1990s 1985-1999 
LBXF04LA 1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) 1995 1990s 1985-1999 
LBXF03LA 2,3,4,7,8-pncdf Lipid Adj (pg/g) 1995 1990s 1985-1999 
LBXF08LA 1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) 1995 1990s 1985-1999 
SSMEL Melamine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
SSCYA Cyanuric acid (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXBPB Lead (ug/dL) 1995 1990s 1985-1999 
LBXBCD Cadmium (ug/L) 2008 2000s 2000-2014 
LBXTHG Mercury, total (ug/L) 1996 1990s 1985-1999 
URXUHG Mercury, urine (ng/mL) 1996 1990s 1985-1999 
URXUBA Barium, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUCO Cobalt, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUCS Cesium, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUMO Molybdenum, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUPB Lead, urine (ng/mL) 1995 1990s 1985-1999 
URXUSB Antimony, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUTL Thallium, urine (ng/mL) 1972 1970s 1970-1984 
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URXUTU Tungsten, urine (ng/mL) 2012 2010s 2000-2014 
URXUUR Uranium, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUAS Urinary total Arsenic (µg/L) #N/A No 
Restrictions 
No Restrictions 
URXUAB Urinary Arsenobetaine (µg/L) #N/A No 
Restrictions 
No Restrictions 
URXUDMA Urinary Dimethylarsonic acid (µg/L) #N/A No 
Restrictions 
No Restrictions 
URXUCD Cadmium, urine (ng/mL) 2008 2000s 2000-2014 
LBXBMN Blood manganese (ug/L) #N/A No 
Restrictions 
No Restrictions 
LBXSCU Serum Copper (ug/dL) #N/A No 
Restrictions 
No Restrictions 
LBXSZN Serum Zinc (ug/dL) #N/A No 
Restrictions 
No Restrictions 
LBXBGM Mercury, methyl (ug/L) 1996 1990s 1985-1999 
URXSCN Urinary thiocyanate (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUIO Iodine, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXNO3 Urinary nitrate (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXUP8 Perchlorate, urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXTRS Urinary Triclosan (ng/mL) 2016 No 
Restrictions 
No Restrictions 
URXBPS Urinary Bisphenol S (ug/L) #N/A No 
Restrictions 
No Restrictions 
URXMPB Methyl paraben (ng/ml) 2015 No 
Restrictions 
No Restrictions 
URXPPB Propyl paraben (ng/ml) 2015 No 
Restrictions 
No Restrictions 
URXBPH Urinary Bisphenol A (ng/mL) 2008 2000s 2000-2014 
URXBPF Urinary Bisphenol F (ug/L) #N/A No 
Restrictions 
No Restrictions 





Trans-nonachlor Lipid Adj (ng/g) 1983 1980s 1970-1984 
LBXOXYL
A 
Oxychlordane Lipid Adj (ng/g) 1983 1980s 1970-1984 
LBXPDEL
A 
p,p'-DDE Lipid Adj (ng/g) 1959 1950s Before 1970s 
LBXDIELA Dieldrin Lipid Adj (ng/g) 1974 1970s 1970-1984 
LBXBHCL
A 
Beta-hexachlorocyclohexane Lipid Adj 
(ng/g) 
1976 1970s 1970-1984 
URXCPM 3,5,6-trichloropyridinol (ug/L) 2000 2000s 2000-2014 
URXOP3 Dimethylthiophosphate (ug/L) 2000 2000s 2000-2014 
URXOPM 3-phenoxybenzoic acid (ug/L) #N/A No 
Restrictions 
No Restrictions 





URXDCB 2,4-dichlorophenol (ug/L) #N/A No 
Restrictions 
No Restrictions 
URXPAR Paranitrophenol (ug/L) 1998 1990s 1985-1999 
URX24D 2,4-D (ug/L) #N/A No 
Restrictions 
No Restrictions 
URXDEA DEET acid (ug/L) #N/A No 
Restrictions 
No Restrictions 
URXCNP Mono(carboxynonyl) phthalate (ng/mL) 2008 2000s 2000-2014 





URXCOP Mono(carboxyoctyl) phthalate (ng/mL) 2008 2000s 2000-2014 
URXMIB Mono-isobutyl pthalate (ng/mL) 2009 2000s 2000-2014 
URXMHP Mono-(2-ethyl)-hexyl phthalate (ng/mL) 2007 2000s 2000-2014 
URXMOH Mono-(2-ethyl-5-oxohexyl) phthalate 
(ng/mL) 
2007 2000s 2000-2014 
URXMZP Mono-benzyl phthalate (ng/mL) 2009 2000s 2000-2014 
URXMHH Mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(ng/mL) 
2007 2000s 2000-2014 
URXECP Mono-2-ethyl-5-carboxypentyl phthalate 
(ng/mL) 
2007 2000s 2000-2014 
URXMBP Mono-n-butyl phthalate (ng/mL) 2009 2000s 2000-2014 
URXMEP Mono-ethyl phthalate (ng/mL) #N/A No 
Restrictions 
No Restrictions 







2009 2000s 2000-2014 










URXETL Enterolactone (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXETD Enterodiol (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXP05 3-phenanthrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP06 1-phenanthrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP07 2-phenanthrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP19 4-phenanthrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP25 2 & 3-Hydroxyphenanthrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP10 1-pyrene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP01 1-napthol (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP02 2-napthol (ng/L) #N/A No 
Restrictions 
No Restrictions 





URXP03 3-fluorene (ng/L) #N/A No 
Restrictions 
No Restrictions 
URXP04 2-fluorene (ng/L) #N/A No 
Restrictions 
No Restrictions 
LBD199LA PCB199 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX180LA PCB180 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX209LA PCB209 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX146LA PCB146 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX170LA PCB170 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX194LA PCB194 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX187LA PCB187 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX153LA PCB153 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX196LA PCB196 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX138LA PCB138 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBXHXCL
A 
3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) 1979 1970s 1970-1984 
LBX118LA PCB118 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX099LA PCB99 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBXPCBL
A 
3,3',4,4',5-pcnb Lipid Adj (pg/g) 1979 1970s 1970-1984 
LBX074LA PCB74 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX028LA PCB28 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX049LA PCB49 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBX044LA PCB44 Lipid Adj (ng/g) 1979 1970s 1970-1984 
LBXPFDE Perfluorodecanoic acid (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXMPAH 2-(N-methyl-PFOSA) acetate (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXPFNA Perfluorononanoic acid (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXPFHS Perfluorohexane sulfonic acid (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXPFOA Perfluorooctanoic acid (ng/mL) 2002 2000s 2000-2014 
LBXPFOS Perfluorooctane sulfonic acid (ng/mL) 2002 2000s 2000-2014 
LBXCOT Cotinine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
URXNAL NNAL , urine (ng/mL) #N/A No 
Restrictions 
No Restrictions 
LBXVXY Blood m-/p-Xylene (ng/ml) #N/A No 
Restrictions 
No Restrictions 
LBXVDB Blood 1,4-Dichlorobenzene (ng/ml) 1987 1980s 1985-1999 



























































URXCYM N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL) #N/A No 
Restrictions 
No Restrictions 




























LBXVTO Blood Toluene (ng/ml) #N/A No 
Restrictions 
No Restrictions 
LBXNM Blood Nitromethane (pg/mL) #N/A No 
Restrictions 
No Restrictions 





Table A1.8. !!"# , !!"#!, calculated #$%&'()#*, and calculated fold difference when $$%&'()#* = 5 
years and (X_age ) ̅  = 31.88 years for all chemical biomarkers, which are ranked by the fold 
difference of chemical biomarker levels between a child of 5 years and an adult of 31.88 years 
(10+"#$%&'()) in descending order. 
Codename Chemical Name !*+, !*+,! schildren Fold Difference 
("#-"#$%&'()) 
URXMZP Mono-benzyl phthalate (ng/mL) -9.67E-03 2.14E-04 0.415 2.598 
URXDMA o-Desmethylangolensin (O-DMA) (ng/mL) -7.51E-03 1.88E-04 0.338 2.176 
URXMC1 Mono-(3-carboxypropyl) phthalate (ng/mL) -7.14E-03 2.01E-04 0.337 2.173 
URXATC 2-amnothiazolne-4-carbxylic acid (ng/mL) -6.48E-03 1.90E-04 0.312 2.049 
URXUTU Tungsten, urine (ng/mL) -6.89E-03 1.48E-04 0.292 1.960 
URXCPM 3,5,6-trichloropyridinol (ug/L) -4.71E-03 2.24E-04 0.288 1.942 
SSURHIBP Mono-2-hydroxy-iso-butyl phthlte (ng/mL) -6.28E-03 1.61E-04 0.285 1.927 
URXMBP Mono-n-butyl phthalate (ng/mL) -5.43E-03 1.79E-04 0.275 1.884 
LBXBR7LA 2,2',4,4',5,5'-hexabromodiphenyl ether lipid adj 
(ng/g) 
-6.59E-03 1.21E-04 0.264 1.839 
URXDEA DEET acid (ug/L) -6.42E-03 1.20E-04 0.260 1.818 
URXMOH Mono-(2-ethyl-5-oxohexyl) phthalate (ng/mL) -5.64E-03 1.44E-04 0.256 1.803 
URXECP Mono-2-ethyl-5-carboxypentyl phthalate 
(ng/mL) 
-5.21E-03 1.46E-04 0.245 1.760 
SSURMHBP Mono-3-hydroxy-n-butyl phthalate (ng/mL) -4.18E-03 1.71E-04 0.236 1.721 
URXUMO Molybdenum, urine (ng/mL) -4.68E-03 1.41E-04 0.228 1.689 
URXMHH Mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(ng/mL) 
-4.89E-03 1.19E-04 0.217 1.650 
URXPAR Paranitrophenol (ug/L) -3.35E-03 1.70E-04 0.213 1.632 
LBXBR5LA 2,2',4,4',5-pentabromodiphenyl lipid adj (ng/g) -4.92E-03 1.05E-04 0.208 1.614 
URXUIO Iodine, urine (ng/mL) -2.79E-03 1.76E-04 0.202 1.594 
URXOP3 Dimethylthiophosphate (ug/L) -2.70E-03 1.76E-04 0.200 1.584 
LBXBR3LA 2,2',4,4'-tetrabromodiphenyl ether lipid ad 
(ng/g) 
-4.67E-03 9.96E-05 0.197 1.576 
URXCOP Mono(carboxyoctyl) phthalate (ng/mL) -5.01E-03 8.47E-05 0.196 1.570 
URXMNM Mono-n-methyl phthalate (ng/mL) -3.65E-03 1.32E-04 0.194 1.562 
URXMIB Mono-isobutyl pthalate (ng/mL) -4.58E-03 9.55E-05 0.192 1.556 
LBXPFHS Perfluorohexane sulfonic acid (ng/mL) -3.01E-03 1.40E-04 0.182 1.520 
LBXMPAH 2-(N-methyl-PFOSA) acetate (ng/mL) -2.65E-03 1.49E-04 0.179 1.510 
URXCNP Mono(carboxynonyl) phthalate (ng/mL) -3.93E-03 9.99E-05 0.178 1.506 
URXUCO Cobalt, urine (ng/mL) -3.64E-03 1.02E-04 0.172 1.485 
LBXBR6LA 2,2',4,4',6-pentabromodiphenyl lipid adj (ng/g) -4.17E-03 7.85E-05 0.169 1.475 
URXHEM N-Ace-S-(2-Hydroxyethyl)-L-cys (ng/mL) -4.59E-03 5.97E-05 0.166 1.467 
URXUP8 Perchlorate, urine (ng/mL) -2.74E-03 1.09E-04 0.153 1.421 
URXETL Enterolactone (ng/mL) -1.80E-03 1.39E-04 0.149 1.409 
URXP10 1-pyrene (ng/L) -4.12E-03 2.88E-05 0.131 1.354 
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LBXBR8LA 2,2',4,4',5,6'-hexabromodiphenyl ether lipid adj 
(ng/g) 
-2.94E-03 7.24E-05 0.131 1.353 
LBX049LA PCB49 Lipid Adj (ng/g) -3.12E-03 6.07E-05 0.128 1.342 
URXBPH Urinary Bisphenol A (ng/mL) -2.88E-03 6.60E-05 0.125 1.334 
URXTTC 2-thoxothazlidne-4-carbxylic acid (ng/mL) -2.31E-03 8.27E-05 0.122 1.324 
LBX044LA PCB44 Lipid Adj (ng/g) -2.84E-03 5.97E-05 0.119 1.317 
URXUBA Barium, urine (ng/mL) -3.42E-03 3.60E-05 0.118 1.312 
URXUSB Antimony, urine (ng/mL) -2.67E-03 6.28E-05 0.117 1.310 
URXDHB N-Ace-S-(3,4-Dihidxybutl)-L-Cys (ng/mL) -1.27E-03 1.12E-04 0.115 1.304 
URXNAL NNAL , urine (ng/mL) -2.24E-03 7.03E-05 0.111 1.291 
LBXF08LA 1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) -2.15E-03 7.07E-05 0.109 1.284 
URX14D 2,5-dichlorophenol (ug/L) -4.78E-04 1.31E-04 0.107 1.281 
URXOPM 3-phenoxybenzoic acid (ug/L) -1.74E-03 6.93E-05 0.097 1.250 
URXDCB 2,4-dichlorophenol (ug/L) -7.03E-04 1.04E-04 0.094 1.242 
URXNO3 Urinary nitrate (ng/mL) -2.66E-03 2.96E-05 0.093 1.238 
URX24D 2,4-D (ug/L) -1.22E-03 7.55E-05 0.087 1.222 
LBX028LA PCB28 Lipid Adj (ng/g) -1.10E-03 7.63E-05 0.085 1.215 
LBXGLY Glycideamide (pmoL/G Hb) -2.61E-03 1.53E-05 0.081 1.206 
URXUUR Uranium, urine (ng/mL) -9.01E-04 7.21E-05 0.076 1.192 
URXUTL Thallium, urine (ng/mL) -1.83E-03 2.40E-05 0.067 1.166 
URXBMA N-Acetyl-S-(benzyl)-L-cysteine (ng/mL) -3.74E-04 7.75E-05 0.066 1.164 
URXP05 3-phenanthrene (ng/L) -9.75E-04 5.23E-05 0.064 1.159 
LBXVDB Blood 1,4-Dichlorobenzene (ng/ml) -3.98E-04 4.82E-05 0.046 1.111 
LBXBR2LA 2,4,4'-tribromodiphenyl ether lipid adj (ng/g) -4.72E-04 4.37E-05 0.044 1.107 
URXUCS Cesium, urine (ng/mL) -3.65E-04 4.58E-05 0.043 1.104 
URXAAM N-Ace-S-(2-carbamoylethyl)-L-cys (ng/mL) -1.08E-03 1.74E-05 0.042 1.100 
URXMHP Mono-(2-ethyl)-hexyl phthalate (ng/mL) -2.18E-03 -2.45E-05 0.041 1.099 
URXETD Enterodiol (ng/mL) -3.72E-04 4.14E-05 0.040 1.096 
URXUPB Lead, urine (ng/mL) 1.51E-03 1.10E-04 0.039 1.095 
LBXPFOA Perfluorooctanoic acid (ng/mL) -5.80E-05 2.97E-05 0.023 1.054 
URX34M 3-methipurc acd & 4-methipurc acd (ng/mL) 7.96E-04 5.81E-05 0.021 1.049 
URXBPF Urinary Bisphenol F (ug/L) -1.08E-04 2.16E-05 0.019 1.044 
SSCYA Cyanuric acid (ng/mL) 8.50E-04 5.46E-05 0.017 1.039 
LBXBMN Blood manganese (ug/L) -8.32E-04 -9.03E-06 0.016 1.037 
LBXVCF Blood Chloroform (pg/ml) -3.96E-04 5.94E-06 0.015 1.035 
URXPHG Phenylglyoxylic acid (ng/mL) 5.81E-04 4.01E-05 0.013 1.031 
LBXACR Acrylamide (pmoL/G Hb) -7.18E-04 -1.19E-05 0.011 1.025 
LBXSCU Serum Copper (ug/dL) 1.19E-04 7.37E-06 0.002 1.005 
LBXSZN Serum Zinc (ug/dL) -7.65E-05 -1.16E-06 0.001 1.003 
URXP03 3-fluorene (ng/L) -1.19E-04 -1.11E-05 -0.005 0.989 
URXSCN Urinary thiocyanate (ng/mL) -1.09E-03 -6.86E-05 -0.020 0.955 
URXP19 4-phenanthrene (ng/L) 5.15E-04 -1.63E-05 -0.026 0.943 
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URXUDMA Urinary Dimethylarsonic acid (µg/L) 1.26E-03 8.43E-06 -0.028 0.938 
URXP06 1-phenanthrene (ng/L) 1.11E-03 -7.23E-06 -0.035 0.922 
LBXBPB Lead (ug/dL) 3.89E-03 8.72E-05 -0.042 0.909 
URXCEM N-Acetyl-S-(2-Carbxyethyl)-L-Cys (ng/mL) 3.01E-03 5.26E-05 -0.043 0.906 
SSMEL Melamine (ng/mL) 3.01E-03 3.89E-05 -0.053 0.886 
LBXNM Blood Nitromethane (pg/mL) 1.93E-03 -2.03E-06 -0.053 0.885 
LBXPFOS Perfluorooctane sulfonic acid (ng/mL) 2.89E-03 3.27E-05 -0.054 0.883 
URXP04 2-fluorene (ng/L) 1.40E-03 -2.36E-05 -0.055 0.882 
URXBPS Urinary Bisphenol S (ug/L) 2.08E-03 -2.58E-06 -0.058 0.875 
URXPMM N-A-S-(3-hydrxprpl-1-metl)-L-cys (ng/mL) 2.85E-03 2.23E-05 -0.060 0.870 
URX2MH 2-Methylhippuric acid (ng/mL) 1.60E-03 -2.60E-05 -0.062 0.867 
LBXVXY Blood m-/p-Xylene (ng/ml) 1.52E-03 -3.36E-05 -0.065 0.861 
LBXVBM Blood Bromodichloromethane (pg/ml) 1.23E-03 -4.78E-05 -0.068 0.856 
URXP02 2-napthol (ng/L) 1.54E-03 -4.08E-05 -0.071 0.849 
LBXPFNA Perfluorononanoic acid (ng/mL) 2.27E-03 -2.83E-05 -0.081 0.829 
URXP01 1-napthol (ng/L) 4.09E-03 3.82E-05 -0.082 0.827 
URXP25 2 & 3-Hydroxyphenanthrene (ng/L) 1.53E-03 -5.82E-05 -0.083 0.826 
URXBP3 Urinary Benzophenone-3 (ng/mL) -6.64E-04 -1.50E-04 -0.091 0.811 
LBXVTO Blood Toluene (ng/ml) 2.57E-03 -3.24E-05 -0.092 0.808 
URXP17 9-fluorene (ng/L) 2.86E-03 -2.95E-05 -0.098 0.797 
URXUAS Urinary total Arsenic (µg/L) 3.37E-03 -1.06E-05 -0.098 0.797 
URXP07 2-phenanthrene (ng/L) 2.59E-03 -5.18E-05 -0.107 0.782 
LBXPFDE Perfluorodecanoic acid (ng/mL) 3.45E-03 -5.77E-05 -0.135 0.734 
LBXF04LA 1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) 5.84E-03 2.91E-05 -0.136 0.731 
URXGAM N-ac-S-(2-carbmo-2-hydxel)-L-cys (ng/mL) 3.27E-03 -7.50E-05 -0.142 0.721 
URXCYM N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL) 3.68E-03 -7.80E-05 -0.155 0.700 
URXTRS Urinary Triclosan (ng/mL) 2.96E-03 -1.16E-04 -0.163 0.686 
URXMAD Mandelic acid (ng/mL) 4.00E-03 -8.60E-05 -0.170 0.676 
URXMPB Methyl paraben (ng/ml) 4.50E-03 -7.57E-05 -0.176 0.667 
URXHPM N-Ace-S-(3-Hydroxypropyl)-L-Cys (ng/mL) 4.78E-03 -7.39E-05 -0.182 0.658 
LBXDIELA Dieldrin Lipid Adj (ng/g) 6.70E-03 -1.99E-05 -0.195 0.639 
URXMEP Mono-ethyl phthalate (ng/mL) 4.95E-03 -8.60E-05 -0.195 0.638 
LBXF03LA 2,3,4,7,8-pncdf Lipid Adj (pg/g) 8.48E-03 4.00E-05 -0.199 0.632 
URXUHG Mercury, urine (ng/mL) 4.61E-03 -1.09E-04 -0.202 0.627 
URXAMC N-Ace-S-(N-methlcarbamoyl)-L-cys (ng/mL) 6.61E-03 -6.21E-05 -0.222 0.599 
LBXBCD Cadmium (ug/L) 7.31E-03 -4.97E-05 -0.232 0.586 
URXPPB Propyl paraben (ng/ml) 4.92E-03 -1.41E-04 -0.234 0.584 
URXBPM N-Acetyl-S-(n-propyl)-L-cysteine (ng/mL) 5.23E-03 -1.63E-04 -0.259 0.551 
LBX099LA PCB99 Lipid Adj (ng/g) 1.00E-02 1.22E-05 -0.260 0.550 
URXMB3 N-A-S-(4-hydrxy-2butn-l-yl)-L-cys (ng/mL) 7.49E-03 -8.33E-05 -0.262 0.548 
LBXPCBLA 3,3',4,4',5-pcnb Lipid Adj (pg/g) 1.01E-02 -4.80E-06 -0.276 0.530 
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URXUAB Urinary Arsenobetaine (µg/L) 7.96E-03 -9.59E-05 -0.283 0.521 
LBX118LA PCB118 Lipid Adj (ng/g) 1.19E-02 4.10E-05 -0.290 0.513 
LBXD05LA 1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) 9.44E-03 -5.05E-05 -0.290 0.513 
LBX074LA PCB74 Lipid Adj (ng/g) 1.25E-02 6.26E-05 -0.290 0.512 
URXHP2 N-Ace-S-(2-hydroxypropyl)-L-cys (ng/mL) 7.77E-03 -1.52E-04 -0.318 0.480 
LBXTHG Mercury, total (ug/L) 8.76E-03 -1.83E-04 -0.368 0.429 
LBXD07LA 1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) 1.19E-02 -6.70E-05 -0.369 0.428 
LBXOXYLA Oxychlordane Lipid Adj (ng/g) 1.41E-02 1.02E-05 -0.370 0.426 
LBXHXCLA 3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) 1.40E-02 3.19E-06 -0.373 0.423 
LBX209LA PCB209 Lipid Adj (ng/g) 1.80E-02 1.16E-04 -0.400 0.398 
LBXBHCLA Beta-hexachlorocyclohexane Lipid Adj (ng/g) 1.53E-02 8.75E-06 -0.405 0.394 
URXUCD Cadmium, urine (ng/mL) 1.44E-02 -9.23E-05 -0.452 0.353 
LBXBGM Mercury, methyl (ug/L) 1.10E-02 -2.23E-04 -0.457 0.349 
LBXD03LA 1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) 1.62E-02 -5.10E-05 -0.471 0.338 
LBXTNALA Trans-nonachlor Lipid Adj (ng/g) 1.75E-02 -5.37E-05 -0.508 0.310 
LBXPDELA p,p'-DDE Lipid Adj (ng/g) 1.84E-02 -1.19E-04 -0.580 0.263 
LBX138LA PCB138 Lipid Adj (ng/g) 1.98E-02 -1.11E-04 -0.613 0.244 
LBX153LA PCB153 Lipid Adj (ng/g) 2.15E-02 -1.28E-04 -0.670 0.214 
LBX146LA PCB146 Lipid Adj (ng/g) 2.26E-02 -1.31E-04 -0.703 0.198 
LBXBB1LA 2,2',4,4',5,5'-hexabromobiphenyl lipid adj (ng/g) 2.10E-02 -2.71E-04 -0.761 0.174 
LBX187LA PCB187 Lipid Adj (ng/g) 2.60E-02 -1.88E-04 -0.836 0.146 
LBX180LA PCB180 Lipid Adj (ng/g) 2.79E-02 -2.21E-04 -0.908 0.124 
LBX170LA PCB170 Lipid Adj (ng/g) 2.84E-02 -2.52E-04 -0.946 0.113 
LBX196LA PCB196 Lipid Adj (ng/g) 3.07E-02 -2.68E-04 -1.020 0.096 
LBXCOT Cotinine (ng/mL) 1.61E-02 -8.17E-04 -1.024 0.095 
LBD199LA PCB199 Lipid Adj (ng/g) 3.34E-02 -2.61E-04 -1.086 0.082 




Figure A1.1. PCB 196 concentrations across the life-stages stratified by NHANEs cycles for 









Text A1.2. Discussion of regression coefficients for NHANES cycles.  
Figure A1.3 summarize the ranges of average log change in chemical biomarker levels 
over the NHANES cycles, termed βcycle throughout the analysis and discussion. These values are 
interpreted as the log change in chemical biomarker concentration for a 2-year cycle increase and 
represent an overall trajectory across the eight NHANES cycles. The distributions of βcycle’s are 
discretized into 5 trend trajectories: highly decreasing (≤ -0.30), moderately decreasing (> -0.30 
and ≤ -0.125), slightly decreasing (> -0.125 and ≤ -0.045), stable (> -0.045 and ≤ 0.041), and 
increasing (> 0.041). The majority of chemical biomarkers have βcycle’s between -0.045 and 0.041, 
implying little or no variation over time. The majority of pesticides and PFASs have negative 
βcycle’s, demonstrating a decrease in chemical biomarker levels over time, while a few pesticides, 






Figure A1.3. Characteristics of the 141 NHANES chemical exposure biomarkers from 16 classes 
for ranges of cycle coefficients, defined as the percent change in chemical concentration due to a 
two-year (one NHANES cycle) increase in time. The classes are ranked by the means of class-
specific age percent differences (Figure 2C). Colors are used to differentiate the chemical classes. 
BFRs, Brominated Flame Retardants; SRCs, Smoking Related Compounds; PAHs, Polycyclic 
Aromatic Hydrocarbons; PCCPCs, Personal Care and Consumer Product Compounds; VOCs, 







Figure A1.4. Association between linear age coefficients and chemical persistency in the human 
body for 144 substances with colors indicating the time trend trajectories and symbols indicating 
the different chemical classes. The same abbreviations for the chemical classes are used as those 






Figure A1.5. Violin plots of PFOA concentrations partitioned by age groups to display the 
distribution with the 5th, 25th, 50th, 75th, and 95th percentiles as indicated by the superimposed 
boxplot and show the frequency of the urinary cadmium biomarker levels represented by the 





Figure A1.6. Violin plots of urinary cadmium concentrations partitioned by age groups to display 
the distribution with the 5th, 25th, 50th, 75th, and 95th percentiles as indicated by the superimposed 
boxplot and show the frequency of the urinary cadmium biomarker levels represented by the 







Appendix 2. Racial Disparities in Chemical Biomarker Concentrations in United States Women 
 
 
Figure A2.1. Panel of correlation plots comparing fold differences for race that adjusted for 
poverty income ratio (PIR) with those that excluded PIR from the regression models. Colors and 
shapes represent the different chemical families. Chemicals were labeled if fold differences 





Figure A2.2. Panel of violin plots showing the distribution of chemical biomarker levels changes 
across categories of poverty income ratio (PIR) and stratified by race for A) an indicator of 
sunscreen use, benzophenone-3, B) a biomarker of smoking, cotinine, C) a chemical used in 
personal care products, ethyl paraben, and D) methyl mercury. Colors represent different 
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Figure A2.3. Panel of correlation plots comparing fold differences for race that adjusted for 
menopause/hysterectomy status with those that excluded this reproductive health variable from 
the regression models. Colors and shapes represent the different chemical families. Chemicals 
were labeled if fold differences changed by greater than 25% when reasons of having irregular 






Figure A2.4. Panel of correlation plots comparing fold differences for race that adjusted for 
parity with those that excluded parity from the regression models. Colors and shapes represent 
the different chemical families. Chemicals were labeled if fold differences changed by greater 






Figure A2.5. Panel of correlation plots comparing fold differences for race that adjusted for 
breastfeeding for at least a month with those that excluded this reproductive health variable from 
the regression models. Colors and shapes represent the different chemical families. Chemicals 
were labeled if fold differences changed by greater than 25% when breastfeeding was considered 






Figure A2.6. Panel of correlation plots comparing fold differences for race that adjusted for iron 
deficiency with those that excluded this nutritional factor from the regression models. Colors and 
shapes represent the different chemical families. Chemicals were labeled if fold differences 







Table A2.1. Indicator (marked by an "X") of which chemical biomarker measurements for a given NHANES cycle was excluded from 
analysis. 
Chemical name Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 
Acrylamide (pmoL/G Hb)         
Glycideamide (pmoL/G Hb)         
2,2',4,4',5,5'-hexabromobiphenyl lipid adj (ng/g)         
2,2',4-tribromodiphenyl ether lipid adj (ng/g)         
2,4,4'-tribromodiphenyl ether lipid adj (ng/g)         
2,2',4,4'-tetrabromodiphenyl ether lipid ad (ng/g)         
2,2',3,4,4'-pentabromodiphenyl ether lipid adj (ng/g)         
2,2',4,4',5-pentabromodiphenyl lipid adj (ng/g)         
2,3',4,4'-tetrabromodiphenyl lipid adj (ng/g)         
2,2',4,4',6-pentabromodiphenyl lipid adj (ng/g)         
2,2',4,4',5,5'-hexabromodiphenyl lipid adj (ng/g)         
2,2',4,4',5,6'-hexabromodiphenyl ether lipid adj (ng/g)         
2,2',3,4,4',5',6-heptabromodiphenyl ether lipid adj (ng/g)         
1,2,3,7,8-pncdd Lipid Adj (pg/g)         
1,2,3,4,7,8-hxcdd Lipid Adj (pg/g)         
1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) X        
1,2,3,7,8,9-hxcdd Lipid Adj (pg/g)         
1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) X        
1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) X        
2,3,7,8-tcdd Lipid Adj (pg/g)         
2,3,7,8-tcdf Lipid Adj (pg/g)         
1,2,3,7,8-pncdf Lipid Adj (pg/g)         
2,3,4,7,8-pncdf Lipid Adj (pg/g) X        
1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) X        
1,2,3,6,7,8-hxcdf Lipid Adj (pg/g)         
1,2,3,7,8,9-hxcdf Lipid Adj (pg/g)         
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2,3,4,6,7,8-hxcdf Lipid Adj (pg/g)         
1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) X        
1,2,3,4,7,8,9-hpcdf Lipid Adj (pg/g)         
1,2,3,4,6,7,8,9-ocdf Lipid Adj (pg/g)         
Cyanuric acid (ng/mL)         
Melamine (ng/mL)         
Cadmium (ug/L)         
Mercury, ethyl (ug/L)         
Mercury, methyl (ug/L)         
Blood manganese (ug/L)         
Lead (ug/dL)         
Mercury, Inorganic (ug/L)         
Serum Copper (ug/dL)         
Serum Zinc (ug/dL)         
Mercury, total (ug/L)         
Urinary Arsenobetaine (µg/L)         
Urinary Arsenocholine (µg/L)         
Urinary total Arsenic (µg/L)         
Urinary Arsenous acid (µg/L)         
Urinary Arsenic acid (µg/L)         
Barium, urine (ng/mL)         
Beryllium, urine (ng/mL)         
Cadmium, urine (ng/mL)         
Cobalt, urine (ng/mL)         
Cesium, urine (ng/mL)         
Urinary Dimethylarsonic acid (µg/L)         
Mercury, urine (ng/mL)         
Urinary Monomethylacrsonic acid (µg/L)         
Molybdenum, urine (ng/mL)         
Lead, urine (ng/mL)         
 221 
 
Platinum, urine (ng/mL)         
Antimony, urine (ng/mL)         
Thallium, urine (ng/mL)         
Urinary Trimethylarsine Oxide (µg/L)         
Tungsten, urine (ng/mL)         
Uranium, urine (ng/mL)         
Urinary nitrate (ng/mL)         
Urinary thiocyanate (ng/mL)         
Iodine, urine (ng/mL)         
Perchlorate, urine (ng/mL)         
Mono-2-hydroxy-iso-butyl phthlte (ng/mL)         
Mono-3-hydroxy-n-butyl phthalate (ng/mL)         
Mono(carboxynonyl) phthalate (ng/mL)         
Mono(carboxyoctyl) phthalate (ng/mL)         
Mono-2-ethyl-5-carboxypentyl phthalate (ng/mL)         
Mono-n-butyl phthalate (ng/mL)         
Mono-(3-carboxypropyl) phthalate (ng/mL)         
Mono-cyclohexyl phthalate (ng/mL)         
Mono-ethyl phthalate (ng/mL)         
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (ng/mL)         
MHNCH (ng/mL)         
Mono-(2-ethyl)-hexyl phthalate (ng/mL)         
Mono-isobutyl pthalate (ng/mL)         
Mono-n-methyl phthalate (ng/mL)         
Mono-isononyl phthalate (ng/mL)         
Mono-(2-ethyl-5-oxohexyl) phthalate (ng/mL)         
Mono-n-octyl phthalate (ng/mL)         
Mono-benzyl phthalate (ng/mL)         
1-napthol (ng/L)         
2-napthol (ng/L)  X       
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3-fluorene (ng/L)         
2-fluorene (ng/L)         
3-phenanthrene (ng/L)         
1-phenanthrene (ng/L)         
2-phenanthrene (ng/L)         
3-fluoranthene (ng/L)         
1-pyrene (ng/L)        X 
9-fluorene (ng/L)      X X  
4-phenanthrene (ng/L)         
2 & 3-Hydroxyphenanthrene (ng/L)         
PCB199 Lipid Adj (ng/g)  X       
PCB28 Lipid Adj (ng/g)         
PCB44 Lipid Adj (ng/g)         
PCB49 Lipid Adj (ng/g)         
PCB52 Lipid Adj (ng/g)         
PCB66 Lipid Adj (ng/g)         
PCB74 Lipid Adj (ng/g) X X       
PCB87 Lipid Adj (ng/g)         
PCB99 Lipid Adj (ng/g) X X       
PCB101 Lipid Adj (ng/g)         
PCB105 Lipid Adj (ng/g)         
PCB110 Lipid Adj (ng/g)         
PCB118 Lipid Adj (ng/g) X X       
PCB128 Lipid Adj (ng/g)         
PCB138 Lipid Adj (ng/g) X X       
PCB146 Lipid Adj (ng/g)         
PCB149 Lipid Adj (ng/g)         
PCB151 Lipid Adj (ng/g)         
PCB153 Lipid Adj (ng/g) X X       
PCB156 Lipid Adj (ng/g)         
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PCB157 Lipid Adj (ng/g)         
PCB167 Lipid Adj (ng/g)         
PCB170 Lipid Adj (ng/g) X X       
PCB172 Lipid Adj (ng/g)         
PCB177 Lipid Adj (ng/g)         
PCB178 Lipid Adj (ng/g)         
PCB180 Lipid Adj (ng/g) X X       
PCB183 Lipid Adj (ng/g)         
PCB187 Lipid Adj (ng/g) X X       
PCB189 Lipid Adj (ng/g)         
PCB194 Lipid Adj (ng/g)  X       
PCB195 Lipid Adj (ng/g)         
PCB196 Lipid Adj (ng/g)  X       
PCB206 Lipid Adj (ng/g)         
PCB209 Lipid Adj (ng/g)         
3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) X        
3,3',4,4',5-pcnb Lipid Adj (pg/g) X        
3,4,4',5-tcb Lipid Adj (pg/g)         
Urinary 4-tert-octylphenol (ng/mL)         
Urinary Benzophenone-3 (ng/mL)         
Urinary Bisphenol F (ug/L)         
Urinary Bisphenol A (ng/mL)         
Urinary Bisphenol S (ug/L)         
Butyl paraben (ng/ml)         
Ethyl paraben  (ng/ml)         
Methyl paraben (ng/ml)         
Propyl paraben (ng/ml)         
Urinary Triclocarban (ng/mL)         
Urinary Triclosan (ng/mL)         
Aldrin Lipid Adj (ng/g)         
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Beta-hexachlorocyclohexane Lipid Adj (ng/g)         
Dieldrin Lipid Adj (ng/g)         
Endrin Lipid Adj (ng/g)         
G-hexachlorocyclohexane Lipid Adj (ng/g)         
Hexachlorobenzene Lipid Adj (ng/g)         
Heptachlor Epoxide Lipid Adj (ng/g)         
Mirex Lipid Adj (ng/g)         
o,p'-DDT Lipid Adj (ng/g)         
Oxychlordane Lipid Adj (ng/g)         
p,p'-DDE Lipid Adj (ng/g)         
p,p'-DDT Lipid Adj (ng/g)         
Trans-nonachlor Lipid Adj (ng/g)         
2,5-dichlorophenol (ug/L)         
2,4,5-trichlorophenol (ug/L)         
2,4-D (ug/L)         
2,4,5-T (ug/L)         
2,4,6-trichlorophenol (ug/L)         
4-fluoro-3-phenoxybenzoic acid (ug/L)         
Atrazine (ug/L)         
Acetochlor mercapturate (ug/L)         
Alachor mercapturate (ug/L)         
Acephate (ug/L)         
Atrazine mercapturate (ug/L)         
Bensulfuron methyl (ug/L)         
dibromovinyl-dimeth prop carboacid (ug/L)         
Carbofuranphenol (ug/L)         
cis dichlorovnl-dimeth carboacid (ug/L)         
Chlorsulfuron (ug/L)         
chloro-hydro-meth-chromen-one/ol (ug/L)         
3,5,6-trichloropyridinol (ug/L)         
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2,4-dichlorophenol (ug/L)         
Diaminochloroatrazine (ug/L)         
DEET acid (ug/L)         
DEET (ug/L)         
Desethyl hydroxy DEET (ug/L)         
diethylaminomethylpyrimidinol/one (ug/L)         
Desethyl atrazine (ug/L)         
Ethametsulfuron methyl (ug/L)         
Ethylenethio urea (ug/L)         
Foramsulfuron (ug/L)         
Halosulfuron (ug/L)         
Malathion diacid (ug/L)         
Metolachlor mercapturate (ug/L)         
Methamidaphos (ug/L)         
Mesosulfuron methyl (ug/L)         
Metsulfuron methyl (ug/L)         
Dimethoate (ug/L)         
Nicosulfuron (ug/L)         
O-methoate (ug/L)         
Dimethylphosphate (ug/L)         
Diethylphosphate (ug/L)         
Dimethylthiophosphate (ug/L)         
Diethylthiophosphate (ug/L)         
Dimethyldithiophosphate (ug/L)         
Diethyldithiophosphate (ug/L)         
3-phenoxybenzoic acid (ug/L)         
O-Phenyl phenol (ug/L)         
Oxasulfuron (ug/L)         
Oxypyrimidine (ug/L)         
Paranitrophenol (ug/L) X        
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Pentachlorophenol (ug/L)         
Primisulfuron methyl (ug/L)         
2-isopropoxyphenol (ug/L)         
Prosulfuron (ug/L)         
Propylenethio urea (ug/L)         
Rimsulfuron (ug/L)         
Desisopropyl atrazine (ug/L)         
Desisopropyl atrazine mercapturate (ug/L)         
Sulfometuron methyl (ug/L)         
Sulfosulfuron (ug/L)         
trans dichlorovnl-dimeth carboacid (ug/L)         
Thifensulfuron methyl (ug/L)         
Triasulfuron (ug/L)         
Triflusulfuron methyl (ug/L)         
2-(N-ethyl-PFOSA) acetate (ng/mL)         
Perfluorobutane sulfonic acid (ng/mL)         
2-(N-methyl-PFOSA) acetate (ng/mL)         
Perfluorodecanoic acid (ng/mL)         
Perfluorododecanoic acid (ng/mL)         
Perfluoroheptanoic acid (ng/mL)         
Perfluorohexane sulfonic acid (ng/mL)         
Perfluorononanoic acid (ng/mL)         
Perfluorooctanoic acid (ng/mL)         
Perfluorooctane sulfonic acid (ng/mL)         
Perfluorooctane sulfonamide (ng/mL)         
Perfluoroundecanoic acid (ng/mL)         
Br. iso of perfluorooctanoate (ug/L)         
Monomethyl branched iso of PFOS (ug/L)         
Linear perfluorooctanoate (ug/L)         
Linear perfluorooctane sulfonate (ug/L)         
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Bis(2-chloroethyl) phosphate (ug/L)         
Bis(1-chloro-2-propyl) phosphate (ug/L)         
Bis(1,3-dichloro-2-propyl) phosphate (ug/L)         
Dibutyl phosphate (ug/L)         
Dibenzyl phosphate (ug/L)         
Di-o-cresyl phosphate (ug/L)         
Di-p-cresyl phosphate (ug/L)         
Diphenyl phosphate (ug/L)         
2,3,4,5-tetrabromobenzoic acid (ug/L)         
Daidzein (ng/mL)  X       
o-Desmethylangolensin (O-DMA) (ng/mL)         
Equol (ng/mL) X X       
Enterodiol (ng/mL) X X X      
Enterolactone (ng/mL) X X       
Genistein (ng/mL)    X     
Cotinine (ng/mL)         
Hydroxycotinine, Serum (ng/mL)         
NNAL , urine (ng/mL)         
Blood 2,5-Dimethylfuran (ng/mL)         
Blood 1,1,1,2-tetrachloroethane (ng/mL)         
Blood Nitromethane (pg/mL)         
Blood Hexane (ng/mL)         
Blood Heptane (ng/mL)         
Blood Octane (ng/mL)         
Blood 1,1-Dichloroethane (ng/mL)         
Blood 1,2-Dichlorobenzene (ng/mL)         
Blood 1,1-Dichloroethene (ng/mL)         
Blood 1,2-Dichloroethane (ng/mL)         
Blood cis-1,2-Dichloroethene (ng/mL)         
Blood 1,1,2-Trichloroethane (ng/mL)         
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Blood 1,2-Dibromo-3-chloropropane (ng/mL)         
Blood trans-1,2-Dichloroethene (ng/mL)         
Blood 1,3-Dichlorobenzene (ng/mL)         
Blood Tetrachloroethene (ng/ml)         
Blood 1,1,2,2-Tetrachloroethane (ng/mL)         
Blood Bromoform (pg/ml)         
Blood Bromodichloromethane (pg/ml) X       X 
Blood Benzene (ng/ml)         
Blood Cyclohexane (ng/mL)         
Blood Chlorobenzene (ng/mL)         
Blood Chloroform (pg/ml) X       X 
Blood Dibromochloromethane (pg/ml)         
Blood Carbon Tetrachloride (ng/ml)         
Blood 1,4-Dichlorobenzene (ng/ml) X X X      
Blood 1,2-dibromoethane (ng/ml)         
Blood Diethyl Ether (ng/mL)         
Blood Dibromomethane (ng/mL)         
Blood 1,2-Dichloropropane (ng/mL)         
Blood 1,4-Dioxane (ng/mL)         
Blood Ethyl Acetate (ng/mL)         
Blood Ethylbenzene (ng/ml)         
Blood Chloroethane (ng/mL)         
Blood furan (ng/ml)         
Blood Hexachloroethane (ng/mL)         
Blood isopropylbenzene (ng/ml)         
Blood Methylene Chloride (ng/mL)         
Blood Methylcyclopentane (ng/mL)         
Blood MTBE (pg/ml)         
Blood Nitrobenzene (ng/mL)         
Blood o-Xylene (ng/ml)         
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Blood Styrene (ng/ml)         
Blood Trichloroethene (ng/ml)         
Blood 1,1,1-Trichloroethane (ng/mL)         
Blood aaa-Trifluorotoluene (ng/mL)         
Blood Tetrahydrofuran (ng/mL)         
Blood Toluene (ng/ml)         
Blood 1,2,3-trichloropropane (ng/ml)         
Blood Vinyl Bromide (ng/mL)         
Blood m-/p-Xylene (ng/ml)         
N-acel-S-(1,2-dichlorovinl)-L-cys (ng/mL)         
N-Acel-S-(2,2-Dichlorvinyl)-L-cys (ng/mL)         
2-Methylhippuric acid (ng/mL)         
3-methipurc acd & 4-methipurc acd (ng/mL)         
N-Ace-S-(2-carbamoylethyl)-L-cys (ng/mL)         
N-Ace-S-(N-methlcarbamoyl)-L-cys (ng/mL)         
2-amnothiazolne-4-carbxylic acid (ng/mL)         
N-Acetyl-S-(benzyl)-L-cysteine (ng/mL)         
N-Acetyl-S-(n-propyl)-L-cysteine (ng/mL)         
N-Acetyl-S-(2-Carbxyethyl)-L-Cys (ng/mL)         
N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL)         
N-Ace-S-(3,4-Dihidxybutl)-L-Cys (ng/mL)         
N-Ace-S-(dimethylphenyl)-L-Cys (ng/mL)         
N-ac-S-(2-carbmo-2-hydxel)-L-cys (ng/mL)         
N-Ace-S-(2-Hydroxyethyl)-L-cys (ng/mL)         
N-Ace-S-(2-hydroxypropyl)-L-cys (ng/mL)         
N-Ace-S-(3-Hydroxypropyl)-L-Cys (ng/mL)         
Mandelic acid (ng/mL)         
N-A-S-(1-HydrxMet)-2-Prpn)-L-Cys (ng/mL)         
N-Ac-S-(2-Hydrxy-3-butnyl)-L-Cys (ng/mL)         
N-A-S-(4-hydrxy-2butn-l-yl)-L-cys (ng/mL)         
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N-ace-S-(phenl-2-hydxyetl)-L-cys (ng/mL)         
Phenylglyoxylic acid (ng/mL)         
N-Acetyl-S-(phenyl)-L-cysteine (ng/mL)         
N-A-S-(3-hydrxprpl-1-metl)-L-cys (ng/mL)         
N-Acetyl-S-(trichlorovinyl)-L-cys (ng/mL)         
2-thoxothazlidne-4-carbxylic acid (ng/mL)         
PCB199 (ng/g)         
PCB28 (ng/g)         
PCB44 (ng/g)         
PCB49 (ng/g)         
PCB52 (ng/g)         
PCB66 (ng/g)         
PCB74 (ng/g)         
PCB87 (ng/g)         
PCB99 (ng/g)         
PCB101 (ng/g)         
PCB105 (ng/g)         
PCB110 (ng/g)         
PCB118 (ng/g)         
PCB128 (ng/g)         
PCB138 (ng/g)         
PCB146 (ng/g)         
PCB149 (ng/g)         
PCB151 (ng/g)         
PCB153 (ng/g)         
PCB156 (ng/g)         
PCB157 (ng/g)         
PCB167 (ng/g)         
PCB170 (ng/g)         
PCB172 (ng/g)         
 231 
 
PCB177 (ng/g)         
PCB178 (ng/g)         
PCB180 (ng/g)         
PCB183 (ng/g)         
PCB187 (ng/g)         
PCB189 (ng/g)         
PCB194 (ng/g)         
PCB195 (ng/g)         
PCB196 (ng/g)         
PCB206 (ng/g)         
PCB209 (ng/g)         
Aldrin (ng/g)         
2,2',4,4',5,5'-hexabromobiphenyl (pg/g)         
Beta-hexachlorocyclohexane (ng/g)         
2,2',4-tribromodiphenyl ether (pg/g)         
2,4,4'-tribromodiphenyl ether (pg/g)         
2,2',4,4'-tetrabromodiphenyl ether (pg/g)         
2,2',3,4,4'-pentabromodiphenyl ether (pg/g)         
2,2',4,4',5-pentabromodiphenyl ether (pg/g)         
2,2',4,4',6-pentabromodiphenyl ether (pg/g)         
2,3',4,4'-tetrabromodiphenyl ether (pg/g)         
2,2',4,4',5,5'-hexabromodiphenyl ether (pg/g)         
2,2',4,4',5,6'-hexabromodiphenyl ether (pg/g)         
2,2',3,4,4',5',6-heptabromodiphenyl ether (pg/g)         
1,2,3,7,8-pncdd (fg/g)         
1,2,3,4,7,8-hxcdd (fg/g)         
1,2,3,6,7,8-hxcdd (fg/g)         
1,2,3,7,8,9-hxcdd (fg/g)         
1,2,3,4,6,7,8-hpcdd (fg/g)         
1,2,3,4,6,7,8,9-ocdd (fg/g)         
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Dieldrin (ng/g)         
Endrin (ng/g)         
2,3,7,8-tcdf (fg/g)         
1,2,3,7,8-pncdf (fg/g)         
2,3,4,7,8-pncdf (fg/g)         
1,2,3,4,7,8-hxcdf (fg/g)         
1,2,3,6,7,8-hxcdf (fg/g)         
1,2,3,7,8,9-hxcdf (fg/g)         
2,3,4,6,7,8-hxcdf (fg/g)         
1,2,3,4,6,7,8-hpcdf (fg/g)         
1,2,3,4,7,8,9-hpcdf (fg/g)         
1,2,3,4,6,7,8,9-ocdf (fg/g)         
Gamma-hexachlorocyclohexane (ng/g)         
Hexachlorobenzene (ng/g)         
Heptachlor Epoxide (ng/g)         
3,3',4,4',5,5'-hxcb (fg/g)         
Mirex (ng/g)         
o,p'-DDT (ng/g)         
Oxychlordane (ng/g)         
3,3',4,4',5-pcnb (pg/g)         
p,p'-DDE (ng/g)         
p,p'-DDT (ng/g)         
3,4,4',5-tcb (fg/g)         
2,3,7,8-tcdd (fg/g)         




Table A2.2. Included chemical biomarkers for analysis with corresponding CAS No. and chemical family classification. 
Chemical Name CAS NO. Chemical Family 
Glycideamide (pmoL/G Hb) 5694-00-8 Acrylamide 
Acrylamide (pmoL/G Hb) 79-06-1 Acrylamide 
2,2',4,4',5,5'-hexabromobiphenyl lipid adj (ng/g) 59080-40-9 Brominated Flame Retardants (BFR) 
2,4,4'-tribromodiphenyl ether lipid adj (ng/g) 41318-75-6 Brominated Flame Retardants (BFR) 
2,2',4,4',5,6'-hexabromodiphenyl ether lipid adj (ng/g) 207122-15-4 Brominated Flame Retardants (BFR) 
2,2',4,4',6-pentabromodiphenyl lipid adj (ng/g) 189084-64-8 Brominated Flame Retardants (BFR) 
2,2',4,4'-tetrabromodiphenyl ether lipid ad (ng/g) 5436-43-1 Brominated Flame Retardants (BFR) 
2,2',4,4',5-pentabromodiphenyl lipid adj (ng/g) 60348-60-9 Brominated Flame Retardants (BFR) 
2,2',4,4',5,5'-hexabromodiphenyl lipid adj (ng/g) 68631-49-2 Brominated Flame Retardants (BFR) 
Bis(2-chloroethyl) phosphate (ug/L) 3040-56-0 Phosphate Flame Retardants (PFR) 
Bis(1-chloro-2-propyl) phosphate (ug/L) 789440-10-4 Phosphate Flame Retardants (PFR) 
Bis(1,3-dichloro-2-propyl) phosphate (ug/L) 72236-72-7 Phosphate Flame Retardants (PFR) 
Dibutyl phosphate (ug/L) 107-66-4 Phosphate Flame Retardants (PFR) 
Diphenyl phosphate (ug/L) 838-85-7 Phosphate Flame Retardants (PFR) 
1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) 57653-85-7 Dioxins 
1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) 3268-87-9 Dioxins 
1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) 35822-46-9 Dioxins 
1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) 70648-26-9 Furans 
2,3,4,7,8-pncdf Lipid Adj (pg/g) 57117-31-4 Furans 
1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) 67562-39-4 Furans 
Lead (ug/dL) 7439-92-1 Metals 
Cadmium (ug/L) 7440-43-9 Metals 
Mercury, total (ug/L) 7439-97-6 Metals 
Mercury, urine (ng/mL) 7439-97-6 Metals 
Barium, urine (ng/mL) 7440-39-3 Metals 
Cobalt, urine (ng/mL) 7440-48-4 Metals 
Cesium, urine (ng/mL) 7440-46-2 Metals 
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Molybdenum, urine (ng/mL) 7439-98-7 Metals 
Lead, urine (ng/mL) 7439-92-1 Metals 
Antimony, urine (ng/mL) 7440-36-0 Metals 
Thallium, urine (ng/mL) 7440-28-0 Metals 
Tungsten, urine (ng/mL) 7440-33-7 Metals 
Uranium, urine (ng/mL) 7440-61-1 Metals 
Urinary total Arsenic (µg/L) 7440-38-2 Metals 
Urinary Arsenobetaine (µg/L) 64436-13-1 Metals 
Urinary Dimethylarsonic acid (µg/L) 75-60-5 Metals 
Cadmium, urine (ng/mL) 7440-43-9 Metals 
Blood manganese (ug/L) 7439-96-5 Metals 
Serum Copper (ug/dL) 7440-50-8 Metals 
Serum Zinc (ug/dL) 7440-66-6 Metals 
Mercury, methyl (ug/L) 22967-92-6 Metals 
Urinary thiocyanate (ng/mL) 302-04-5 Other 
Iodine, urine (ng/mL) 7553-56-2 Other 
Urinary nitrate (ng/mL) 14797-55-8 Other 
Perchlorate, urine (ng/mL) 14797-73-0 Other 
Urinary Triclosan (ng/mL) 3380-34-5 Personal Care & Consumer Product Compounds 
Urinary Bisphenol S (ug/L) 80-09-1 Personal Care & Consumer Product Compounds 
Butyl paraben (ng/ml) 94-26-8 Personal Care & Consumer Product Compounds 
Ethyl paraben  (ng/ml) 120-47-8 Personal Care & Consumer Product Compounds 
Methyl paraben (ng/ml) 99-76-3 Personal Care & Consumer Product Compounds 
Propyl paraben (ng/ml) 94-13-3 Personal Care & Consumer Product Compounds 
Urinary Bisphenol A (ng/mL) 80-05-7 Personal Care & Consumer Product Compounds 
Urinary Bisphenol F (ug/L) 620-92-8 Personal Care & Consumer Product Compounds 
Urinary Benzophenone-3 (ng/mL) 131-57-7 Personal Care & Consumer Product Compounds 
Trans-nonachlor Lipid Adj (ng/g) 39765-80-5 Pesticides 
Oxychlordane Lipid Adj (ng/g) 27304-13-8 Pesticides 
p,p'-DDE Lipid Adj (ng/g) 72-55-9 Pesticides 
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Dieldrin Lipid Adj (ng/g) 60-57-1 Pesticides 
Beta-hexachlorocyclohexane Lipid Adj (ng/g) 319-85-7 Pesticides 
3,5,6-trichloropyridinol (ug/L) 6515-38-4 Pesticides 
Dimethylthiophosphate (ug/L) 1112-38-5 Pesticides 
3-phenoxybenzoic acid (ug/L) 3739-38-6 Pesticides 
2,5-dichlorophenol (ug/L) 583-78-8 Pesticides 
2,4-dichlorophenol (ug/L) 120-83-2 Pesticides 
Paranitrophenol (ug/L) 100-02-7 Pesticides 
DEET acid (ug/L) 72236-23-8 Pesticides 
Mono(carboxynonyl) phthalate (ng/mL) 26761-40-0 Phthalates & Plasticizers 
Mono(carboxyoctyl) phthalate (ng/mL) 898544-09-7 Phthalates & Plasticizers 
Mono-isobutyl pthalate (ng/mL) 30833-53-5 Phthalates & Plasticizers 
Mono-(2-ethyl)-hexyl phthalate (ng/mL) 4376-20-9 Phthalates & Plasticizers 
Mono-(2-ethyl-5-oxohexyl) phthalate (ng/mL) 40321-98-0 Phthalates & Plasticizers 
Mono-benzyl phthalate (ng/mL) 2528-16-7 Phthalates & Plasticizers 
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (ng/mL) 40321-99-1 Phthalates & Plasticizers 
Mono-2-ethyl-5-carboxypentyl phthalate (ng/mL) 40809-41-4 Phthalates & Plasticizers 
Mono-n-butyl phthalate (ng/mL) 131-70-4 Phthalates & Plasticizers 
Mono-ethyl phthalate (ng/mL) 2306-33-4 Phthalates & Plasticizers 
Mono-n-methyl phthalate (ng/mL) 4376-18-5 Phthalates & Plasticizers 
Mono-(3-carboxypropyl) phthalate (ng/mL) 66851-46-5 Phthalates & Plasticizers 
o-Desmethylangolensin (O-DMA) (ng/mL) 21255-69-6 Phytoestrogens 
Enterolactone (ng/mL) 78473-71-9 Phytoestrogens 
Enterodiol (ng/mL) 80226-00-2 Phytoestrogens 
Daidzein (ng/mL) 486-66-8 Phytoestrogens 
Equol (ng/mL) 531-95-3 Phytoestrogens 
Genistein (ng/mL) 446-72-0 Phytoestrogens 
3-phenanthrene (ng/L) 605-87-8 Polyaromatic Hydrocarbons (PAH) 
1-phenanthrene (ng/L) 2433-56-9 Polyaromatic Hydrocarbons (PAH) 
2-phenanthrene (ng/L) 605-55-0 Polyaromatic Hydrocarbons (PAH) 
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4-phenanthrene (ng/L) 7651-86-7 Polyaromatic Hydrocarbons (PAH) 
2 & 3-Hydroxyphenanthrene (ng/L) 605-55-0 Polyaromatic Hydrocarbons (PAH) 
1-pyrene (ng/L) 129-00-0 Polyaromatic Hydrocarbons (PAH) 
1-napthol (ng/L) 90-15-3 Polyaromatic Hydrocarbons (PAH) 
2-napthol (ng/L) 135-19-3 Polyaromatic Hydrocarbons (PAH) 
9-fluorene (ng/L) 484-17-3 Polyaromatic Hydrocarbons (PAH) 
3-fluorene (ng/L) 6344-67-8 Polyaromatic Hydrocarbons (PAH) 
2-fluorene (ng/L) 2443-58-5 Polyaromatic Hydrocarbons (PAH) 
3-fluoranthene (ng/L) 205-82-3 Polyaromatic Hydrocarbons (PAH) 
PCB199 Lipid Adj (ng/g) 52663-75-9 Polychlorinated Biphenyls (PCB) 
PCB180 Lipid Adj (ng/g) 35065-29-3 Polychlorinated Biphenyls (PCB) 
PCB209 Lipid Adj (ng/g) 2051-24-3 Polychlorinated Biphenyls (PCB) 
PCB170 Lipid Adj (ng/g) 35065-30-6 Polychlorinated Biphenyls (PCB) 
PCB194 Lipid Adj (ng/g) 35694-08-7 Polychlorinated Biphenyls (PCB) 
PCB187 Lipid Adj (ng/g) 52663-68-0 Polychlorinated Biphenyls (PCB) 
PCB153 Lipid Adj (ng/g) 35065-27-1 Polychlorinated Biphenyls (PCB) 
PCB196 Lipid Adj (ng/g) 42740-50-1 Polychlorinated Biphenyls (PCB) 
PCB138 Lipid Adj (ng/g) 35065-28-2 Polychlorinated Biphenyls (PCB) 
3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) 32774-16-6 Polychlorinated Biphenyls (PCB) 
PCB118 Lipid Adj (ng/g) 31508-00-6 Polychlorinated Biphenyls (PCB) 
PCB99 Lipid Adj (ng/g) 38380-01-7 Polychlorinated Biphenyls (PCB) 
3,3',4,4',5-pcnb Lipid Adj (pg/g) 57465-28-8 Polychlorinated Biphenyls (PCB) 
PCB74 Lipid Adj (ng/g) 32690-93-0 Polychlorinated Biphenyls (PCB) 
PCB49 Lipid Adj (ng/g) 41464-40-8 Polychlorinated Biphenyls (PCB) 
PCB44 Lipid Adj (ng/g) 41464-39-5 Polychlorinated Biphenyls (PCB) 
Perfluorodecanoic acid (ng/mL) 335-76-2 Per- and Polyfluoroalkyl Substances (PFAS) 
2-(N-methyl-PFOSA) acetate (ng/mL) 2355-31-9 Per- and Polyfluoroalkyl Substances (PFAS) 
Perfluorononanoic acid (ng/mL) 375-95-1 Per- and Polyfluoroalkyl Substances (PFAS) 
Perfluorohexane sulfonic acid (ng/mL) 355-46-4 Per- and Polyfluoroalkyl Substances (PFAS) 
Perfluorooctanoic acid (ng/mL) 335-67-1 Per- and Polyfluoroalkyl Substances (PFAS) 
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Perfluorooctane sulfonic acid (ng/mL) 1763-23-1 Per- and Polyfluoroalkyl Substances (PFAS) 
Cotinine (ng/mL) 486-56-6 Smoking Related Compounds 
NNAL , urine (ng/mL) 76014-81-8 Smoking Related Compounds 
Blood m-/p-Xylene (ng/ml) 108-38-3/106-42-3 Volatile Organic Compounds (VOC) 
Blood 1,4-Dichlorobenzene (ng/ml) 106-46-7 Volatile Organic Compounds (VOC) 
Blood Bromodichloromethane (pg/ml) 75-27-4 Volatile Organic Compounds (VOC) 
Phenylglyoxylic acid (ng/mL) 611-73-4 Volatile Organic Compounds (VOC) 
N-Ace-S-(2-hydroxypropyl)-L-cys (ng/mL) 75-56-9 Volatile Organic Compounds (VOC) 
N-A-S-(4-hydrxy-2butn-l-yl)-L-cys (ng/mL) 106-99-0 Volatile Organic Compounds (VOC) 
3-methipurc acd & 4-methipurc acd (ng/mL) 27115-49-7 Volatile Organic Compounds (VOC) 
N-Acetyl-S-(benzyl)-L-cysteine (ng/mL) 19542-77-9 Volatile Organic Compounds (VOC) 
N-Acetyl-S-(n-propyl)-L-cysteine (ng/mL) 106-94-5 Volatile Organic Compounds (VOC) 
Mandelic acid (ng/mL) 90-64-2 Volatile Organic Compounds (VOC) 
N-Ace-S-(2-carbamoylethyl)-L-cys (ng/mL) 81690-92-8 Volatile Organic Compounds (VOC) 
N-Ace-S-(N-methlcarbamoyl)-L-cys (ng/mL) 103974-29-4 Volatile Organic Compounds (VOC) 
2-amnothiazolne-4-carbxylic acid (ng/mL) 16899-18-6 Volatile Organic Compounds (VOC) 
N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL) 74514-75-3 Volatile Organic Compounds (VOC) 
2-thoxothazlidne-4-carbxylic acid (ng/mL) 20933-67-9 Volatile Organic Compounds (VOC) 
2-Methylhippuric acid (ng/mL) 42013-20-7 Volatile Organic Compounds (VOC) 
N-A-S-(3-hydrxprpl-1-metl)-L-cys (ng/mL) 33164-70-4 Volatile Organic Compounds (VOC) 
N-Acetyl-S-(2-Carbxyethyl)-L-Cys (ng/mL) 51868-61-2 Volatile Organic Compounds (VOC) 
N-Ace-S-(3-Hydroxypropyl)-L-Cys (ng/mL) 23127-40-4 Volatile Organic Compounds (VOC) 
N-Ace-S-(3,4-Dihidxybutl)-L-Cys (ng/mL) 144889-50-9 Volatile Organic Compounds (VOC) 
Blood Toluene (ng/ml) 108-88-3 Volatile Organic Compounds (VOC) 
Blood Nitromethane (pg/mL) 75-52-5 Volatile Organic Compounds (VOC) 
Blood Chloroform (pg/ml) 67-66-3 Volatile Organic Compounds (VOC) 
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Table A2.3. NHANES codenames for survey weights used for a given chemical biomarker and NHANES cycle. 
Chemical name Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 
Glycideamide (pmoL/G Hb) NA NA WTMEC2YR WTMEC2YR NA NA NA NA 
Acrylamide (pmoL/G Hb) NA NA WTMEC2YR WTMEC2YR NA NA NA NA 
2,2',4,4',5,5'-hexabromobiphenyl lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,4,4'-tribromodiphenyl ether lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4,4',5,6'-hexabromodiphenyl ether lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4,4',6-pentabromodiphenyl lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4,4'-tetrabromodiphenyl ether lipid ad (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4,4',5-pentabromodiphenyl lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',3,4,4',5',6-heptabromodiphenyl ether lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4,4',5,5'-hexabromodiphenyl lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,3',4,4'-tetrabromodiphenyl lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',3,4,4'-pentabromodiphenyl ether lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
2,2',4-tribromodiphenyl ether lipid adj (ng/g) NA NA WTSB2YR NA NA NA NA NA 
1,2,3,6,7,8-hxcdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,7,8-hxcdd Lipid Adj (pg/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
1,2,3,7,8-pncdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
2,3,7,8-tcdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,6,7,8,9-ocdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,7,8,9-hxcdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,6,7,8-hpcdd Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,6,7,8-hxcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,7,8-hxcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
2,3,4,7,8-pncdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
2,3,4,6,7,8-hxcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,6,7,8-hpcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,6,7,8,9-ocdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
Melamine (ng/mL) NA NA WTSBMEL NA NA NA NA NA 
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Cyanuric acid (ng/mL) NA NA WTSBMEL NA NA NA NA NA 
Lead (ug/dL) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTSH2YR 
Cadmium (ug/L) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTSH2YR 
Mercury, total (ug/L) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTSH2YR 
Mercury, Inorganic (ug/L) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTSH2YR 
Mercury, urine (ng/mL) WTMEC4YR WTMEC4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Barium, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Cobalt, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Cesium, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Molybdenum, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Lead, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Platinum, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR NA NA 
Antimony, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Thallium, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Tungsten, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Uranium, urine (ng/mL) NA WTSHM2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary total Arsenic (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Arsenous acid (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Arsenobetaine (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Arsenocholine (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Dimethylarsonic acid (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Monomethylacrsonic acid (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Cadmium, urine (ng/mL) WTSHM4YR WTSHM4YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Blood manganese (ug/L) NA NA NA NA NA NA WTMEC2YR WTSH2YR 
Serum Copper (ug/dL) NA NA NA NA NA NA WTSA2YR WTSA2YR 
Serum Zinc (ug/dL) NA NA NA NA NA NA WTSA2YR WTSA2YR 
Mercury, methyl (ug/L) NA NA NA NA NA NA WTMEC2YR WTSH2YR 
Urinary Triclocarban (ng/mL) NA NA NA NA NA NA NA WTSB2YR 
Urinary Triclosan (ng/mL) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Urinary Bisphenol S (ug/L) NA NA NA NA NA NA NA WTSB2YR 
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Urinary 4-tert-octylphenol (ng/mL) NA NA NA WTSB2YR WTSB2YR WTSB2YR NA NA 
Butyl paraben (ng/ml) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Ethyl paraben  (ng/ml) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Methyl paraben (ng/ml) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Propyl paraben (ng/ml) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Urinary Bisphenol A (ng/mL) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Urinary Bisphenol F (ug/L) NA NA NA NA NA NA NA WTSB2YR 
Urinary Benzophenone-3 (ng/mL) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mirex Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Trans-nonachlor Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Oxychlordane Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Heptachlor Epoxide Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
p,p'-DDE Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Dieldrin Lipid Adj (ng/g) NA WTSPO2YR WTSB2YR NA NA NA NA NA 
Endrin Lipid Adj (ng/g) NA WTSPO2YR WTSB2YR NA NA NA NA NA 
Aldrin Lipid Adj (ng/g) NA WTSPO2YR WTSB2YR NA NA NA NA NA 
p,p'-DDT Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Hexachlorobenzene Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
2,4,5-trichlorophenol (ug/L) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR NA NA 
2,4,6-trichlorophenol (ug/L) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR NA NA 
Beta-hexachlorocyclohexane Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
Pentachlorophenol (ug/L) NA NA WTSC2YR NA NA NA NA NA 
Dimethylphosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Diethylthiophosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Diethylphosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
3,5,6-trichloropyridinol (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
Dimethylthiophosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
cis dichlorovnl-dimeth carboacid (ug/L) WTSPP4YR WTSPP4YR NA NA NA NA NA NA 
trans dichlorovnl-dimeth carboacid (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
3-phenoxybenzoic acid (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
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2,5-dichlorophenol (ug/L) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
2,4-dichlorophenol (ug/L) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Paranitrophenol (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
2,4-D (ug/L) WTSPP4YR WTSPP4YR WTSC2YR NA WTSC2YR WTSC2YR NA NA 
diethylaminomethylpyrimidinol/one (ug/L) NA WTSPP2YR NA NA NA NA NA NA 
Oxypyrimidine (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
Dimethyldithiophosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
DEET acid (ug/L) NA NA NA NA WTSC2YR WTSC2YR WTSC2YR WTSC2YR 
Desethyl hydroxy DEET (ug/L) NA NA NA NA WTSC2YR WTSC2YR WTSC2YR WTSC2YR 
DEET (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR WTSC2YR WTSC2YR 
Alachor mercapturate (ug/L) WTSPP2YR NA NA NA NA NA NA NA 
Malathion diacid (ug/L) WTSPP2YR NA NA NA WTSC2YR WTSC2YR NA NA 
O-Phenyl phenol (ug/L) NA NA WTSC2YR WTSB2YR WTSB2YR WTSB2YR NA NA 
Ethylenethio urea (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
MHNCH (ng/mL) NA NA NA NA NA NA WTSA2YR WTSB2YR 
Mono-isononyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono(carboxynonyl) phthalate (ng/mL) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-2-hydroxy-iso-butyl phthlate (ng/mL) NA NA NA NA NA NA NA WTSB2YR 
Mono(carboxyoctyl) phthalate (ng/mL) NA NA NA WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-isobutyl phthalate (ng/mL) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-(2-ethyl)-hexyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-(2-ethyl-5-oxohexyl) phthalate (ng/mL) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-benzyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (ng/mL) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-2-ethyl-5-carboxypentyl phthalate (ng/mL) NA NA WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-n-butyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-ethyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
Mono-n-methyl phthalate (ng/mL) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA 
Mono-3-hydroxy-n-butyl phthalate (ng/mL) NA NA NA NA NA NA NA WTSB2YR 
Mono-(3-carboxypropyl) phthalate (ng/mL) NA WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSB2YR 
 242 
 
Mono-cyclohexyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR NA NA 
o-Desmethylangolensin (O-DMA) (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
Enterolactone (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
Enterodiol (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
3-phenanthrene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA 
1-phenanthrene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
2-phenanthrene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA 
4-phenanthrene (ng/L) NA NA WTSB2YR WTSB2YR NA NA WTSA2YR NA 
2 & 3-Hydroxyphenanthrene (ng/L) NA NA NA NA NA NA NA WTSA2YR 
1-pyrene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
1-napthol (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
2-napthol (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
9-fluorene (ng/L) NA NA WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA 
3-fluorene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
2-fluorene (ng/L) NA WTSPH2YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR WTSA2YR 
3-fluoranthene (ng/L) WTSPH4YR WTSPH4YR NA NA NA NA NA NA 
PCB199 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB172 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB206 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB180 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB209 Lipid Adj (ng/g) NA NA WTSC2YR NA NA NA NA NA 
PCB189 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB146 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB156 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB170 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB194 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB157 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB195 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB187 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB153 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
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PCB167 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB196 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB138 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB177 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
3,3',4,4',5,5'-hxcb Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB183 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB118 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB128 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB99 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB105 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB178 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
3,3',4,4',5-pcnb Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB74 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
3,4,4',5-tcb Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB28 Lipid Adj (ng/g) WTSPO2YR NA WTSC2YR NA NA NA NA NA 
PCB52 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB149 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB151 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB101 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB87 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB66 Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
PCB110 Lipid Adj (ng/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
PCB49 Lipid Adj (ng/g) NA NA WTSC2YR NA NA NA NA NA 
PCB44 Lipid Adj (ng/g) NA NA WTSC2YR NA NA NA NA NA 
Perfluoroundecanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorododecanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorodecanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorooctane sulfonamide (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR NA 
2-(N-methyl-PFOSA) acetate (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorononanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
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Linear perfluorooctane sulfonate (ug/L) NA NA NA NA NA NA NA WTSB2YR 
Monomethyl branched iso of PFOS (ug/L) NA NA NA NA NA NA NA WTSB2YR 
Linear perfluorooctanoate (ug/L) NA NA NA NA NA NA NA WTSB2YR 
Br. iso of perfluorooctanoate (ug/L) NA NA NA NA NA NA NA WTSB2YR 
Perfluorohexane sulfonic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorooctanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluorooctane sulfonic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Perfluoroheptanoic acid (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Cotinine (ng/mL) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR 
NNAL , urine (ng/mL) NA NA NA NA WTMEC2YR WTMEC2YR WTMEC2YR NA 
Blood Tetrachloroethene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood o-Xylene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood m-/p-Xylene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Benzene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,4-Dichlorobenzene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Bromodichloromethane (pg/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-ace-S-(phenl-2-hydxyetl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Ace-S-(2-Hydroxyethyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Phenylglyoxylic acid (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood Dibromochloromethane (pg/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-Ace-S-(2-hydroxypropyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-A-S-(4-hydrxy-2butn-l-yl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSVOC2Y WTSA2YR 
Blood 2,5-Dimethylfuran (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
3-methipurc acd & 4-methipurc acd (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Acetyl-S-(benzyl)-L-cysteine (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Acetyl-S-(n-propyl)-L-cysteine (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-ac-S-(2-carbmo-2-hydxel)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Acetyl-S-(phenyl)-L-cysteine (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood MTBE (pg/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Mandelic acid (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
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N-Ace-S-(2-carbamoylethyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Ace-S-(N-methlcarbamoyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
2-amnothiazolne-4-carbxylic acid (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-acetyl-S-(2-cyanoethyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
2-thoxothazlidne-4-carbxylic acid (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
2-Methylhippuric acid (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Ac-S-(2-Hydrxy-3-butnyl)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-A-S-(3-hydrxprpl-1-metl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Acetyl-S-(2-Carbxyethyl)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Ace-S-(3-Hydroxypropyl)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Ace-S-(3,4-Dihidxybutl)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood Ethylbenzene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Styrene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA NA 
Blood Toluene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA WTSVOC2Y 
Blood Bromoform (pg/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Nitromethane (pg/mL) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood furan (ng/ml) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Chloroform (pg/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Urinary thiocyanate (ng/mL) NA WTMEC2YR NA WTMEC2YR WTMEC2YR WTSA2YR WTSA2YR WTSA2YR 
Iodine, urine (ng/mL) NA WTUIO2YR WTSC2YR WTSC2YR WTMEC2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary nitrate (ng/mL) NA WTMEC2YR NA WTMEC2YR WTMEC2YR WTSA2YR WTSA2YR WTSA2YR 
Perchlorate, urine (ng/mL) NA WTMEC2YR WTSC2YR WTMEC2YR WTMEC2YR WTSA2YR WTSA2YR WTSA2YR 
1,2,3,7,8,9-hxcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
1,2,3,4,7,8,9-hpcdf Lipid Adj (pg/g) NA WTSPO2YR WTSC2YR NA NA NA NA NA 
1,2,3,7,8-pncdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
2,3,7,8-tcdf Lipid Adj (pg/g) WTSPO4YR WTSPO4YR WTSC2YR NA NA NA NA NA 
Beryllium, urine (ng/mL) WTSHM2YR WTSHM2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR NA NA 
Urinary Arsenic acid (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR 
Urinary Trimethylarsine Oxide (µg/L) NA NA WTSA2YR WTSA2YR WTSA2YR WTSA2YR WTSA2YR NA 
Mercury, ethyl (ug/L) NA NA NA NA NA NA WTMEC2YR WTSH2YR 
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o,p'-DDT Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
G-hexachlorocyclohexane Lipid Adj (ng/g) WTSPO4YR WTSPO4YR WTSB2YR NA NA NA NA NA 
4-fluoro-3-phenoxybenzoic acid (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
2,4,5-T (ug/L) WTSPP4YR WTSPP4YR WTSC2YR NA WTSC2YR WTSC2YR NA NA 
Prosulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Carbofuranphenol (ug/L) WTSPP4YR WTSPP4YR WTSC2YR NA NA NA NA NA 
chloro-hydro-meth-chromen-one/ol (ug/L) NA WTSPP2YR NA NA NA NA NA NA 
Oxasulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Desethyl atrazine (ug/L) NA NA NA NA WTSC2YR NA NA NA 
Desisopropyl atrazine mercapturate (ug/L) NA NA NA NA WTSC2YR NA NA NA 
Diaminochloroatrazine (ug/L) NA NA NA NA WTSC2YR NA NA NA 
Desisopropyl atrazine (ug/L) NA NA NA NA WTSC2YR NA NA NA 
Atrazine mercapturate (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR NA NA NA 
Diethyldithiophosphate (ug/L) WTSPP4YR WTSPP4YR WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Chlorsulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Sulfosulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
dibromovinyl-dimeth prop carboacid (ug/L) WTSPP4YR WTSPP4YR NA NA WTSC2YR WTSC2YR NA NA 
Metolachlor mercapturate (ug/L) NA WTSPP2YR NA NA NA NA NA NA 
Acetochlor mercapturate (ug/L) NA WTSPP2YR NA NA NA NA NA NA 
2-isopropoxyphenol (ug/L) WTSPP4YR WTSPP4YR WTSC2YR NA NA NA NA NA 
Methamidaphos (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
O-methoate (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Acephate (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Dimethoate (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Ethametsulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Metsulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Nicosulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Propylenethio urea (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Mono-n-octyl phthalate (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSB2YR NA NA 
2-(N-ethyl-PFOSA) acetate (ng/mL) WTMEC2YR NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR NA 
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Perfluorobutane sulfonic acid (ng/mL) NA NA WTSA2YR WTSA2YR WTSC2YR WTSC2YR WTSA2YR WTSB2YR 
Blood Hexachloroethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood Carbon Tetrachloride (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-Acetyl-S-(trichlorovinyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood 1,1,2,2-Tetrachloroethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood 1,1,1-Trichloroethane (ng/mL) WTSVOC4Y NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-Ace-S-(dimethylphenyl)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood Nitrobenzene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-acel-S-(1,2-dichlorovinl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
N-Acel-S-(2,2-Dichlorvinyl)-L-cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood 1,2,3-trichloropropane (ng/ml) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Trichloroethene (ng/ml) WTSVOC4Y WTSVOC4Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,2-Dichlorobenzene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,2-Dichloropropane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood 1,2-Dichloroethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Methylene Chloride (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,3-Dichlorobenzene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Chlorobenzene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
N-A-S-(1-HydrxMet)-2-Prpn)-L-Cys (ng/mL) NA NA NA WTSVOC2Y NA NA WTSA2YR WTSA2YR 
Blood isopropylbenzene (ng/ml) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood Dibromomethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood Hexane (ng/mL) NA NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood trans-1,2-Dichloroethene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood Heptane (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Octane (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Cyclohexane (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Diethyl Ether (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Ethyl Acetate (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Chloroethane (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Methylcyclopentane (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
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Blood Tetrahydrofuran (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Sulfometuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Atrazine (ug/L) NA NA NA NA WTSC2YR NA NA NA 
Triasulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Halosulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Triflusulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Primisulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Rimsulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Thifensulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Bensulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Foramsulfuron (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Mesosulfuron methyl (ug/L) NA NA WTSC2YR WTSC2YR WTSC2YR NA NA NA 
Blood 1,1,1,2-tetrachloroethane (ng/mL) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,1,2-Trichloroethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood 1,1-Dichloroethane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood 1,1-Dichloroethene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood cis-1,2-Dichloroethene (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA 
Blood 1,2-Dibromo-3-chloropropane (ng/mL) NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y NA NA 
Blood 1,2-dibromoethane (ng/ml) NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood 1,4-Dioxane (ng/mL) NA NA NA NA NA WTSVOC2Y WTSVOC2Y WTSVOC2Y 
Blood aaa-Trifluorotoluene (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Blood Vinyl Bromide (ng/mL) NA NA NA NA NA NA NA WTSVOC2Y 
Albumin, urine (ug/mL) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR 
Albumin, urine (mg/L) NA NA NA WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR 
Creatinine, urine (mg/dL) WTMEC4YR WTMEC4YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR 
Creatinine, urine (umol/L) NA NA NA WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR WTMEC2YR 
Bis(2-chloroethyl) phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Bis(1-chloro-2-propyl) phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Bis(1,3-dichloro-2-propyl) phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Dibutyl phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
 249 
 
Dibenzyl phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Di-o-cresyl phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Di-p-cresyl phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Diphenyl phosphate (ug/L) NA NA NA NA NA NA NA WTSC2YR 
2,3,4,5-tetrabromobenzoic acid (ug/L) NA NA NA NA NA NA NA WTSC2YR 
Daidzein (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
Equol (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
Genistein (ng/mL) WTSPH4YR WTSPH4YR WTSB2YR WTSB2YR WTSB2YR WTSA2YR NA NA 
Hydroxycotinine, Serum (ng/mL) NA NA NA NA NA NA NA WTMEC2YR 
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Table A2.4. NHANES codenames for survey weights used in children aged 3-11 years old for a given Per- and Polyfluoroalkyl Substance 
(PFAS) and NHANES cycle. 
 
Chemical name Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 
Perfluoroundecanoic acid (ng/mL)        WTSS2YR 
Perfluorododecanoic acid (ng/mL)        WTSS2YR 
Perfluorodecanoic acid (ng/mL)        WTSS2YR 
Perfluorooctane sulfonamide (ng/mL)        WTSS2YR 
2-(N-methyl-PFOSA) acetate (ng/mL)        WTSS2YR 
Perfluorononanoic acid (ng/mL)        WTSS2YR 
Linear perfluorooctane sulfonate (ug/L)        WTSS2YR 
Monomethyl branched iso of PFOS (ug/L)        WTSS2YR 
Linear perfluorooctanoate (ug/L)        WTSS2YR 
Br. iso of perfluorooctanoate (ug/L)        WTSS2YR 
Perfluorohexane sulfonic acid (ng/mL)        WTSS2YR 
Perfluoroheptanoic acid (ng/mL)        WTSS2YR 
2-(N-ethyl-PFOSA) acetate (ng/mL)        WTSS2YR 
Perfluorobutane sulfonic acid (ng/mL)        WTSS2YR 
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Table A2.5. Number of participants by race and menopause/hysterectomy status 
 
 
Menopause – No 
Regular Periods 
Menopause – Yes Menopause – No 
Irregular Periods 
Mexican Americans 3338 1566 466 
Non-Hispanic Blacks 3338 2070 313 
Non-Hispanic Whites 4937 5122 611 
Other Hispanics 1098 741 99 
Other Race/Multi-Racial 1108 512 84 
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0 81 164 199 31 22 
1 575 803 1507 258 240 
2 709 952 2510 384 317 
3 717 667 1742 284 176 
4 431 381 775 152 88 
5 238 197 330 92 34 
6 144 113 173 33 25 
7 101 82 69 10 10 
8 70 39 37 9 7 
9 38 17 24 7 7 
10 52 17 12 5 1 
11 44 16 9 5 3 
12 7 9 2 3 0 
13 4 0 0 3 0 
15 4 0 0 0 0 
17 0 1 0 0 0 
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Table A2.7. Number of participants by breastfeeding status and race. 
 
 
Breastfed – No 
Do not have children 
Breastfeed – Yes Breastfed – No 
Have children 
Mexican Americans 81 1925 821 
Non-Hispanic Blacks 164 1223 1640 
Non-Hispanic Whites 199 3516 2668 
Other Hispanics 31 728 311 
Other Race/Multi-Racial 22 454 187 
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Table A2.8. Number of participants by race and iron deficiency status. 
 
 
Iron deficient - No Iron deficient – Yes 
Mexican Americans 7100 812 
Non-Hispanic Blacks 5991 1989 
Non-Hispanic Whites 12187 911 
Other Hispanics 2289 358 






Appendix 3. Biomarker-Based Occupational Exposome 
 
Figure A3.1. Bar plot showing number of participants by included chemical. Participants have data available for age, sex, race, industrial 





Figure A3.2. Heatmap of dichotomized biomarker measurements by participants and included chemicals to show sparsity of the 
chemical biomarker dataset. NHANES participants have data available for age, sex, race, industrial sector, and occupational title. 
Chemical biomarkers are grouped by chemical class. Participants are order by number of measured chemicals, which ranges from 0 to 




Figure A3.3. Bar plot showing the number of participants by each sector-collar combination. The sector-collar combinations are 






Figure A3.4. Bar plot showing the percentage of male versus female participants for each sector-collar combination. The sector-collar 






Figure A3.5. Bar plot showing the percentage of Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, and 
Other Race/Multi-Racial participants for each sector-collar combination. The sector-collar combinations are ordered from highest 






Figure A3.6. Bar plot showing the percentage of poverty income categories for each sector-collar combination. The sector-collar 




Figure A3.7. Box plot of distribution of lead in blood. Far-left statistics are the mean chemical biomarker concentration. The middle-
left statistics are the percent differences except for the “reference” group of “Public Administration – White Collars” and the 
“NHANES population”. The NHANES population includes all participants with measurements for lead, including the sector-collar 
combinations. The middle-right statistics are the p-values corrected for multiple comparison with the Benjamini and Hochberg FDR 
procedure of 5%. Far-right statistics are the sample size of each sector-collar combinations. Purple triangle represents the mean 





Figure A3.8. Box plot of distribution of total arsenic in urine. Far-left statistics are the mean chemical biomarker concentration. The 
middle-left statistics are the percent differences except for the “reference” group of “Public Administration – White Collars” and the 
“NHANES population”. The NHANES population includes all participants with measurements for total arsenic, including the sector-
collar combinations. The middle-right statistics are the p-values corrected for multiple comparison with the Benjamini and Hochberg 
FDR procedure of 5%. Far-right statistics are the sample size of each sector-collar combinations. Purple triangle represents the mean 
concentration of total arsenic for a given sector-collar combination. Results are adjusted for age, sex, and race. 
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Table A3.1. Job occupation description with corresponding collar category. 
Job Occupation Description Collar Category 
Building & Grounds Cleaning, Maintenance Occupations Blue-collar 
Food Preparation, Serving Occupations Blue-collar 
Personal Care, Service Occupations Blue-collar 
Farming, Fishing, Forestry Occupations Blue-collar 
Installation, Maintenance, Repair Occupations Blue-collar 
Construction, Extraction Occupations Blue-collar 
Production Occupations Blue-collar 
Transportation, Material Moving Occupations Blue-collar 
Armed Forces Blue-collar 
Management Occupations White-collar 
STEM, Social, and Legal Services Occupations White-collar 
Healthcare Practitioner, Technical Occupations White-collar 
Education, Training, Library Occupations White-collar 
Arts, Design, Entertainment, Sports, Media Occupations White-collar 
Healthcare Support Occupations White-collar 
Sales & Related Occupations White-collar 
Office, Administrative Support Occupations White-collar 
Protective Service Occupations White-collar 
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Table A3.2. List of excluded tobacco and soy metabolites and their corresponding chemical class. 
Chemical Chemical Class 
Cotinine (ng/mL) Smoking Related Compounds 
NNAL , urine (ng/mL) Smoking Related Compounds 
o-Desmethylangolensin (O-DMA) (ng/mL) Soy Metabolites 
Enterolactone (ng/mL) Soy Metabolites 
Enterodiol (ng/mL) Soy Metabolites 
Daidzein (ng/mL) Soy Metabolites 
Equol (ng/mL) Soy Metabolites 
Genistein (ng/mL) Soy Metabolites 
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Table A3.3. Sample size required to detect significant differences. x% power mean that a study has a x% chance of ending up with a p-
value of less than 5% in a statistical test when the effect size (or regression coefficient) is a corresponding value if the sample size is a 
particular number. For example, a study has a 70% chance of detecting a significance difference with a regression coefficient of 0.37 
when the sample size is 90 participants. 
Effect Size (or Regression Coefficients) 90% Power 80% Power 70% Power 
0.01 209952 156800 123008 
0.02 52488 39200 30752 
0.03 23328 17422 13668 
0.04 13122 9800 7688 
0.05 8398 6272 4920 
0.06 5832 4356 3417 
0.07 4285 3200 2510 
0.08 3281 2450 1922 
0.09 2592 1936 1519 
0.1 2100 1568 1230 
0.11 1735 1296 1017 
0.2 525 392 308 
0.3 233 174 137 
0.31 218 163 128 
0.32 205 153 120 
0.33 193 144 113 
0.34 182 136 106 
0.35 171 128 100 
0.36 162 121 95 
0.37 153 115 90 
0.38 145 109 85 
0.39 138 103 81 
0.4 131 98 77 
0.5 84 63 49 
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0.6 58 44 34 
0.7 43 32 25 
0.8 33 25 19 
0.9 26 19 15 




Table A3.4. Table of description, clinical thresholds, and sample size of each physiological indicator. Lower bound of the threshold 
implies that values below the threshold are unfavorable or indicative of high risk. Upper bound of the threshold implies that values 
above the threshold are unfavorable or indicative of high risk. 
   Clinical Thresholds 









Body Composition         
Body Mass Index 
(kg/m**2)  23834 
Measure of body fat based on height and 
weight. This measure is used to screen for 
weight categories associated with health 
problems. Lower measurements indicate 
underweighted, whereas higher 
measurements indicate overweight or 
obesity. 
18.5-19 24.9-25     
Standing Height (cm)  23931 Distance between the lowest and highest points of a person standing upright.       
Subscapular Skinfold 
(mm)  14381 
Subscapular skinfold is skinfold thickness 
measured under the lowest point of the 
shoulder blade. It also serves as a measure 
for subcutaneous fat. 
      
Triceps Skinfold (mm)  16305 
Triceps skinfold is skinfold thickness 
measured back side middle upper arm. It 
also serves as a measure for subcutaneous 
fat. 
      
Waist Circumference 
(cm)  23255 
A measurement taken around the abdomen 
at the level of the umbilicus (belly button). 
This measure is used to screen for patients 
with weight-related health problems. 
Higher measurements may indicate higher 
risk for heart disease and type 2 diabetes. 
   90-102  80-88 
Weight (kg) 23858 Quantifier of heaviness. It serves as a nutrition screen tool and is valuable in       
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monitoring fluid balance and calculating 
medication doses.  
Relative Fat Mass Index 
(-)  23240 
The relative fat mass formula is a new 
index for measuring body fatness that can 
be easily accessible to health practitioners 
trying to treat overweight patients who 
often face serious health consequences like 
diabetes, high blood pressure and heart 
disease. Higher index indicates higher body 
fat, which is associated with increased risk 
of poor health and early mortality. 
  8-13 19-25 21-24 33-36 
Cardiovascular System         
60 sec. pulse (30 sec. 
pulse * 2):  23123 
Normal resting heart rate is the number of 
heart beats per minute. It is calculated by 
multiplying the number of beats in 30 
seconds by 2. Higher pulse may indicate 
lack of arterial blood flow or heart disease. 
50-60 80-100     
Diastolic: Average blood 
pressure (mm Hg)  22990 
A measure of the force exerted by blood 
against artery walls during contraction or 
beating of the heart. Higher measurements 
indicate hypertension, while lower 
measurements indicate hypotension. 
60 80-90     
Systolic: Average blood 
pressure (mm Hg)  23045 
A measure of the force exerted by blood 
when heart relaxes between beats. Higher 
measurements indicate hypertension, while 
lower measurements indicate hypotension. 
90 130-140     
Direct HDL-Cholesterol 
(mg/dL)  22772 
High-density lipoprotein (HDL) is often 
called “good” cholesterol. It removes 
cholesterol from the bloodstream. Higher 
levels of HDL are associated with lower 
risk of heart disease. 
  40  50  
LDL-cholesterol (mg/dL)  10696 
Low-density lipoprotein (LDL) is often 
called “bad” cholesterol. It delivers 
cholesterol to the body. Higher levels are 
 100-130     
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associated with increased risk in heart 
disease. 
Ratio of LDL to HDL 
Cholesterol (-)  10696 
This ratio is calculated by dividing the LDL 
cholesterol number by the HDL cholesterol 
number. Higher ratios are indicative of 
higher risk of heart disease. 
 1.4     
Ratio of Total to HDL 
Cholesterol (-)  22771 
This ratio is calculated by dividing the total 
cholesterol number by the HDL cholesterol 
number. Higher ratios are indicative of 
higher risk of heart disease. 
   5  4.4 
Total cholesterol (mg/dL)  22772 
A measure of the total amount of 
cholesterol in your blood. It includes both 
low-density lipoprotein (LDL) cholesterol 
and high-density lipoprotein (HDL) 
cholesterol. Higher measurements are 
associated with increased risk in heart 
diseases. 
 200     
Triglycerides (mg/dL)  22722 
Triglycerides are another type of fat in your 
blood. When you eat more calories than 
your body can use, it turns the extra calories 
into triglycerides. Higher measurements are 
associated with increased risk in heart 
diseases. 
 150     
Immune System         
C-reactive protein 
(mg/dL)  17059 
C-reactive protein (CRP) is a substance 
produced by the liver in response to 
inflammation. A high level of CRP in the 
blood is a marker of inflammation. It can be 
caused by a wide variety of conditions, 
from infection to cancer. Higher 
measurements are indicative of 
inflammation.  
 0.1-0.2     
White blood cell count 
(1000 cells/uL) 22977 
Cells of the immune system that are 
involved in protecting the body against 
infection and foreign invaders. The count is 
4-15 10-11     
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the number of white blood cells in a sample 
of blood to serve as a general evaluation of 
health. A higher count may indicate 
inflammation, an infection, or disease of 
bone marrow. 
Metabolic System         
Alkaline phosphatase 
(U/L)  19819 
Alkaline phosphatase (ALP) is an enzyme 
found in several tissues throughout the 
body. The highest concentrations of ALP 
are present in the cells that comprise bone 
and the liver. Elevated levels of ALP in the 
blood are most commonly caused by liver 
disease or bone disorders. 
20-44 116-147     
Glucose, plasma (mg/dL)  11202 
Fasting blood sugar provides vital clues 
about how the body is managing blood 
sugar levels. High levels of fasting blood 
sugar suggest that the body has been unable 
to lower the levels of sugar in the blood. 
This points to either insulin resistance or 
inadequate insulin production, and in some 
cases, both. 
60-70 99-126     
Glycohemoglobin:(%)  22957 
A glycohemoglobin test, or hemoglobin 
A1c, is a blood test that checks the amount 
of sugar (glucose) bound to 
the hemoglobin in the red blood cells. The 
level of glycohemoglobin is increased in the 
red blood cells of persons with poorly 
controlled diabetes mellitus. 
 5.7-7     
Homeostatic Model 
Assessment of Insulin 
Resistance (-)  
9579 
HOMA-IR stands for Homeostatic Model 
Assessment of Insulin Resistance. The 
meaningful part of the acronym is “insulin 
resistance”. It marks for both the presence 
and extent of any insulin resistance. It is a 
way to reveal the dynamic between baseline 
(fasting) blood sugar and the responsive 
 1.4-2.9     
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hormone insulin. Higher indices indicate 
increase resistance to insulin. 
Ratio of Insulin to 
Glucose  9579 
This measure is calculated by dividing the 
concentration of insulin in blood with the 
concentration of blood glucose. It serves as 
a measure of insulin resistance. Higher 
indices indicate increase resistance to 
insulin. 
 0.2-0.3     
Nephrology          
Albumin (g/dL)  22733 
A protein made in the liver that helps keep 
fluid in the bloodstream, so it doesn’t leak 
into other tissues. It also carries nutrients 
throughout the body. Low albumin levels 
can indicate liver or kidney damage, while 
higher measurements may indicate 
dehydration or diarrhea. 
3.4-3.5 5.4-5.5     
Blood urea nitrogen 
(mg/dL)  22732 
This test measures the amount of nitrogen 
in the patient’s blood that comes from the 
waste product urea. Urea is made when 
proteins break down in the body. Urea is 
made in the liver and eliminated in the 
urine. When kidneys are not healthy, they 
have trouble removing blood urea nitrogen, 
leading to elevated concentrations in the 
blood. Lower levels may indicate a diet low 
in proteins, malnutrition, or liver damage. 
6-10 20-21     
Creatinine (mg/dL)  19821 
Creatinine is a chemical waste product of 
creatine, an amino acid made by the liver 
and stored in the liver. Creatinine is the 
result of normal muscle metabolism. Low 
creatinine levels may indicate muscle 
disease, liver disease, or excessive water 
loss. Higher levels. May indicate kidney 
damage, kidney infection, reduced 
circulation to the kidneys, and dehydration. 





(mL/min/1.73 m2)  
19821 
An estimated GFR (eGFR) calculated from 
serum creatinine using an isotope dilution 
mass spectrometry (IDMS) traceable 
equation is a simple and effective way to 
detect chronic kidney disease. Lower rates 
indicate kidney dysfunction.  
60-90      
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Table A3.5. Number of participants with a given number of measured chemicals. For example, 297 participants have measurements 
available for 98 chemical biomarkers. 




































































































Table A3.6. Description of each hierarchical clustering method. 
Linkage Method Description 
Single (nearest neighbor) Distance between two clusters is determined by a pair 
of elements that are closest to each other. At each step, 
if a pair of elements, with the shortest distance, do not 
belong in the same cluster, then the two clusters will be 
combined. 
Complete (farthest neighbor) Distance between two clusters is determined by a pair 
of elements that are farthest from each other. At each 
step, if a pair of elements, with the shortest distance, do 
not belong in the same cluster, then the two clusters 
will be combined. 
Average (unweighted pair group method with 
arithmetic mean or UPGMA) 
Distance between two clusters is determined by the 
average of all distances between each pairs of distance 
in either clusters.  
McQuitty (Weighted Pair Group Method with 
Arithmetic Mean or WPGMA) 
Distance of two nearest clusters (i and j) to another 
cluster (k) is the arithmetic mean of average distances 




Table A3.7. Cophenetic correlation coefficients by linkage methods for clustering of the sector-collar combinations based on chemical 
exposure profiles. 
Linkage Method Cophenetic Correlation Coefficients 
Single (nearest neighbor) 0.2828052 
Complete (farthest neighbor) 0.5536748 
Average (unweighted pair group method with 
arithmetic mean or UPGMA) 0.5671026 
McQuitty (Weighted Pair Group Method with 





Table A3.8. Cophenetic correlation coefficients by linkage methods for clustering of the sector-
collar combinations based on physiological response profiles. 
Linkage Method Cophenetic Correlation Coefficients 
Single (nearest neighbor) 0.1859953 
Complete (farthest neighbor) 0.644285 
Average (unweighted pair group method with 
arithmetic mean or UPGMA) 0.6781713 
McQuitty (Weighted Pair Group Method with 








Appendix 4. Characterization of Linear and Non-linear Associations between Physiological 
Indicators and All-Cause Mortality 
 
Figure A4.1. Schematic description of curation process and analytical methods. Schematic 
description of the process to curate the physiological measurements and of the analytical methods 
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Figure A4.2. Stairway plot of hazard ratios displaying the relative mortality risk for age and 
alphabet soup plot of prediction performance for linear and non-linear models. Results were 





Figure A4.3. Histogram of measurements for each physiological indicator in all participants. 




Figure A4.4. Alphabet soup plot displaying the Concordance Index for the associations with all-
cause mortality for all physiological indicators across all studied models. Results are adjusted for 
age, sex, and race/ethnicity. Error bars represent the 95% Confidence Intervals defined through 




Figure A4.5. Alphabet soup plot displaying the AIC for the associations with all-cause mortality 
for all physiological indicators across all studied models. Results are adjusted for age, sex, and 
race/ethnicity. Error bars represent the 95% Confidence Intervals defined through bootstrapping 
for 1000 replicates. 




Figure A4.6. Scatterplot of the sample size and prediction performance displayed for the A) AIC, 






Figure A4.7. Alphabet soup plot of Nagelkerke R2 on all participants (0) and participants within 
the 1st to 99th (1), 5th to 95th (2), and 10th to 90th percentiles (3). Results are adjusted for age, sex, 
and race/ethnicity. Error bars represent the 95% Confidence Intervals defined through 




Figure A4.8. Alphabet soup plot of the AIC on all participants (0) and participants within the 1st to 
99th (1), 5th to 95th (2), and 10th to 90th percentiles (3). Results are adjusted for age, sex, and 
race/ethnicity. Error bars represent the 95% Confidence Intervals defined through bootstrapping 




Figure A4.9. Alphabet soup plot of the Concordance Index on all participants (0) and participants 
within the 1st to 99th (1), 5th to 95th (2), and 10th to 90th percentiles (3). Results are adjusted for age, 
sex, and race/ethnicity. Error bars represent the 95% Confidence Intervals defined through 




Figure A4.10. Volcano Plots of Nagelkerke R2 and test statistics used to indicate statistical 






Figure A4.11. Stairway hazard ratios across all models to describe the relative mortality risk for 
A) Body Mass Index, B) Average Systolic Blood Pressure, C) Ratio of Total to HDL Cholesterol, 
D) C-Reactive Proteins, E) Homeostatic Model Assessment of Insulin Resistance, and F) 
Glomerular Filtration Rate when all participants are included. Relative risks for mortality from the 
novemtiles model are represented by the boxes with the width representing the range of a 
novemtile and the height representing the 95% Confidence Interval of the hazard ratio. The mean 
hazard ratio for each novemtile is presented by a digit. The hazard compares participants in a 
novemtile to those in the reference group at the 5th novemtile. The red and blue lines represent the 
relative mortality risk with respect to median of a physiological indicator for the linear and spline 
models, respectively. The dashed navy line represents when the hazard ratio is 10% higher than 
the minimum hazard ratio. The navy diamonds indicate the concentration at which the hazard ratio 
shows a 10% increase from the minimum hazard ratio. The purple dot represents the median for a 
physiological indicator. The pink lines and rectangles represent the values of the clinical thresholds 
with the width of the rectangles representing the ranges of the threshold. The set of tick marks 
along the base of the plot represent the distribution of a physiological indicator with increased 






Figure A4.7. Stairway plots of hazard ratios across all models to describe the relative mortality 





Figure A4.8. Stairway plots of hazard ratios across all models to describe the relative mortality 




Figure A4.9. Stairway plots of hazard ratios across all models to describe the relative mortality 









Figure A4.10. Stairway plots of hazard ratios across all models to describe the relative mortality 








Figure A4.11. Stairway plots of hazard ratios across all models to describe the relative mortality 





Figure A4.12. Sex-stratified non-linear associations between all-cause mortality and each 
physiological indicator with available sex-specific clinical thresholds. The non-linear 
associations were determined using a cubic spline regression model adjusted for age and 
race/ethnicity. Participants with measurements between the 1st and 99th percentiles of a 
physiological indicator are included. The purple and orange lines represent the relative mortality 
risk with respect to median of a physiological indicator for males and females, respectively. The 
black dot represents the median for a physiological indicator. The dashed navy line represents 
when the hazard ratio is 10% higher than the minimum hazard ratio. The navy diamonds indicate 
the concentration at which the hazard ratio shows a 10% increase from the minimum hazard 
ratio. The pink lines and rectangles represent the values of the clinical thresholds with the width 





Figure A4.13. Sex-stratified non-linear associations between all-cause mortality and each 






Figure A4.14. Sex-stratified non-linear associations between all-cause mortality and each 




Figure A4.15. Sex-stratified non-linear associations between all-cause mortality and each 





Figure A4.16. Sex-stratified non-linear associations between all-cause mortality and each 






Figure A4.17. Sex-stratified non-linear associations between all-cause mortality and each 







Figure A4.18. Stairway plot of hazard ratios describing the associations between all-cause 
mortality and BMI with and without adjusting for smoking. Smoking was defined using log-




Table A4.1. Number of participants by mortality status, gender, and race for the entire NHANES population and subpopulations with 
data for each physiological indicator. 






























(48.3) 8562 (19.0) 3286 (7.3) 
20312 
(45.1) 9665 (21.5) 3207 (7.2) 



















































































(19.02) 3243 (7.33) 
19954 
(45.11) 9466 (21.4) 
3155 
(7.13) 




























































































Diastolic: Average blood 










(19.25) 3092 (7.36) 
19260 
(45.84) 8615 (20.5) 
2962 
(7.05) 
Systolic: Average blood 
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(19.05) 3133 (7.31) 
19483 
(45.44) 9091 (21.2) 
3004 
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Homeostatic Model Assessment 









































































(18.79) 2874 (7.8) 
16626 
(45.14) 7623 (20.7) 
2788 
(7.57) 
Estimated Glomerular Filtration 










(18.79) 2874 (7.8) 
16626 
(45.14) 7623 (20.7) 
2788 
(7.57) 
a The NHANES population is defined as the sample with data available for age, gender, and race. Mortality data is available for participants who are 18 years or 
older.  
b The NHANES subpopulation is defined as the sample with data available for mortality, age, gender, and race. 






Table A4.2. Percentiles of age (years) for the entire NHANES population and subpopulations with data for each physiological indicator. 
Name Min 1st 5th 10th Median Mean 90th 95th 99th Max 
NHANES Population a 0 0 1 2 23 30.67 69 78 84 85 
NHANES Subpopulation b 18 18 19 21 46 47.09 75 80 85 85 
Body Mass Index (kg/m**2) c 18 18 19 21 46 46.88 75 80 85 85 
Standing Height (cm) c 18 18 19 21 46 46.89 75 80 85 85 
Subscapular Skinfold (mm) c 18 18 19 20 45 46.76 76 80 85 85 
Triceps Skinfold (mm) c 18 18 19 20 45 46.85 76 80 85 85 
Waist Circumference (cm) c 18 18 19 21 45 46.66 74 80 85 85 
Weight (kg) c 18 18 19 21 46 46.98 75 80 85 85 
Relative Fat Mass Index (-) c   18 18 19 21 45 46.57 74 80 85 85 
60 sec. pulse (30 sec. pulse * 2) c 18 18 19 21 46 47.14 75 80 85 85 
Direct HDL-Cholesterol (mg/dL) c 18 18 19 21 46 47.12 75 80 85 85 
LDL-cholesterol (mg/dL) c 18 18 19 21 46 47.23 75 80 85 85 
Triglycerides (mg/dL) c 18 18 19 21 46 47.11 75 80 85 85 
Total cholesterol (mg/dL) c 18 18 19 21 46 47.12 75 80 85 85 
Diastolic: Average blood pressure (mm 
Hg) c 18 18 19 21 46 47.00 75 80 85 85 
Systolic: Average blood pressure (mm 
Hg) c 18 18 19 21 46 47.10 75 80 85 85 
Ratio of LDL to HDL Cholesterol (-) c 18 18 19 21 46 47.23 75 80 85 85 
Ratio of Total to HDL Cholesterol (-) c 18 18 19 21 46 47.12 75 80 85 85 
C-reactive protein (mg/dL) c 18 18 19 21 46 47.09 76 80 85 85 
White blood cell count (1000 cells/uL) c 18 18 19 21 46 47.19 75 80 85 85 
Glycohemoglobin (%) c 18 18 19 21 46 47.19 75 80 85 85 
Glucose, plasma (mg/dL) c 18 18 19 21 46 47.32 75 80 85 85 
Alkaline phosphatase (U/L) c 18 18 19 21 46 47.27 75 80 85 85 
Homeostatic Model Assessment of Insulin 
Resistance (-) c 18 18 19 21 46 47.17 75 80 85 85 
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Ratio of Insulin to Glucose 
(uU*dL)/(mg*mL) c 18 18 19 21 46 47.17 75 80 85 85 
Albumin (g/dL) c 18 18 19 21 46 47.11 75 80 85 85 
Blood urea nitrogen (mg/dL) c 18 18 19 21 46 47.11 75 80 85 85 
Creatinine (mg/dL) c 18 18 19 21 46 47.27 75 80 85 85 
Estimated Glomerular Filtration Rate 
(mL/min/1.73 m2) c 18 18 19 21 46 47.27 75 80 85 85 
a The NHANES population is defined as the sample with data available for age, gender, and race. Mortality data is available for participants who are 18 years or 
older.  
b The NHANES subpopulation is defined as the sample with data available for mortality, age, gender, and race. 





Table A4.3. Percentiles of time to death (month) for a NHANES subpopulation and the subpopulations with data for each physiological 
indicator. 
Name Min 1st 5th 10th Median Mean 90th 95th 99th Max 
NHANES Subpopulation a 1 13 19 27 93 97.52 177 189 199 201 
Body Mass Index (kg/m**2) b 1 13 19 27 93 97.52 177 189 199 201 
Standing Height (cm) b 1 13 19 27 93 97.64 177 189 199 201 
Subscapular Skinfold (mm) b 1 13 50 65 116 118.63 183 192 199 201 
Triceps Skinfold (mm) b 1 13 49 65 116 118.86 183 192 199 201 
Waist Circumference (cm) b 1 13 20 27.7 94 98.40 177 189 199 201 
Weight (kg) b 1 13 19 27 92 97.41 177 189 199 201 
Relative Fat Mass Index (-) b 1 13 20 28 94 98.49 178 189 199 201 
60 sec. pulse (30 sec. pulse * 2) b 1 12 19 27 93 97.42 177 189 199 201 
Direct HDL-Cholesterol (mg/dL) b 1 13 19 27 93 97.52 177 189 199 201 
LDL-cholesterol (mg/dL) b 1 13 19 27 91 96.45 176 189 198 201 
Triglycerides (mg/dL) b 1 13 19 27 93 97.60 177 189 199 201 
Total cholesterol (mg/dL) b 1 13 19 27 93 97.52 177 189 199 201 
Diastolic: Average blood pressure (mm 
Hg) b 1 13 19 27 92 97.40 177 189 199 201 
Systolic: Average blood pressure (mm Hg) 
b 1 13 19 27 92 97.38 177 189 199 201 
Ratio of LDL to HDL Cholesterol (-) b 1 13 19 27 91 96.45 176 189 198 201 
Ratio of Total to HDL Cholesterol (-) b 1 13 19 27 93 97.52 177 189 199 201 
C-reactive protein (mg/dL) b 1 13 49 65 117 118.82 183 192 199 201 
White blood cell count (1000 cells/uL) b 1 13 19 27 93 97.45 177 189 199 201 
Glycohemoglobin (%) b 1 13 19 27 93 97.47 177 189 199 201 
Glucose, plasma (mg/dL) b 1 13 19 27 93 97.67 177 189 198 201 
Alkaline phosphotase (U/L) b 1 13 19 25 83 89.85 168 190 199 201 
Homeostatic Model Assessment of Insulin 
Resistance (-) b 1 13 39 46 104 109.08 181 191 199 201 
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Ratio of Insulin to Glucose 
(uU*dL)/(mg*mL) b 1 13 39 46 104 109.08 181 191 199 201 
Albumin (g/dL) b 1 13 19 27 93 97.58 177 189 199 201 
Blood urea nitrogen (mg/dL) b 1 13 19 27 93 97.58 177 189 199 201 
Creatinine (mg/dL) b 1 13 19 25 83 89.85 168 190 199 201 
Estimated Glomerular Filtration Rate 
(mL/min/1.73 m2) b 1 13 19 25 83 89.85 168 190 199 201 
a The NHANES subpopulation is defined as the sample with data available for mortality, age, gender, and race.  





Table A4.4. Definition, interpretation, and justification of prediction measures. 
 Definition Interpretation Justification 
Akaike Information 
Criterion (AIC) 
Estimator of the relative 
amount of information 
lost by a model 
A lower AIC implies 
higher quality of the 
model and minimum 
information lost. 
The AIC is useful for 
comparing models but is 
not informative when 
interpreting the goodness 
of fit of a single isolated 
model. 
Concordance Index Proportion of concordant 
pairs divided by the total 
number of all possible 
pairs.  
The Concordance Index 
represents the model 
ability to correctly rank 
the survival times based 
on the individual risk 
scores. A Concordance 
Index of 1 implies a 
perfect prediction, while 
0.5 implies random 
predictions.  
The Concordance Index is 
the standard measure for 
model assessment in 
survival analysis. 
Nagelkerke R2 Adjusted version of the 
Cox & Snell R2 that 
adjusted for the scale of 
the statistics to range 
from 0 to 1. The Cox & 
Snell R2 reflect the 
improvement of the given 
model over the intercept 
model. 
A Nagelkerke R2 of 1 
implies a perfect model.  
The Nagelkerke R2 better 
highlights the overfitting 
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